Cancer treatment using cell-targeted therapy and related research protocols

Targeted therapeutic agents, such as CARs and antibody conjugates, address the resistance of CBFA2T3-GLIS2(C/G) AML by specifically targeting FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1, enhancing immune cell recognition and improving treatment efficacy in AML and other cancers.

JP2024542027AInactive Publication Date: 2024-11-13FRED HUTCHINSON CANCER RESEARCH CENTER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024525659
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-12
Filing Date
2022-11-02
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer treatments, such as surgery, chemotherapy, and radiotherapy, are ineffective against highly malignant subtypes of pediatric acute myeloid leukemia (AML) characterized by the CBFA2T3-GLIS2(C/G) fusion gene, leading to low survival rates due to high resistance.

Method used

Development of targeted therapeutic agents, including chimeric antigen receptors (CARs) and antibody conjugates, that specifically target cancer cells expressing FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1, utilizing binding domains like farletuzumab scFv to enhance immune cell recognition and destruction of these cells.

Benefits of technology

The targeted therapy effectively eliminates cancer cells while sparing normal hematopoietic cells, improving survival rates in AML and other cancers by leveraging genetically engineered immune cells to recognize and kill cancer-specific surface markers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542027000001_ABST
    Figure 2024542027000001_ABST
Patent Text Reader

Abstract

Described herein are targeted therapeutics for the treatment of cancers expressing FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and / or FRAS1. The targeted therapeutics may include chimeric antigen receptors (CARs) expressed by immune cells or antibody targeted therapeutics. The targeted therapeutics may be used to treat a variety of cancers, including solid tumors and hematological cancers, such as CBFA2T3-GLIS2 acute myeloid leukemia (C / G AML).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 274,914, filed November 2, 2021, and U.S. Provisional Patent Application No. 63 / 371,265, filed August 12, 2022, both of which are incorporated by reference in their entireties as if fully set forth herein.

[0002] Sequence Listing Reference The sequence listing associated with this application is provided in XML format instead of paper and is incorporated herein by reference. The name of the XML file containing the sequence listing is 2SF5710.xml. The XML file is 147KB, was created on October 28, 2022, and was submitted electronically via the Patent Center.

[0003] The present disclosure provides targeted cancer therapy for cancer cells expressing FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1. The targeted therapy may include a chimeric antigen receptor (CAR) expressed by immune cells, such as T cells. The cancers to be treated include various solid tumors and hematological cancers. [Background technology]

[0004] According to the World Health Organization, cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Besides traditional cancer treatments, such as surgery, chemotherapy, and radiation therapy, more targeted treatments have emerged to specifically target cancer cells by identifying and utilizing specific molecular changes primarily found in those cells. For example, immune cells can be engineered to target and kill cancer cells. Many of these immune cells are engineered T cells that are engineered to express a chimeric antigen receptor (CAR) that recognizes a protein or molecule expressed on the surface of the cancer cell so that they can recognize and kill the cancer cell. Furthermore, antibodies or binding fragments thereof that bind to proteins or molecules expressed on the surface of the cancer cell can be used to induce an immune response against the cancer cell. These antibodies or binding fragments thereof can be conjugated to cytotoxic drugs to further enhance their cytotoxic effect.

[0005] Many cancer types, such as leukemia, peritoneal cancer, fallopian tube cancer, ovarian cancer, endometrial cancer, cervical cancer, breast cancer, bladder cancer, renal cell carcinoma, pituitary tumors, lung cancer, uterine cancer, squamous cell carcinoma, ureteral cancer, urethral cancer, osteosarcoma, and transitional cell carcinoma, would benefit from further development of CAR-based therapies.

[0006] For example, childhood acute myeloid leukemia (AML) is a heterogeneous group of diseases classified based on morphology, lineage, and genetic features (Rubnitz, Blood 119:5980-8, 2012), and its prognosis depends on cytogenetic and molecular features. Despite improvements in survival and remission induction rates, outcomes vary widely depending on the biological subtype of AML (Kim, Blood Res. 55(Suppl):S5-S13, 2020). Genomic investigations of AML have led to new genomic classification and predictive biomarkers to better stratify risk and survival outcomes (Arber, Semin Hematol. 56:90-5, 2019, and Arber et al., Blood 127:2391-405, 2016). One such genetic prognostic marker is the CBFA2T3-GLIS2(C / G) fusion gene. The C / G fusion gene characterizes a highly aggressive, pediatric-specific subtype of leukemia. This subtype of AML is highly resistant to conventional treatments, resulting in a low survival rate of 15-30% (Masetti et al., Br J Haematol. 184(3):337-347, 2019). Due to the significant morbidity and mortality associated with C / G AML, efforts to identify new treatments are under ongoing research. Summary of the Invention

[0007] The present disclosure provides targeted therapy against cancer cells expressing FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and / or FRAS1. Pediatric acute myeloid leukemia (AML) provides an example of a cancer type that may be treated with targeted therapy against cancer cells expressing FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and / or FRAS1. Leukemia, peritoneal cancer, fallopian tube cancer, ovarian cancer, endometrial cancer, cervical cancer, breast cancer, bladder cancer, renal cell carcinoma, pituitary tumor, lung cancer, uterine cancer, squamous cell carcinoma, ureteral cancer, urethral cancer, osteosarcoma, and transitional cell carcinoma provide examples of cancer types that may be treated with targeted therapy against cancer cells expressing FOLR1.

[0008] In certain embodiments, the targeted therapeutic agent disclosed herein comprises a chimeric antigen receptor (CAR) expressed by an immune cell, e.g., a T cell. In certain embodiments, the CAR comprises a binding domain that binds to FOLR1, a spacer of IgG4, a transmembrane domain of CD28, and an intracellular effector domain of 4-1BB / CD3ζ. The targeted therapeutic agent may also comprise an antibody conjugate, e.g., an antibody-drug conjugate, an antibody-radioisotope conjugate, or an antibody-nanoparticle conjugate.

[0009] Some of the drawings presented herein may be better understood in color, and Applicant considers the color drawings to be part of the original submission and reserves the right to present color images of the drawings in later proceedings. [Brief description of the drawings]

[0010] [Figure 1A] CBFA2T3-GLIS2(C / G)- cord blood (CB) cells induce leukemias that recapitulate the primary disease. Diagram of experimental design. [Figure 1B] CBFA2T3-GLIS2(C / G)-cord blood (CB) cells induce leukemias that recapitulate the primary disease. Kaplan-Meier survival curves of NSG-SGM3 mice transplanted with green fluorescent protein (GFP)-CB control and C / G-CB cells. Statistical differences in survival were assessed using the log-rank Mantel-Cox. [Figure 1C] CBFA2T3-GLIS2 (C / G)-cord blood (CB) cells induce leukemias that recapitulate the primary disease. Hematoxylin and eosin (H&E) staining of representative histology of femurs taken from mice transplanted with C / G-CB cells (top) and of C / G-positive patient samples after leukemia progression (bottom). PDX represent leukemic cells derived from C / G patients. Magnification: left (2.5x), middle (5x), right (C / G-CB 40x, PDX, 20x). [Figure 1D]CBFA2T3-GLIS2(C / G)- cord blood (CB) cells induce leukemias that recapitulate primary disease. Comparison of RAM immunophenotypic expression in C / G-CB cells harvested from bone marrow of representative mice at necropsy with primary patient samples and PDX bone marrow xenograft cells. In all three samples, malignant cells were gated based on human CD45 expression and side scatter (SSC). [Figure 1E] CBFA2T3-GLIS2(C / G)-cord blood (CB) cells induce leukemias that recapitulate primary disease. Left and center, representative immunohistochemistry showing high expression of ERG (10x magnification) and CD56 (5x magnification) in the thigh of a representative mouse engrafted with C / G-CB cells. Right, small aggregates of blasts with high CD56 expression detected in a bone marrow biopsy of a chemotherapy-resistant C / G fusion positive patient, consistent with residual, adherent, patchy disease distribution (100x magnification). [Figure 1F] CBFA2T3-GLIS2(C / G)-cord blood (CB) cells induce leukemias that recapitulate the primary disease. Kaplan-Meier plots showing survival in primary (1°), secondary (2°) and tertiary (3°) transplants of C / G-CB cells. [Figure 1G] CBFA2T3-GLIS2(C / G)- cord blood (CB) cells induce leukemias that recapitulate primary disease. Engraftment of C / G-CB cells in bone marrow during symptomatic leukemia, shown as percent of human CD45+. [Figure 1H] CBFA2T3-GLIS2(C / G)- cord blood (CB) cells induce leukemias that recapitulate primary disease. Quantification of CD56+ cells among human CD45+ cells isolated from bone marrow (BM) at autopsy after progression of symptomatic leukemia. [Figure 1I] CBFA2T3-GLIS2 (C / G)- cord blood (CB) cells induce leukemias that recapitulate the primary disease. Expression of acute megakaryocytic leukemia (AMKL) markers CD41 and CD42 in C / G-CB and PDX cells harvested from bone marrow at autopsy. C / G-CB cells were gated on human CD45+ cells. PDX cells were gated on human CD45+CD56+ cells. [Figure 1J]CBFA2T3-GLIS2(C / G)- cord blood (CB) cells induce leukemias that recapitulate the primary disease. Quantification of CD41 / CD42 subsets shown in Figure 1I. Bars indicate the mean + / - standard error of the mean (SEM). [Diagram 2] C / G-CB cells form tight clusters in the bone marrow of mice (related to Figures 1A-1J). Histology of femurs harvested from primary, secondary, and tertiary transplants of C / G-CB cells. [Figure 3A] Expression of CD56 and AMKL markers in C / G-CB xenograft cells after progression of symptomatic leukemia in NSG-SGM3 mice. Percentage of human CD45+ cells in bone marrow, spleen, liver and peripheral blood (PB) in primary (1°), secondary (2°) and tertiary (3°) transplants of mice transplanted with C / G-CB cells. [Figure 3B] Expression of CD56 and AMKL markers in C / G-CB xenograft cells following progression of symptomatic leukemia in NSG-SGM3 mice. Percentage of CD56+ in mouse tissues as described in FIG. 3A. [Figure 3C] Expression of CD56 and AMKL markers in C / G-CB xenograft cells following progression of symptomatic leukemia in NSG-SGM3 mice Percentage of CD41 / CD42 subsets in mouse tissues described in Figure 3A. [Figure 4A] Endothelial cells (ECs) enhance the proliferative potential of C / G-CB cells and promote leukemic progression. Diagram of experimental design. [Figure 4B] Endothelial cells (EC) enhance the proliferation potential of C / G-CB cells and promote leukemic progression. Growth kinetics of C / G-CB and GFP-CB cells in EC co-culture or myeloid promoting conditions (MC). Data are shown as mean + / - standard deviation from three technical replicates. [Figure 4C]Endothelial cells (EC) enhance the proliferation potential of C / G-CB cells and promote leukemic progression. C / GCB cells grown in EC co-culture for 9 weeks were either replated directly into EC co-cultures (direct contact) or into EC transwells (indirect contact) or placed in liquid culture containing serum-free growth medium (SFEM) II (+SCF, FLT3L, and TPO). After 7 days, the number of GFP+ cells was quantified by flow cytometry. Data are shown as the mean + / - standard deviation from three technical replicates. [Figure 4D] Endothelial cells (EC) enhance the proliferative potential of C / G-CB cells and promote leukemic progression. At weeks 6 and 12, a fraction of each culture was transferred to MegaCult cultures. Megakaryocyte (Mk) progenitor-derived colonies were counted and enumerated. Data were normalized to 500 input cells at the start of EC coculture or MC culture. Representative colonies stained with anti-human CD41 and alkaline phosphatase detection system are shown. Data are presented as mean + / - standard deviation from three technical replicates. [Figure 4E] Endothelial cells (ECs) enhance the proliferation potential of C / G-CB cells and promote leukemic progression. Equal numbers of C / G-CB and GFPCB cells were transplanted into NSG-SGM3 mice at the indicated time points (5–10 × 106 / mouse). Due to insufficient proliferation, GFP-CB cells were not transplanted after 3 weeks in either condition, and similarly, for C / G-CB cells, they were not transplanted after 6 weeks in MC culture. Median survival times and Kaplan-Meier survival curves are shown. C / G-CB (N=3 mice / group), GFP-CB (N=2 mice / group). [Figure 4F] Endothelial cells (EC) enhance the proliferative potential of C / G-CB cells and promote leukemic progression. Quantification of CD56+ cells among human CD45+ cells over several weeks in culture. Data are shown as mean + / - standard deviation from three technical replicates. [Figure 4G]Endothelial cells (EC) enhance the proliferative potential of C / G-CB cells and promote leukemic progression. Quantification of CD41 / CD42 subset cells among human CD45+ cells over several weeks in culture. Data are shown as mean + / - standard deviation from three technical replicates. [Figure 4H] Endothelial cells (EC) enhance the proliferation potential of C / G-CB cells and promote leukemic progression. Unsupervised clustering of C / G-CB and GFP-CB cells by uniform manifold and projection (UMAP) analysis of primary AML samples. Dashed circles indicate C / G-CB cells co-cultured with EC at 6 and 12 weeks. NBM = normal bone marrow. [Figure 4I] Endothelial cells (ECs) enhance the proliferative potential of C / G-CB cells and promote leukemic progression. Heatmap of genes differentially expressed in C / G-CB and GFP-CB cells in EC cocultures or MCs. [Figure 4J] Endothelial cells (EC) enhance the proliferative potential of C / G-CB cells and promote leukemic progression. GSEA plot of C / G and HSC signature genes compared to C / G-CB cells in EC co-cultures and MCs. [Figure 5A] Evaluation of RAM and AMKL markers in C / G-CB cells isolated from mice transplanted with engineered cells cultured in EC co-culture or MC. Percentage of human CD45+ cells in bone marrow, spleen, liver, and peripheral blood from mice transplanted with C / G-CB and GFP-CB cells at the indicated time points in EC co-culture or MC. [Figure 5B]Evaluation of RAM and AMKL markers in C / G-CB cells isolated from mice transplanted with engineered cells cultured on EC co-culture or MC. Percentage of CD41 / CD42 subsets among live human CD45+ in mouse tissues listed in Figure 5A. Data analyzing CB cells in the liver of mice transplanted with GFP-CB cells from MC cultures is not included due to insufficient cells present in the sample. Data from peripheral blood from two mice transplanted with C / G-CB cells grown on MC are also not included due to insufficient cells present in the sample. [Figure 5C] Evaluation of RAM and AMKL markers in C / G-CB cells isolated from mice transplanted with engineered cells cultured in EC co-culture or MC. Percentage of CD56+ cells among live human CD45+ cells in mouse tissues listed in Figure 5A. Data analyzing CB cells in the liver of mice transplanted with GFP-CB cells from MC cultures is not included due to insufficient cells present in the sample. Data from peripheral blood from two mice transplanted with C / G-CB cells grown on MC is also not included due to insufficient cells present in the sample. [Figure 6A] C / G-CB cells cultured with EC recapitulate the immunophenotype and morphology of C / G fusion-positive AML. Expression of RAM immunophenotype in C / G-CB cells after 6 weeks in EC coculture or MC. [Figure 6B] C / G-CB cells cultured with EC recapitulate the immunophenotype and morphology of C / G fusion-positive AML. Quantification of CD41 / CD42 subsets at the indicated time points in EC cocultures or MCs. [Figure 6C] C / G-CB cells cultured with EC recapitulate the immunophenotype and morphology of C / G fusion-positive AML. Morphological evaluation of C / G-CB cells cultured with EC or with MC for 9 weeks showed features of megakaryocytic differentiation, including open chromatin, prominent nucleoli, and vacuolated cytoplasm with abundant, focal, basophilic and cytoplasmic blebbing. [Figure 7A]ECs promote transformation of C / G-CB cells. Schematic diagram of transduction and long-term culture of cord blood CD34+ HSPCs from secondary donors. [Figure 7B] EC promotes transformation of C / G-CB cells. Growth rate of transduced cells over several days with EC or MC, measured by cumulative number of GFP+ cells. Shown are the mean + / - standard error from three technical replicates. The growth rate constant k was determined by regression analysis using the equation N(t)=N(0)ekt, where t is measured in days. [Figure 7C] EC promote transformation of C / G-CB cells. After 6 and 12 weeks of culture, a fraction of each culture was transferred to megacult and Mk colonies were counted. Data are normalized to CD34+ input cells at the start of culture and are shown as the mean + / - standard deviation from three technical replicates. [Figure 7D] ECs promote transformation of C / G-CB cells. Expression of RAM immunophenotype in C / G-CB cells after 6 weeks in EC coculture or MC. [Figure 8A] C / G specific genes and pathways recapitulated in C / G-CB cells cultured with ECs and C / G-CB cells cultured with MCs. Expression of ERG, BMP2 and GATA1 (Labeled Expression (Log2 cpm)) in GFP-CB cells and C / G-CB cells in EC and MC conditions over weeks, as well as C / G fusion positive primary and normal bone marrow samples. Univariate gene set enrichment (ssGSEA) scores (Labeled Enrichment Score) of Hedgehog, TGFB and WNT signaling pathways for GFP-CB and C / G-CB cells and normal bone marrow and primary fusion positive samples. [Figure 8B] C / G-specific genes and pathways recapitulated in C / G-CB cells cultured with ECs and C / G-CB cells cultured with MCs. Pathways upregulated (left) and downregulated (right) in C / G-CB cells in EC coculture compared to MCs. [Figure 9A]C / G-specific gene expression. Heatmap showing the expression of C / G-specific focal adhesion and cell adhesion molecule genes. Unsupervised hierarchical clustering shows the clustering of C / G-CB cells cultured with ECs for 6 and 12 weeks, and primary C / G samples. [Figure 9B] C / G-specific gene expression. Heatmap showing expression of genes associated with primary C / G fusion-positive AML. Unsupervised hierarchical clustering shows clustering of C / G-CB cells cultured with ECs for 6 and 12 weeks with primary C / G samples. [Figure 9C] Expression of C / G-specific genes. Heatmap showing expression of HSC signature genes. Unsupervised hierarchical clustering shows clustering of C / G-CB cells cultured with ECs for 6 and 12 weeks with primary C / G samples. [Figure 10A] Integrative transcriptomics of primary samples and C / G-CBs identifies FOLR1 therapeutic targets. Diagram of computational workflow for identifying C / G-specific CAR targets. For details, see Methods and Figure 11. Normal tissues include bulk bone marrow (BM) samples and peripheral blood (PB) CD34+ samples. [Figure 10B] Integrative transcriptomics of primary samples and C / G-CBs identifies FOLR1 therapeutic targets. Expression of C / G-specific CAR targets in primary fusion-positive patients and normal bone marrow (NBM). [Figure 10C] Integrative transcriptomics of primary samples and C / G-CB identifies FOLR1 therapeutic targets. Expression of C / G-specific CAR targets in C / G-CB and GFP-CB cells. [Figure 10D] Integrative transcriptomics of primary samples and C / G-CBs identifies FOLR1 therapeutic targets. Top, a gating strategy was used based on CD45 expression and SSC to identify AML cells and normal lymphocytes, monocytes, and myeloid cells in four representative patients. Bottom, FOLR1 expression in AML blast subpopulations and normal cells. [Figure 10E]Integrative transcriptomics of primary samples and C / G-CBs identifies FOLR1 therapeutic targets. Quantification of FOLR1 expression (geometric mean fluorescence intensity, MFI) among N=15 patients in AML blasts and their normal counterparts. Autofluorescence was used as control. ***, p<0.0005 (paired Student's t-test) [Figure 10F] Integrative transcriptomics of primary samples and C / G-CBs identifies FOLR1 therapeutic targets. Expression of FOLR1 over weeks in EC co-cultures with GFP-CB and C / G-CB. [Figure 10G] Integrative transcriptomics of primary samples and C / G-CBs identifies FOLR1 therapeutic targets. Quantification of FOLR1+ cells over weeks in EC co-cultures with GFP-CBs and C / G-CBs. [Figure 11]Identification of C / G fusion-specific CAR targets. (Related to FIG. 10A) Flow diagram of the identification of genes and CAR-T targets restricted to AML. The procedure involves three main steps: 1) From the log10 transformed normalized gene expression, determine the ratio of expression in AML primary samples to healthy normal hematopoietic tissue samples (bulk bone marrow and CD34+ peripheral blood). The ratio is calculated for each gene from the mean AML expression and the mean normal hematopoietic tissue expression, where the normal tissue value is the divisor and measures above or below expression. A normal curve was fitted to these ratios and this procedure was completed for all heterogeneous AML samples as groups and repeated within fusion and mutation subtypes, and genes with ratios above +2 standard deviations and not expressed in normal hematopoietic tissue were retained for further analysis (N=607). 2) If these AML-restricted genes were found to be significantly overexpressed in fusion-positive patient samples compared to healthy bone marrow, they were further selected and further overexpressed in C / G-CB at 6 and 12 weeks in EC coculture and not expressed in GFP-CB controls, resulting in several target candidates (N=42). 3) Optimal CAR-T targets were selected by identification of candidate genes with cell surface localization ability and those not expressed in healthy tissue controls as described in step 1, but expressed in more than 75% of C / G patient samples with moderate to high expression levels (N=6). [Figure 12] Expression of FOLR1 transcripts in C / G-CB cells cultured with EC. RT-PCR analysis of FOLR1 expression in engineered CB cells and the fusion-positive cell lines M07e and WSU-AML. Expression is normalized as fold change relative to Wk3 samples of GFP-CB / EC. [Figure 13A]Preclinical efficacy of FOLR1 CAR T cells against C / G AML cells. Cytolytic activity of unengineered or FOLR1 CAR-transduced CD8 T cells after 6 hours of co-culture with C / G-CB, WSU-AML, Kasumi-1 FOLR1+ and Kasumi-1 parental cells. Data shown are mean leukocyte specific lysis + / - SD from three technical replicates at the indicated effector:target (E:T) ratios. Data are representative of two donors (see related data in Figure 16). [Figure 13B] Preclinical efficacy of FOLR1 CAR T cells against C / G AML cells. Concentrations of IL-2, IFN-γ, and TNF-α secreted in the supernatants 24 hours after T cell / AML ​​co-culture at an E:T ratio of 1:1, as measured by ELISA. Data are representative of two donors and shown as mean + / - SD from three technical replicates (see related data in Figures 17A-17F). When cytokine concentrations were too low to distinguish, numbers on the x-axis indicate the mean concentration. Statistical significance was determined by unpaired Student's t-test, assuming unequal variances. p<0.05 (*), p<0.005 (**), p<0.0005 (***). [Figure 13C] Preclinical efficacy of FOLR1 CAR T cells against C / G AML cells. Representative flow cytometry analysis of cell proliferation after 4 days of co-culture with target cells at an E:T ratio of 1:1 for unmanipulated and FOLR1 CAR T cells labeled with Cell Proliferation Dye (Celltrace). CAR T cells divided rapidly and Celltrace fluorescence faded after 4 hours of co-culture with FOLR1 positive AML cells. Data are representative of 2 donors. [Figure 13D] Preclinical efficacy of FOLR1 CAR T cells against C / G AML cells. Bioluminescence images of C / G-CB, WSU-AML, Kasumi-1 FOLR1+ and Kasumi-1 leukemia in mice treated with unmanipulated or FOLR1 CAR T cells at 5x106 T cells per mouse. N=5 mice / group. The radiance scale indicates increasing leukemia from blue to red, with X indicating death. [Figure 14A] In vivo efficacy of FOLR1-directed CAR T. (Related to Figures 13A-13D). Quantification of leukemia burden over time based on IVIS radiance in CBFA2T3-GLIS2 transduced HSPC, WSU-AML, Kasumi-1 FOLR1+ and Kasumi-1 xenografts either unmanipulated or treated with FOLR1 CAR T cells at 5x106 / mouse. Leukemia burden is shown per mouse. N=5 mice / group. [Figure 14B] In vivo efficacy of FOLR1-directed CAR T. (Related to Figures 13A-13D). Quantification of human T cells in mouse peripheral blood at the indicated time points after T cell injection. Shown is the frequency of human CD45+CD3+ among DAPI- cells. N=5 mice / group. Data shown are the mean + / - standard deviation from 5 mice. *, p<0.05 (unpaired Student's t-test) [Figure 14C] In vivo efficacy of FOLR1-directed CAR T. (Related to Figures 13A-13D). Kaplan-Meier survival curves of xenografts unengineered or treated with FOLR1 CAR T cells. N=5 / group. Statistical significance of survival was assessed using the log-rank Mantel-Cox. Note: Two C / G-CB-bearing mice treated with CAR T cells died without leukemia and no T cells present in bone marrow, spleen, and liver tissues and peripheral blood, as judged by flow cytometry analysis. [Figure 15A]FORL1-directed CAR T efficiently eliminates C / G-CB cells without affecting HSPC viability. A gating strategy was used to identify hPSC subsets from representative CD34 enriched bone marrow samples from healthy donors. Shown is a representative of 3 donors. The immunophenotype of HSPCs is as follows: CD34+CD38-CD90+CD45RA- (hematopoietic stem cells, HSCs), CD34+CD38-CD90-CD45RA- (multipotent progenitors, MPPs), CD34+CD38-CD90-CD45RA+ multilymphoid progenitors, MLPs), CD34+CD38+CD10+ (common lymphoid progenitors, CLPs), CD34+CD38+CD10-CD123-CD45RA- (megakaryocytic-erythroid progenitors, MEPs), CD34+CD38+CD10-CD123+CD45RA- (common myeloid progenitors, CMPs), and CD34+CD38+CD10-CD123+CD45RA+ (granulocytic-monocytic progenitors, GMPs). [Figure 15B] FORL1-directed CAR T efficiently eliminates C / G-CB cells without affecting HSPC viability. Histogram of FOLR1 expression in normal HSPC subsets. [Figure 15C] FORL1-directed CAR T efficiently eliminates C / G-CB cells without affecting HSPC viability. Quantification of FOLR1+ percent in HSPC subsets from C / G-CB cells (>12 weeks from EC coculture) and three CD34-enriched samples from healthy donors. [Figure 15D] FORL1-directed CAR T efficiently eliminates C / G-CB cells without affecting HSPC viability. Percent specific lysis in C / G-CB cells and HSPC subsets shown in Figure 15C after 4 hours of incubation with unengineered or FOLR1 CAR T cells at an E:T ratio of 2:1. Note that data points for C / G-CB cells are from two technical replicates. Only two of three normal CD34+ samples were used in this experiment. [Figure 15E]FORL1-directed CAR T efficiently eliminates C / G-CB cells without affecting HSPC viability. After 4 hours, co-cultures of healthy donor CD34+ and either unmanipulated or MSLN CAR T cells at an E:T ratio of 2:1 were transferred to methylcellulose containing cytokines for colony-forming cell (CFC) assays. Colonies derived from erythroid (E), granulocyte-macrophage (G, M, and GM) and multipotent granulocyte, erythroid, macrophage, megakaryocyte (GEMM) progenitors were counted and enumerated after 7–10 days. Data are shown as mean + / - SD from three technical replicates per donor. No significant differences in total colony numbers were detected between co-cultures of unmanipulated and FOLR1 CAR T cells in normal HSPCs, as determined by unpaired Student's t-test, assuming unequal variances. Statistical significance was determined by unpaired Student's t-test, assuming unequal variances. [Figure 15F] FORL1-directed CAR T efficiently eliminates C / G-CB cells without affecting HSPC viability. After 4 h, co-cultures of C / G-CB cells with either unengineered or MSLN CAR T cells at an E:T ratio of 2:1 were transferred to methylcellulose containing cytokines for colony forming cell (CFC) assays. Total colonies from C / G-CB cells are counted. Statistical significance was determined by unpaired Student's t-test assuming unequal variances. p<0.05 (*), p<0.005 (**), p<0.0005 (***). [Figure 16] Expression of C / G transcripts in C / G-CB cells. RT-PCR analysis of C / G expression in engineered CB cells and the fusion-positive cell lines M07e and WSU-AML. [Figure 17A]FOLR1 CAR constructs and reactivity of short, medium and long FOLR1 CAR T cells. Schematic of second generation FOLR1 CAR constructs with different IgG4 spacer lengths. SP=GM-CSFR signal peptide, scFv=single chain variable fragment, TM=transmembrane domain, CD=co-stimulatory domain, SD=stimulatory domain, tCD19=truncated CD19, a transduction marker. This anti-FOLR1 scFv can be swapped for different binding domains, including those that bind MEGF10, HPSE2, KLRF2, PCDH19, FRAS1, or other binding domains that bind FOLR1. [Figure 17B] FOLR1 CAR constructs and reactivity of short, medium, and long FOLR1 CAR T cells. Expression of FOLR1 in C / G-CB, M07e, WSU-AML, Kasumi-1 FOLR1+ and Kasumi-1 parental cells. [Figure 17C] FOLR1 CAR constructs and reactivity of short, medium, and long FOLR1 CAR T cells. Cytolytic activity of CD8 T cells unengineered or transduced with short, medium, or long FOLR1 CAR constructs against C / G-CB, M07e, WSU-AML, Kasumi-1 FOLR1+ and Kasumi-1 parental cells in a 6 hour assay. Shown is the mean percent specific lysis + / - SD from three technical replicates at the indicated effector:target (E:T) ratios. [Figure 17D] FOLR1 CAR constructs and reactivity of short, medium, and long FOLR1 CAR T cells. Concentrations of IL-2, IFN-γ, and TNF-α secreted in the supernatant after 24 hours of CD8 T cell / AML ​​co-culture at an E:T ratio of 1:1. Shown are the mean + / - SD from three technical replicates. [Figure 17E]FOLR1 CAR constructs and reactivity of short, medium, and long FOLR1 CAR T cells. Representative flow plots showing expression of NFAT, NF-kB, and AP-1 in Jurkat Nur77 reporters transduced with FOLR1 CAR constructs cultured alone (top) or co-cultured with Kasumi-1 FOLR1+ target cells at an E:T ratio of 1:1 for 24 hours (bottom). Kasumi-1 FOLR1+ cells were labeled with Violet Cell Proliferation Dye to distinguish them from Jurkat cells. Transduced Jurkat cells were gated based on tCD19 expression. Numbers in the upper right corner indicate the percentage of positive cells. Analysis was performed 4 days after transduction. [Figure 17F] FOLR1 CAR constructs and reactivity of short, medium, and long FOLR1 CAR T cells. Quantification of the percentage of NFAT+, NF-kB+, and AP-1+ cells in Figure 17E. [Figure 18] Antibody information. [Figure 19]Sequences in support of the present disclosure include IgG4 hinge coding sequence-A (SEQ ID NO:1), IgG4 hinge coding sequence-B (SEQ ID NO:2), IgG4 hinge S10P (SEQ ID NO:135), hinge+middle spacer (DS) (SEQ ID NO:136), IgG4-int(DS) coding sequence (SEQ ID NO:3), IgG4-long coding sequence (SEQ ID NO:4), CD3ζ coding sequence (SEQ ID NO:5), CD3ζ protein-A (SEQ ID NO:6), CD3ζ protein-B (SEQ ID NO:7), 4-1BB signaling coding sequence-A (SEQ ID NO:8), 4-1BB signaling coding sequence-B (SEQ ID NO:9), 4-1BB protein-A (SEQ ID NO:10), 4-1BB protein-B (SEQ ID NO:11), 4-1BB protein-A (SEQ ID NO:12), 4-1BB protein-B (SEQ ID NO:13), 4-1BB protein-B (SEQ ID NO:14), 4-1BB protein-B (SEQ ID NO:15), 4-1BB protein-C (SEQ ID NO:16), 4-1BB protein-D (SEQ ID NO:17), 4-1BB protein-D (SEQ ID NO:18), 4-1BB protein-D (SEQ ID NO:19), 4-1BB protein-D (SEQ ID NO:20), 4-1BB protein-D (SEQ ID NO:21), 4-1BB protein-D (SEQ ID NO:22), 4-1BB protein-D (SEQ ID NO:23), 4-1BB protein-D (SEQ ID NO:24), 4-1BB protein-D (SEQ ID NO:25), 4-1BB protein-D (SEQ ID NO:26), 4-1BB protein-D (SEQ ID NO:27), 4-1BB protein-D (SEQ ID SEQ ID NO:10), 4-1BB protein-B (SEQ ID NO:11), CD28TM coding sequence-A (SEQ ID NO:12), CD28TM coding sequence-B (SEQ ID NO:13), CD28TM coding sequence-C (SEQ ID NO:14), CD28TM protein-A (SEQ ID NO:15), CD28TM protein-B (SEQ ID NO:16), T2A coding sequence (SEQ ID NO:137), P2A (SEQ ID NO:17), T2A (SEQ ID NO:18), E2A (SEQ ID NO:19), F2A (SEQ ID NO:20), tCD19 coding sequence (SEQ ID NO:117), Psi (SEQ ID NO:118), RRE (SEQ ID NO:119), and Flap (SEQ ID NO:120). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] For many years, the treatment of choice for cancer has been surgery, chemotherapy, and / or radiation therapy. In recent years, more targeted therapies have emerged to specifically target cancer cells by identifying and exploiting specific molecular and / or immunophenotypic changes predominantly found in those cells. For example, many cancer cells preferentially express certain antigens on their cell surface, and these antigens provide targets for successful antibody and cell-based therapies.

[0012] Although targeted therapies have been successful in the treatment of many cancers, targeted therapy for acute myeloid leukemia (AML) remains a challenge given the high overlap in target antigens expressed in AML and normal hematopoietic cells.

[0013] Pediatric acute myeloid leukemia (AML) is a heterogeneous group of diseases classified based on morphology, lineage, and genetic features (Rubnitz, Blood 119:5980-8, 2012), and its prognosis depends on several cytogenetic and molecular features. Despite improvements in overall survival and remission induction rates for children with AML over the past 30 years, outcomes vary widely depending on the biological subtype of AML (Kim, Blood Res. 55(Suppl):S5-S13, 2020). Genomic investigations of AML have led to new genomic classification and predictive biomarkers to better stratify risk and survival outcomes (Arber, Semin Hematol. 56:90-5, 2019, and Arber et al., Blood 127:2391-405, 2016). One such genetic prognostic marker is the CBFA2T3-GLIS2(C / G) fusion gene. The C / G fusion gene characterizes a highly malignant, pediatric-specific subtype of leukemia, which is highly resistant to conventional treatments and has a low survival rate of 15-30% (Masetti et al., Br J Haematol. 184(3):337-347, 2019).

[0014] Genes restricted to C / G AML and other AML were discovered through extensive target discovery efforts by TARGET and Target Pediatric AML (TpAML). These genes were further filtered to include genes upregulated in both C / G AML and C / G-cord blood (CB) cells cultured with endothelial cells, and to include genes encoding proteins restricted to the plasma membrane. This resulted in seven C / G fusion-specific targets, namely FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and FRAS1, which were confirmed to be highly expressed in C / G patients and C / G-CB cells, but completely silent in normal hematopoiesis. The present disclosure provides targeted therapeutic treatments with binding domains that bind FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1 for the treatment of AML, including C / G AML.

[0015] The targeted therapeutic agents that bind to FOLR1 disclosed herein may further be used to treat other cancers, including other leukemias, peritoneal cancer, fallopian tube cancer, ovarian cancer (e.g., epithelial ovarian cancer), endometrial cancer, cervical cancer, breast cancer (e.g., triple-negative breast cancer, HER2- breast cancer), bladder cancer, renal cell carcinoma, pituitary tumors, lung cancer (e.g., lung adenocarcinoma or epithelial lung cancer, e.g., non-small cell lung cancer), uterine cancer, squamous cell carcinoma, ureteral cancer, urethral cancer, osteosarcoma, or transitional cell carcinoma.

[0016] Particular examples of targeted therapeutics disclosed herein include chimeric antigen receptors (CARs). In certain embodiments, the CAR comprises a binding domain that binds to FOLR1. In certain embodiments, the binding domain that binds to FOLR1 is farletuzumab scFv. In certain embodiments, the CAR comprises a binding domain that binds to MEGF10. In certain embodiments, the CAR comprises a binding domain that binds to HPSE2. In certain embodiments, the CAR comprises a binding domain that binds to KLRF2. In certain embodiments, the CAR comprises a binding domain that binds to PCDH19. In certain embodiments, the CAR comprises a binding domain that binds to FRAS1.

[0017] In certain embodiments, the present disclosure provides a CAR having an intermediate spacer region. In certain embodiments, the intermediate spacer region comprises the hinge region and CH3 domain of IgG4. In certain embodiments, the spacer is a short spacer. In certain embodiments, the spacer is a long spacer.

[0018] In certain embodiments, the present disclosure provides CARs with transmembrane domains, including those of CD28. In certain embodiments, the present disclosure provides CARs with intracellular effector domains, including those of 4-1BB and CD3ζ signaling domains.

[0019] In a particular embodiment, the CAR comprising a binding domain that binds to FOLR1 is encoded by SEQ ID NO: 134.

[0020] The present disclosure also provides targeted therapeutics for the treatment of cancer that are based on a form of antibody, for example, an antibody drug conjugate, an antibody radioisotope conjugate, an antibody immunotoxin conjugate, or an antibody nanoparticle conjugate.

[0021] The present disclosure also provides methods and assays for further investigating the cancer biology of C / G AML. The cancer biology of C / G AML can be investigated by developing models of C / G AML cells prepared by transducing C / G fusion genes into target cells. In certain embodiments, the cells include cord blood (CB) hematopoietic stem and progenitor cells (HSPCs). CB-HSPC cells transduced with C / G fusion genes are referred to herein as C / G-CB cells. Furthermore, to model C / G AML cells, the microenvironment of C / G AML is reconstituted by culturing the transduced cells either in animal models or in monoculture under conditions that stimulate the microenvironment. In certain embodiments, the conditions that stimulate the microenvironment include co-culture with endothelial cells. In certain embodiments, the conditions that stimulate the microenvironment include bone marrow-promoting conditions.

[0022] Aspects of the present disclosure are described herein with further details and options as follows: (i) immune cells, (ii) cell sample collection and cell enrichment, (iii) genetic engineering of cell populations to express chimeric antigen receptors (CARs), (iii-a) genetic engineering techniques, (iii-b) subcomponents of CARs, (iii-bi) binding domains, (iii-b-ii) spacer regions, (iii-b-iii) transmembrane domains, (iii-b-iv) intracellular effector domains, (iii-bv) linkers, (iii-b-vi) control mechanisms including tag cassettes, transduction markers, and / or suicide switches, (iv) cell activation culture conditions, (v) ex vivo produced cell preparations, (vi) antibody conjugates, (vii) compositions, (viii) methods of use, (ix) baseline levels obtained from control populations, (x) methods of cell transformation, (xi) exemplary embodiments, (xii) experimental examples, and (xiii) conclusions. These headings are provided for organizational purposes only and do not limit the scope or interpretation of the present disclosure.

[0023] (i) Immune cells. The present disclosure describes cells engineered to express a CAR. The engineered cells may include T cells, B cells, natural killer (NK) cells, NK-T cells, monocytes / macrophages, lymphocytes, hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), and / or a mixture of HSCs and HPCs (i.e., HSPCs). In certain embodiments, the engineered cells include T cells.

[0024] Several different subsets of T cells have been discovered, each with different functions. For example, the majority of T cells have a T cell receptor (TCR) that exists as a complex of several proteins. The actual T cell receptor is produced by independent T cell receptor alpha and beta (TCRα and TCRβ) genes and is composed of two separate peptide chains called the α- and β-TCR chains.

[0025] γδ T cells represent a small subset of T cells that have a distinct T cell receptor (TCR) on their surface. In γδ T cells, the TCR is composed of one γ chain and one δ chain. This group of T cells is less common than αβ T cells (2% of all T cells).

[0026] CD3 is expressed on all mature T cells. Activated T cells express 4-1BB (CD137), CD69, and CD25. CD5 and the transferrin receptor are also expressed on T cells.

[0027] T cells can be further classified into helper cells (CD4+ T cells) and cytotoxic T cells, including cytolytic T cells (CTL, CD8+ T cells). T helper cells assist other white blood cells in immunological processes, including maturation of B cells into plasma cells and activation of cytotoxic T cells and macrophages, among other functions. These cells are also known as CD4+ T cells, since they express the CD4 protein on their surface. Helper T cells are activated by MHC class II molecules expressed on the surface of antigen-presenting cells (APCs) when present with peptide antigens. Once activated, they divide rapidly and secrete small proteins called cytokines, which regulate or support an active immune response.

[0028] Cytotoxic T cells destroy virus-infected and tumor cells and are involved in transplant rejection. These cells are also known as CD8+ T cells because they express the CD8 glycoprotein on their surface. These cells recognize targets by binding to antigens associated with MHC class I, which is present on the surface of almost every cell in the body.

[0029] As used herein, "central memory" T cells (or "TCM") refer to antigen-experienced CTLs that express CD62L or CCR7 and CD45RO on their surface, and do not express or express less CD45RA compared to naive cells. In certain embodiments, central memory cells are positive for expression of CD62L, CCR7, CD25, CD127, CD45RO, and CD95, and express less CD45RA compared to naive cells.

[0030] As used herein, "effector memory" T cells (or "TEMs") refer to antigen-experienced T cells that do not express CD62L on their surface or express less of it compared to central memory cells, and do not express or express less of CD45RA compared to naive cells. In certain embodiments, effector memory cells are negative for expression of CD62L and CCR7 compared to naive or central memory cells, and have variable expression of CD28 and CD45RA. Effector T cells are positive for granzyme B and perforin compared to memory or naive T cells.

[0031] As used herein, "naive" T cells refer to T cells that have not experienced an antigen, which express CD62L and CD45RA, and do not express CD45RO, in comparison to central or effector memory cells. In certain embodiments, naive CD8+ T lymphocytes are characterized by the expression of phenotypic markers of naive T cells, including CD62L, CCR7, CD28, CD127, and CD45RA.

[0032] Natural killer cells (also known as NK cells, K cells, and killer cells) are activated in response to interferon or macrophage-derived cytokines. They play a role in containing viral infections while the adaptive immune response generates antigen-specific cytotoxic T cells that can clear the infection. NK cells express CD8, CD16, and CD56, but not CD3.

[0033] NK cells include NK-T cells. NK-T cells are a specialized population of T cells that express a semi-invariant T cell receptor (TCRab) and a surface antigen that is normally associated with natural killer cells. NK-T cells contribute to antibacterial and antiviral immune responses and promote tumor-associated immune surveillance or immune suppression. Like natural killer cells, NK-T cells can also induce perforin, Fas, and TNF-related cytotoxicity. Activated NK-T cells can produce IFN-γ and IL-4. In certain embodiments, NK-T cells are CD3+ / CD56+.

[0034] Macrophages (and their precursors, monocytes) are present in all tissues in the body (and occasionally in microglia, Kupffer cells, and osteoclasts), where they engulf apoptotic cells, pathogens, and other non-self components. Monocytes / macrophages express CD11b, F4 / 80, CD68, CD11c, IL-4Rα, and / or CD163.

[0035] Immature dendritic cells (i.e., before activation) engulf antigens and other non-self components at their outer periphery and then, in their activated form, migrate to T cell areas of lymphoid tissues where they present antigens to T cells. Dendritic cells express CD1a, CD1b, CD1c, CD1d, CD21, CD35, CD39, CD40, CD86, CD101, CD148, CD209, and DEC-205.

[0036] Hematopoietic stem / progenitor cells or HSPCs refer to the combination of hematopoietic stem cells and hematopoietic progenitor cells.

[0037] Hematopoietic stem cells refer to undifferentiated hematopoietic cells that are capable of either self-renewal in vivo and essentially unlimited proliferation in vitro, and can differentiate into all other hematopoietic cell types.

[0038] Hematopoietic progenitor cells are hematopoietic stem cells or cells derived from fetal tissue that can further differentiate into mature cell types. In certain embodiments, hematopoietic progenitor cells are CD24 lo Lin - CD117 + Hematopoietic progenitor cells. HPCs can differentiate into (i) myeloid progenitor cells that ultimately give rise to monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes / platelets, or dendritic cells, or (ii) lymphoid progenitor cells that ultimately give rise to T cells, B cells, and NK cells.

[0039] HSPCs can be positive for specific markers that are expressed at increased levels in HSPCs relative to other hematopoietic cell types. For example, such markers include CD34, CD43, CD45RO, CD45RA, CD59, CD90, CD109, CD117, CD133, CD166, HLA DR, or combinations thereof. Also, the HSPCs can be negative for markers that are expressed relative to other hematopoietic cell types. For example, such markers include Lin, CD38, or combinations thereof. Preferably, the HSPCs are negative for CD34 + It is a cell.

[0040] The expression that a cell or population of cells is "positive" for or expresses a particular marker refers to the detectable presence of the particular marker on or within the cell. When referring to a surface marker, the term can refer to the presence of surface expression detected by flow cytometry, for example, by staining with an antibody that specifically binds to the marker and detecting the antibody, where the staining is detectable by flow cytometry at a level substantially greater than that detected using an isotype-matched control under otherwise identical conditions and the same procedure, and / or at a level substantially similar to that for cells known to be positive for the marker, and / or at a level substantially higher than that for cells known to be negative for the marker.

[0041] The expression that a cell or a population of cells is "negative" for a particular marker or lacks expression of the marker refers to the absence of substantial detectable presence of the particular marker on or within the cell.When referring to a surface marker, the term can refer to the absence of surface expression detected by flow cytometry, for example, by staining with an antibody that specifically binds to the marker and detecting the antibody, where the staining is not detected by flow cytometry at a level substantially greater than that detected by using an isotype-matched control under otherwise identical conditions and performing the same procedure, and / or at a level substantially lower than that for cells known to be positive for the marker, and / or at a level substantially similar to that for cells known to be negative for the marker.

[0042] The cells that are genetically engineered according to the teachings of the present disclosure may be patient-derived (autologous) or allogeneic, as appropriate, as well as in vivo or ex vivo. In certain embodiments, the genetically engineered cells comprise CD4+ or CD8+ T cells.

[0043] (ii) Cell sample collection and cell enrichment. Methods for sample collection and enrichment are known to those of skill in the art. In some embodiments, the cells are derived from a cell line. In certain embodiments, the cells are derived from a human. In some embodiments, the cells are obtained from a xenogeneic source, e.g., mouse, rat, non-human primate, or pig.

[0044] In some embodiments, the T cells are derived or isolated from a sample, such as whole blood, peripheral blood mononuclear cells (PBMCs), white blood cells, bone marrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node, gut-associated lymphoid tissue, mucosa-associated lymphoid tissue, spleen, other lymphoid tissue, liver, lung, stomach, intestine, colon, kidney, pancreas, breast, bone, prostate, cervix, testes, ovaries, tonsils, or other organs, and / or cells derived therefrom. In certain embodiments, cells from the circulating blood of a subject are obtained, for example, by apheresis or leukapheresis. In certain embodiments, the sample includes lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, HSCs, HPCs, HSPCs, red blood cells, and / or platelets, and in some aspects includes cells other than red blood cells and platelets, which require further processing.

[0045] In some embodiments, blood cells collected from a subject are washed to remove the plasma fraction and place the cells in a suitable buffer or medium for subsequent processing steps. In certain embodiments, the cells are washed with phosphate buffered saline (PBS). In some embodiments, the washing solution lacks calcium and / or magnesium and / or many or all divalent cations. Washing can be accomplished using a semi-automated "flow-through" centrifuge (e.g., Cobe 2991 cell processor, Baxter) according to the manufacturer's instructions. Tangential flow filtration (TFF) can also be performed. In certain embodiments, the cells can be resuspended in various biocompatible buffers after washing, such as PBS without Ca++ / Mg++.

[0046] The isolation may involve one or more of a variety of cell preparation and separation steps, including separation based on one or more properties, such as size, density, sensitivity or resistance to a particular reagent, and / or affinity for an antibody or other binding partner, e.g., immunoaffinity. In certain embodiments, the isolation is performed sequentially and / or simultaneously using the same device or equipment in a single process stream. In certain embodiments, the isolation, culture, and / or manipulation of the different populations is performed from the same starting material, e.g., from the same sample.

[0047] In certain embodiments, samples can be enriched for T cells using density-based cell separation and related methods. For example, white blood cells can be separated from other cell types contained in peripheral blood by lysing red blood cells and centrifugation of the sample on a Percoll or Ficoll gradient.

[0048] In certain embodiments, bulk T cell populations that are not enriched for a particular T cell type may be used. In certain embodiments, selected T cell types may be enriched and / or isolated based on positive and / or negative selection based on cell markers. In positive selection, cells with bound cell markers are retained for further use. In negative selection, cells that are not bound by capture agents, such as antibodies against cell markers, are retained for further use. In some instances, both fractions may be retained for further use.

[0049] The separation does not necessarily result in the enrichment or removal of 100% of a particular cell population or cell that expresses a particular marker.For example, the positive selection or enrichment of a particular type of cell refers to increasing the number or percentage of such cells, but does not necessarily result in the complete absence of cells that do not express the marker.Similarly, the negative selection, removal or depletion of a particular type of cell refers to decreasing the number or percentage of such cells, but does not necessarily result in the complete removal of all such cells.

[0050] In some instances, multiple separation steps are performed and the positively or negatively selected fraction from one step is subjected to another separation step, eg, a subsequent positive or negative selection.

[0051] In some embodiments, antibodies or binding domains against cell markers are attached to a solid support or matrix, such as magnetic or paramagnetic beads, allowing for the separation of cells for positive and / or negative selection. For example, in some embodiments, the cells and cell populations are separated or isolated using immunomagnetic (or affinity magnetic) separation techniques (reviewed in Methods in Molecular Medicine, vol. 58: Metastasis Research Protocols, Vol. 2: Cell Behavior In Vitro and In Vivo, p 17-25 Edited by: SA Brooks and U. Schumacher (Copyright) Humana Press Inc., Totowa, NJ). See also US 4,452,773, US 4,795,698, US 5,200,084, and EP 452342.

[0052] In some embodiments, affinity-based selection is via magnetic activated cell sorting (MACS) (Miltenyi Biotec, Auburn, CA). The MACS system allows for high purity selection of cells with attached magnetized particles. In certain embodiments, MACS operates in a mode where non-target and target species are eluted sequentially after application of an external magnetic field. That is, cells attached to magnetized particles are fixed in place and unattached species are eluted. Then, after this first elution step is completed, the species captured in this magnetic field and not eluted are released in some way that allows them to be eluted and recovered. In certain embodiments, the non-target cells are labeled and depleted from the heterogeneous population of cells.

[0053] In some embodiments, the cell populations described herein are collected and enriched (or depleted) via flow cytometry, where cells stained for multiple cell surface markers are carried in a fluid stream. In some embodiments, the cell populations described herein are collected and enriched (or depleted) via preparative-scale (FACS) sorting. In certain embodiments, the cell populations described herein are collected and enriched (or depleted) by the use of a microelectromechanical system (MEMS) chip in combination with a FACS-based detection system (see, e.g., WO 2010 / 033140, Cho et al. (2010) Lab Chip 10, 1567-1573, and Godin et al. (2008) J Biophoton. 1(5):355-376). In both cases, cells can be labeled with multiple markers, allowing for the isolation of specific cell subsets with high purity.

[0054] Cell markers for different T cell subpopulations are described above. In certain embodiments, specific T cell subpopulations, such as cells that are positive for or express high levels of one or more surface markers, such as CCR7, CD45RO, CD8, CD27, CD28, CD62L, CD127, CD4, and / or CD45RA T cells, are isolated by positive or negative selection techniques. CD3+, CD28+ T cells can be positively selected and expanded using anti-CD3 / anti-CD28 conjugated magnetic beads (e.g., DYNABEADS® M-450 CD3 / CD28 T Cell Expander).

[0055] In certain embodiments, a CD8+ or CD4+ selection step is used to separate CD4+ helper and CD8+ cytotoxic T cells. Such CD8+ and CD4+ populations can be further divided into subpopulations by positive or negative selection for markers expressed or relatively highly expressed in one or more subpopulations of naive, memory, and / or effector T cells.

[0056] In some embodiments, enrichment of central memory T (TCM) cells is performed. In certain embodiments, memory T cells are present in both CD62L subsets of CD8+ peripheral blood lymphocytes. PBMCs can be enriched or depleted for CD62L, CD8 and / or CD62L+CD8+ fractions using, for example, anti-CD8 and anti-CD62L antibodies.

[0057] In some embodiments, enrichment for central memory T (TCM) cells is based on positive or high surface expression of CCR7, CD45RO, CD27, CD62L, CD28, CD3, and / or CD127. In some aspects, it is based on negative selection for cells expressing or highly expressing CD45RA and / or granzyme B. In some aspects, isolation of a CD8+ population enriched for TCM cells is performed by depletion of cells expressing CD4, CD14, CD45RA, and positive selection or enrichment for cells expressing CCR7, CD45RO, and / or CD62L. In one aspect, enrichment for central memory T (TCM) cells is performed starting from a negative fraction of cells selected on the basis of CD4 expression, which is subjected to negative selection on the basis of expression of CD14 and CD45RA, and positive selection on the basis of CD62L. Such selections in some aspects are performed simultaneously, and in other aspects sequentially in either order. In some embodiments, the same CD4 expression-based selection step used to prepare the CD8+ cell population or subpopulation is also used to generate the CD4+ cell population or subpopulation, and thus both the positive and negative fractions from the CD4-based separation are retained and optionally used in one or more subsequent further positive or negative selection steps.

[0058] In certain embodiments, a sample of PBMCs or other leukocyte samples is subjected to selection of CD4+ cells, where both the negative and positive fractions are retained, which are then subjected to negative selection based on expression of CD14 and CD45RA or RORl, and positive selection based on markers characteristic of central memory T cells, e.g., CCR7, CD45RO, and / or CD62L, in either order.

[0059] In certain embodiments, PBMCs are isolated on Lymphoprep (StemCell Technologies, Catalog No. 07851). In certain embodiments, CD4+ and / or CD8+ T cells are isolated from PBMCs using negative magnetic selection. In certain embodiments, negative magnetic selection comprises the use of Easy Sep Human CD4+ T Cell Isolation Kit II (StemCell Technologies, Catalog No. 17952) and Easy Sep Human CD8+ T Cell Isolation Kit II (StemCell Technologies, Catalog No. 17953).

[0060] Other cell types can be enriched based on known marker profiles and techniques, for example, CD34+ HSCs, HSPs, and HSPCs can be enriched using anti-CD34 antibodies directly or indirectly coupled to magnetic particles in combination with a magnetic cell separator, e.g., the CliniMACS® Cell Separation System (Miltenyi Biotec, Bergisch Gladbach, Germany).

[0061] (iii) Engineering the cell population to express a chimeric antigen receptor (CAR). The cell population is engineered to express a chimeric antigen receptor (CAR) as described herein.

[0062] (iii-a) Genetic engineering techniques. The desired gene encoding the CAR disclosed herein can be introduced into cells by any method known in the art, including transfection, electroporation, microinjection, lipofection, calcium phosphate transfection, infection with a viral or bacteriophage vector containing the gene sequence, cell fusion, chromosomal gene transfer, microcellular gene transfer, spheroplast fusion, in vivo nanoparticle delivery, etc. Many techniques for introducing foreign genes into cells are known in the art (see, e.g., Loeffler and Behr, 1993, Meth. Enzymol. 217:599-618; Cohen, et al., 1993, Meth. Enzymol. 217:618-644; Cline, 1985, Pharmac. Ther. 29:69-92) and can be used, provided that they do not unduly disrupt the development and physiological functions required by the recipient cells. The technique allows for the gene to be stably introduced into the cell, so that it is expressible by the cell and, in some cases, preferably heritable and expressible by the cell's progeny.

[0063] The term "gene" refers to a nucleic acid sequence (used synonymously with polynucleotide or nucleotide sequence) that encodes a CAR. This definition includes various sequence polymorphisms, mutations, and / or sequence variants, but such changes do not substantially affect the function of the encoded CAR. The term "gene" can include not only the coding sequence, but also regulatory regions, such as promoters, enhancers, and termination regions. The term can further include variants resulting from alternative splicing sites, along with all introns and other DNA sequences that are spliced ​​out of the mRNA transcript. The gene sequence that encodes the molecule can be DNA or RNA that directs the expression of the chimeric molecule. These nucleic acid sequences can be sequences of DNA strands that are transcribed into RNA or RNA sequences that are translated into proteins. The nucleic acid sequences include both full-length nucleic acid sequences and non-full-length sequences that are derived from full-length proteins. The sequences can also include degenerate codons of the native sequence or sequences that can be introduced to provide codon preferences for a particular cell type. Portions of the complete gene sequence are referenced throughout this disclosure, as will be understood by those of skill in the art.

[0064] Genetic sequences encoding CARs are provided herein and can also be readily prepared from the relevant amino acid sequences by synthetic or recombinant methods and other descriptions provided herein. In embodiments, the genetic sequence encoding any of these sequences can also have one or more restriction enzyme sites at the 5' and / or 3' end of the coding sequence to facilitate removal of the genetic sequence encoding the sequence and replacement with another genetic sequence encoding a different sequence. In embodiments, the genetic sequence encoding the sequence can be codon optimized for expression in mammalian cells.

[0065] "Encoding" refers to the property of a particular sequence of nucleotides contained in a gene, e.g., a cDNA or mRNA, to serve as a template for the synthesis of other polymers, e.g., a defined sequence of amino acids. Thus, a gene encodes a protein when the protein is produced in a cell or other biological system by transcription and translation of the mRNA corresponding to that gene. A "gene sequence encoding a protein" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence or amino acid sequences of substantially similar structure and function.

[0066] The polynucleotide gene sequences encoding the multiple parts of the CAR to be expressed can be operably linked to each other and to the relevant regulatory sequences. For example, functional linkage can exist between regulatory sequences and foreign nucleic acid sequences to cause the latter to be expressed. In another example, a first nucleic acid sequence can be operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence when the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, if necessary or useful, link the coding regions in the same reading frame.

[0067] In any of the embodiments described herein, the polynucleotide can include a polynucleotide encoding a self-cleaving polypeptide, the polynucleotide encoding the self-cleaving polypeptide being disposed between the polynucleotide encoding the CAR construct and the polynucleotide encoding the transduction marker (e.g., tCD19 or tEGFR). Exemplary self-cleaving polypeptides include 2A peptides from porcine teschovirus-1 (P2A), Thosea asigna virus (T2A), equine rhinitis A virus (E2A), foot and mouth disease virus (F2A), or variants thereof (see FIG. 36). Further exemplary nucleic acid and amino acid sequences of 2A peptides are described, for example, in Kim et al. (PLOS One 6:e18556 (2011).

[0068] A "vector" is a nucleic acid molecule capable of transporting another nucleic acid. A vector can be, for example, a plasmid, cosmid, virus, or phage. An "expression vector" is a vector that, when present in the appropriate environment, is capable of directing the expression of a protein encoded by one or more genes that the vector carries.

[0069] "Lentivirus" refers to a genus of retroviruses that are capable of infecting dividing and non-dividing cells. Some examples of lentiviruses include HIV (human immunodeficiency viruses, including HIV types 1 and 2), equine infectious anemia virus, feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), and simian immunodeficiency virus (SIV).

[0070] A "retrovirus" is a virus with an RNA genome. A "gammaretrovirus" refers to a genus of the Retroviridae family. Exemplary gammaretroviruses include murine stem cell virus, murine leukemia virus, feline leukemia virus, feline sarcoma virus, and avian reticuloendotheliosis virus.

[0071] Retroviral vectors (see Miller, et al., 1993, Meth. Enzymol. 217:581-599) may be used. In such embodiments, the gene to be expressed is cloned into the retroviral vector in order to deliver it to the cell. In certain embodiments, the retroviral vector contains all of the cis-acting sequences necessary for packaging and integration of the viral genome, i.e., (a) long terminal repeats (LTRs), or portions thereof, at each end of the vector, (b) primer binding sites for negative and positive strand DNA synthesis, and (c) packaging signals necessary for integration of genomic RNA into virions. Further details on retroviral vectors can be found in Boesen, et al., 1994, Biotherapy 6:291-302; Clowes, et al., 1994, J. Clin. Invest. 93:644-651; Kiem, et al., 1994, Blood 83:1467-1473; Salmons and Gunzberg, 1993, Human Gene Therapy 4:129-141; and Grossman and Wilson, 1993, Curr. Opin. in Genetics and Devel. 3:110-114. Adenoviruses, adeno-associated viruses (AAV) and alphaviruses can also be used. Kozarsky and Wilson, 1993, Current Opinion in Genetics and Development 3:499-503, Rosenfeld, et al., 1991, Science 252:431-434, Rosenfeld, et al., 1992, Cell 68:143-155, Mastrangeli, et al. al., 1993, J. Clin. Invest. 91:225-234, Walsh, et al., 1993, Proc. Soc. Exp. Bioi. Med. 204: 289-300, and Lundstrom, 1999, J. Recept. Signal Transduct.Other gene transfer methods include the use of mammalian artificial chromosomes (Vos, 1998, Curr. Op. Genet. Dev. 8:351-359), liposomes (Tarahovsky and Ivanitsky, 1998, Biochemistry (Mosc) 63:607-618), ribozymes (Branch and Klotman, 1998, Exp. Nephrol. 6:78-83), and triplex DNA (Chan and Glazer, 1997, J. Mol. Med. 75:267-282).

[0072] There are numerous viral vectors that are suitable for use within the scope of this disclosure, including those identified for human gene therapy applications (see Pfeifer and Verma, 2001, Ann. Rev. Genomics Hum. Genet. 2:177). Methods of using retroviral and lentiviral vectors and packaging cells for transducing mammalian host cells with viral particles containing a CAR transgene are described, for example, in US 8,119,772; Walchli, et al., 2011, PLoS One 6:327930; Zhao, et al., 2005, J. Immunol. 174:4415; Engels, et al., 2003, Hum. Gene Ther. 14:1155; Frecha, et al., 2010, Mol. Ther. 18:1748; and Verhoeyen, et al., 2009, Methods Mol. Biol. 506:97. Retroviral and lentiviral vector constructs and expression systems are also commercially available.

[0073] Targeted genetic engineering methods can also be used. The CRISPR (clustered regularly interspaced short palindromic repeats) / Cas (CRISPR associated protein) nuclease system is an engineered nuclease system used in bacterial based genetic engineering. Information regarding the CRISPR-Cas system and its components can be found in, for example, US8697359, US8771945, US8795965, US8865406, US8871445, US8889356, US8889418, US8895308, US8906616, US8932814, US8945839, US8993233 and US8999641 and US8999641. and related applications WO2014 / 018423, WO2014 / 093595, WO2014 / 093622, WO2014 / 093635, WO2014 / 093655, WO2014 / 093661, WO2014 / 093694, WO2014 / 093701, WO2014 / 093709, WO2014 / 093712, WO2014 / 093718, WO2014 / 145599, WO2014 / 204723, WO2014 / 204724, WO2014 / 204725, WO2014 / 204726, WO2 014 / 204727, WO2014 / 204728, WO2014 / 204729, WO2015 / 065964, WO2015 / 089351, WO2015 / 089354,

[0023] These and other related applications are described in WO2015 / 089364, WO2015 / 089419, WO2015 / 089427, WO2015 / 089462, WO2015 / 089465, WO2015 / 089473 and WO2015 / 089486, WO2016205711, WO2017 / 106657, WO2017 / 127807 and related applications thereof.

[0074] Particular embodiment uses zinc finger nuclease (ZFN) as gene editing agent.ZFN is a class of site-specific nuclease that is engineered to bind and cut DNA at specific position.ZFN is used to introduce double strand break (DSB) at specific site of DNA sequence, which allows ZFN to target unique sequence in genome of various different cells.For further information regarding ZFNs and ZFNs useful within the teachings of the present disclosure, see, e.g., US 6,534,261, US 6,607,882, US 6,746,838, US 6,794,136, US 6,824,978, 6,866,997, US 6,933,113, 6,979,539, US 7,013,219, US 7,030,215, US 7,220,719, US 7,241,573, US 7,241,574, US 7,585,849, US 7,595,376, US 6,903,185, US 6,479,626, US 2003 / 0232410 and US 2009 / 0203140 and Gaj et al., Nat Methods,2012,9(8):805-7, Ramirez et al., Nucl Acids Res,2012,40(12):5560-8, Kim et al.,Genome Res,2012,22(7):1327-33, Urnov et al.,Nature Reviews Genetics,2010,11:636-646, Miller,et al.Nature biotechnology 25,778-785(2007), Bibikova,et al.Science 300,764(2003), Bibikova,et al.Genetics 161,1169-1175(2002), Wolfe,et al.Annual review of biophysics and biomolecular structure 29, 183-212 (2000); Kim, et al. Proceedings of the National Academy of Sciences of the United States of America 93, 1156-1160 (1996); and Miller, et al. The EMBO journal 4, 1609-1614 (1985).

[0075] Certain embodiments may use transcription activator-like effector nuclease (TALEN) as a gene editing agent. TALEN refers to a fusion protein that includes a transcription activator-like effector (TALE) DNA binding protein and a DNA cleavage domain. TALEN is used to edit genes and genomes by inducing double DSB in DNA, which induces repair mechanisms in cells. In general, for a DNA cleavage domain, two TALENs need to bind to the target DNA site and be located on both sides of it to form a dimer and induce DSB. Further information on TALENs can be found in US 8,440,431, US 8,440,432, US 8,450,471, US 8,586,363, and US 8,697,853, as well as Joung and Sander, Nat Rev Mol Cell Biol, 2013, 14(l):49-55; Beurdeley et al., Nat Commun, 2013, 4:1762; Scharenberg et al., Curr Gene Ther, 2013, 13(4):291-303; Gaj et al., Nat Methods, 2012, 9(8):805-7; Miller, et al. Nature biotechnology 29, 143-148(2011); Christian, et al. Genetics 186, 757-761(2010); Boch, et al. al. Science 326, 1509-1512 (2009), and Moscow, & Bogdanove, Science 326, 1501 (2009).

[0076] Certain embodiments may use MegaTALs as gene editing agents. MegaTALs have a single-stranded rare-cleaving nuclease structure, in which a TALE is fused to the DNA cleavage domain of meganucleases. Meganucleases, also known as homing endonucleases, are a single peptide chain and have both DNA recognition and nuclease functions in the same domain. In contrast to TALENs, megaTALs only require the delivery of a single peptide chain for functional activity.

[0077] Nanoparticles that result in selective in vivo genetic modification of target cell types have been described and may be used within the teachings of the present disclosure. In certain embodiments, the nanoparticles may be those described in WO2014153114, WO2017181110, and WO201822672.

[0078] In certain embodiments, T cells are transduced with a lentivirus encoding a CAR.

[0079] (iii-b) CAR subcomponents. As described above, CAR molecules contain several different subcomponents that allow engineered cells to recognize and kill unwanted cells, such as cancer cells. The subcomponents include at least an extracellular component and an intracellular component. The extracellular component contains a binding domain that specifically binds to a marker that is selectively present on the surface of unwanted cells. The binding domain binds to such a marker, and the intracellular component activates the cell and destroys the bound cell. CARs further contain a transmembrane domain that links the extracellular component to the intracellular component, and other subcomponents that can enhance the function of the CAR. For example, the inclusion of a spacer region and / or one or more linker sequences allows the CAR to have additional conformational flexibility, often enhancing the ability of the binding domain to bind to a target cell marker.

[0080] (iii-bi) Binding domains. The present disclosure provides CARs with binding domains that bind to FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1.

[0081] Binding domains include any substance that binds to a cell marker to form a complex. The choice of binding domain may depend on the type and number of cell markers that characterize the surface of the target cell. Examples of binding domains include cell marker ligands, receptor ligands, antibodies, peptides, peptide aptamers, receptors (e.g., T cell receptors), or combinations and engineered fragments or forms thereof.

[0082] An antibody is an example of a binding domain, including whole antibodies or binding fragments of antibodies, such as Fv, Fab, Fab', F(ab')2, and single chain (sc) forms, and fragments thereof that specifically bind to a cell marker (e.g., FOLR1).Antibodies or antigen-binding fragments can include all or a portion of polyclonal antibodies, monoclonal antibodies, human antibodies, humanized antibodies, synthetic antibodies, non-human antibodies, recombinant antibodies, chimeric antibodies, bispecific antibodies, minibodies, and linear antibodies.

[0083] Antibodies are produced from two genes, a heavy chain gene and a light chain gene. Generally, an antibody contains two identical copies of a heavy chain and two identical copies of a light chain. Within the variable heavy and variable light chains, segments called complementarity determining regions (CDRs) determine epitope binding. Each heavy chain has three CDRs (i.e., CDRH1, CDRH2, and CDRH3), and each light chain has three CDRs (i.e., CDRL1, CDRL2, and CDRL3). The CDR regions are flanked by framework regions (FRs). The precise amino acid sequence boundaries of a given CDR or FR can be determined by Kabat et al. (1991) "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (Kabat numbering scheme), Al-Lazikani et al. (1997) J Mol Biol 273:927-948 (Chothia numbering scheme), Maccallum et al. (1996) J Mol Biol 262:732-745 (Contact numbering scheme), Martin et al. (1989) Proc. Natl. Acad. Sci., 86:9268-9272 (AbM numbering scheme), North et al. The boundaries of a given CDR or FR may be easily determined using any of a number of well-known schemes, including those described by et al. (2011) J. Mol. Biol. 406(2):228-56 (North numbering scheme), Lefranc MP et al. (2003) Dev Comp Immunol 27(1):55-77 (IMGT numbering scheme), and Honegger and Pluckthun (2001) J Mol Biol 309(3):657-670 ("Aho" numbering scheme). The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, Kabat's scheme is based on structural alignment, while Chothia's scheme is based on structural information.The numbering for both the Kabat and Chothia schemes is based on the length of the sequence of the most common antibody region, with insertions accommodated by the insertion letter, e.g., "30a," and deletions found in some antibodies. The two schemes place certain insertions and deletions ("indels") in different positions, resulting in different numbering. The Contact scheme is based on the analysis of complex crystal structures and is similar in many ways to the Chothia numbering scheme. In certain embodiments, the CDR sequences of the antibodies disclosed herein follow the Kabat numbering. The North numbering uses longer sequences for structural analysis of the conformation of the CDR loops. CDR residues can be identified using software programs, e.g., ABodyBuilder.

[0084] Folate receptor 1 (FOLR1) is encoded by the FOLR1 gene. In certain embodiments, the binding domain binds to FOLR1. In certain embodiments, the amino acid sequence of human FOLR1 comprises the following sequence: MAQRMTTQLLLLLVWVAVVGEAQTRIAWARTELLNVCMNAKHHKEKPGPEDKLHEQCRPWRKNACCSTNTSQEAHKDVSYLYRENWNHCGEMAPACKRHFIQDTCLYECSPNLGPWIQQVDQSWRKERVLNVPLCKEDCEQWWEDCRTSYTCKSNWHKGWNWTSGFNKCAVGAACQPFHFYFPTPTVLCNEIWTHSYKVSNYSRGSGRCIQMWFDPAQGNPNEEVARFYAAAMSGAGPWAAWPFLLSLALMLLWLLS (sequence number 21).

[0085] In certain embodiments, the FOLR1 binding domain comprises a farletuzumab scFv. In certain embodiments, the farletuzumab scFv comprises the following sequence: DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS (sequence number 22).

[0086] In certain embodiments, the FOLR1 binding domain comprises a farletuzumab scFv. In certain embodiments, the farletuzumab scFv comprises the following sequence: EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSSGGGGSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK (sequence number 23).

[0087] In certain embodiments, the FOLR1 binding domain comprises a farletuzumab antibody (MorAb-003). In certain embodiments, the FOLR1 binding domain is a human or humanized binding domain, comprising a variable heavy chain comprising a CDRH1 sequence comprising GYGLS (SEQ ID NO: 24), a CDRH2 sequence comprising MISSGGSYTYYADSVKG (SEQ ID NO: 25), and a CDRH3 sequence comprising HGGDPAWFAY (SEQ ID NO: 26), and a variable light chain comprising a CDRL1 sequence comprising SVSSSISSNNLH (SEQ ID NO: 27), a CDRL2 sequence comprising GTSNLAS (SEQ ID NO: 28), and a CDRL3 sequence comprising QQWSSYPYMYT (SEQ ID NO: 29), according to the Kabat numbering scheme.

[0088] In certain embodiments, the FOLR1 binding domain comprises a farletuzumab antibody. In certain embodiments, the sequence that binds to human FOLR1 is the following sequence: EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS (SEQ ID NO: 30), and the following sequence: The light chain region comprises: DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK (SEQ ID NO: 31).

[0089] In certain embodiments, the FOLR1 binding domain has the following sequence: and the variable heavy chain region encoded by the sequence:

[0033] The variable light chain region is encoded by the following sequence: GATATTCAGCTTACTCAAAGTCCGAGTAGTCTGTCTGCCTCAGTTGGCGATAGGGTGACCATCACTTGCTCCGTAAGTAGTTCTATTTCTTCCAACAACCTGCATTGGTATCAACAGAAACCAGGTAAAGCACCTAAGCCGTGGATCTACGGAACGTCCAACCTTGCGTCTGGCGTACCAAGCCGGTTCTCCGGGAGTGGGAGTGGTACAGATTACACATTTACTATCAGTTCTCTTCAACCGGAAGACATTGCCACATATTATTGCCAGCAATGGTCATCTTACCCCTATATGTACACATTTGGTCAGGGTACAAAGGTTGAAATAAAA (SEQ ID NO: 139).

[0090] In certain embodiments, the FOLR1 binding domain comprises a huMOV19 (M9346A) antibody. In certain embodiments, the FOLR1 binding domain is a human or humanized binding domain, and comprises a variable heavy chain comprising a CDRH1 sequence comprising GYFMN (SEQ ID NO: 32), a CDRH2 sequence comprising RIHPYDGDTFYNQKFQG (SEQ ID NO: 33), and a CDRH3 sequence comprising YDGSRAMDY (SEQ ID NO: 34), and a variable light chain comprising a CDRL1 sequence comprising KASQSVSFAGTSLMH (SEQ ID NO: 35), a CDRL2 sequence comprising RASNLEA (SEQ ID NO: 36), and a CDRL3 sequence comprising QQSREYPYT (SEQ ID NO: 37), according to the Kabat numbering scheme.

[0091] In certain embodiments, the FOLR1 binding domain comprises huMOV19 version 1.00. In certain embodiments, the sequence that binds to human FOLR1 comprises the following sequence: QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS (SEQ ID NO:38), and a variable heavy chain region comprising the following sequence: The variable light chain region comprises: DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLNISPVEAEDAATYYCQQSREYPYTFGGGTKLEIKR (SEQ ID NO: 39).

[0092] In certain embodiments, the FOLR1 binding domain comprises huMOV19 version 1.60. In certain embodiments, the sequence that binds to human FOLR1 comprises the following sequence: QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS (SEQ ID NO: 40), and a variable heavy chain region comprising the following sequence: The variable light chain region comprises: DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIKR (SEQ ID NO: 41).

[0093] In certain embodiments, the FOLR1 binding domain comprises the RA15-7 antibody. In certain embodiments, the FOLR1 binding domain is a human or humanized binding domain, comprising a variable heavy chain comprising a CDRH1 sequence comprising DFYMN (SEQ ID NO: 42), a CDRH2 sequence comprising FIRNKANGYTTEFNPSVKG (SEQ ID NO: 43), and a CDRH3 sequence comprising TLYGYAYYYVMDA (SEQ ID NO: 44), and a variable light chain comprising a CDRL1 sequence comprising RTSEDIFRNLA (SEQ ID NO: 45), a CDRL2 sequence comprising DTNRLAD (SEQ ID NO: 46), and a CDRL3 sequence comprising QQYDNYPLT (SEQ ID NO: 47), according to the Kabat numbering scheme.

[0094] In certain embodiments, the FOLR1 binding domain comprises the RA15-7 antibody. In certain embodiments, the sequence that binds to human FOLR1 comprises the following sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFTDFYMNWVRQPPGKAPEWLGFIRNKANGYTTEFNPSVKGRFTISRDNSKNSLYLQMNSLKTEDTATYYCARTLYGYAYYYVMDAWGQGTLVTVSS (SEQ ID NO: 48), and the following sequence: The variable light chain region comprises: DIQMTQSPSSLSASLGDRVTITCRTSEDIFRNLAWYQQKPGKAPKLLIYDTNRLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQYDNYPLTFGQGTKLEIK (SEQ ID NO: 49).

[0095] In certain embodiments, the FOLR1 binding domain comprises huFR1-48. In certain embodiments, the FOLR1 binding domain is a human or humanized binding domain and comprises a variable heavy chain comprising a CDRH1 sequence comprising NYWMQ (SEQ ID NO:50), a CDRH2 sequence comprising AIYPGNGDSRYTQKFQG (SEQ ID NO:51), and a CDRH3 sequence comprising RDGNYAAY (SEQ ID NO:52), and a variable light chain comprising a CDRL1 sequence comprising RASENIYSNLA (SEQ ID NO:53), a CDRL2 sequence comprising AATNLAD (SEQ ID NO:54), and a CDRL3 sequence comprising QHFWASPYT (SEQ ID NO:55), according to the Kabat numbering scheme.

[0096] In certain embodiments, the FOLR1 binding domain comprises huFR1-48. In certain embodiments, the sequence that binds to human FOLR1 comprises the following sequence: QVQLVQSGAEVAKPGASVKLSCKASGYTFTNYWMQWIKQRPGQGLEWIGAIYPGNGDSRYTQKFQGKATLTADKSSSTAYMQVSSLTSEDSAVYYCARRDGNYAAYWGQGTLVTVSA (SEQ ID NO:56), and the following sequence: The variable light chain region comprises: DIQMTQSPSSLSVSVGERVTITCRASENIYSNLAWYQQKPGKSPKLLVYAATNLADGVPSRFSGSESGTDYSLKINSLQPEDFGSYYCQHFWASPYTFGQGTKLEIKR (SEQ ID NO:57).

[0097] In certain embodiments, the FOLR1 binding domain comprises huFR1-49. In certain embodiments, the FOLR1 binding domain is a human or humanized binding domain and comprises a variable heavy chain comprising a CDRH1 sequence comprising NYWMY (SEQ ID NO:58), a CDRH2 sequence comprising AIYPGNSDTTYNQKFQG (SEQ ID NO:59), and a CDRH3 sequence comprising RHDYGAMDY (SEQ ID NO:60), and a variable light chain comprising a CDRL1 sequence comprising RASENIYTNLA (SEQ ID NO:61), a CDRL2 sequence comprising TASNLAD (SEQ ID NO:62), and a CDRL3 sequence comprising QHFWVSPYT (SEQ ID NO:63), according to the Kabat numbering scheme.

[0098] In certain embodiments, the FOLR1 binding domain comprises huFR1-49. In certain embodiments, the sequence that binds to human FOLR1 comprises the following sequence: The variable heavy chain region comprises the sequence: QVQLQQSGAVVAKPGASVKMSCKASGYTFTNYWMYWIKQRPGQGLELIGAIYPGNSDTTYNQKFQGKATLTAVTSANTVYMEVSSLTSEDSAVYYCTKRHDYGAMDYWGQGTSVTVSS (SEQ ID NO: 64), and the variable light chain region comprises the sequence: DIQMTQSPSSLSVSVGERVTITCRASENIYTNLAWYQQKPGKSPKLLVYTASNLADGVPSRFSGSGSGTDYSLKINSLQPEDFGTYYCQHFWVSPYTFGQGTKLEIKR (SEQ ID NO: 64).

[0099] In certain embodiments, the FOLR1 binding domain comprises huFR1-57. In certain embodiments, the FOLR1 binding domain is a human or humanized binding domain and comprises a variable heavy chain comprising a CDRH1 sequence comprising SFGMH (SEQ ID NO:66), a CDRH2 sequence comprising YISSGSSTISYADSVKG (SEQ ID NO:67), and a CDRH3 sequence comprising EAYGSSMEY (SEQ ID NO:68), and a variable light chain comprising a CDRL1 sequence comprising RASQNINNNLH (SEQ ID NO:69), a CDRL2 sequence comprising YVSQSVS (SEQ ID NO:70), and a CDRL3 sequence comprising QQSNSWPHYT (SEQ ID NO:71), according to the Kabat numbering scheme.

[0100] In certain embodiments, the FOLR1 binding domain comprises huFR1-57. In certain embodiments, the sequence that binds to human FOLR1 comprises the following sequence: EVQLVESGGGLVQPGGSRRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSSTISYADSVKGRFTISRDNSKKTLLLQMTSLRAEDTAMYYCAREAYGSSMEYWGQGTLVTVSS (SEQ ID NO: 72), and the following sequence: The variable light chain region comprises: EIVLTQSPATLSVTPGDRVSLSCRASQNINNNLHWYQQKPGQSPRLLIKYVSQSVSGIPDRFSGSGSGTDFTLSISSVEPEDFGMYFCQQSNSWPHYTFGQGTKLEIKR (SEQ ID NO: 73).

[0101] In certain embodiments, the FOLR1 binding domain comprises huFR1-65. In certain embodiments, the FOLR1 binding domain is a human or humanized binding domain and comprises a variable heavy chain comprising a CDRH1 sequence comprising SYTMH (SEQ ID NO: 74), a CDRH2 sequence comprising YINPISGYTNYNQKFQG (SEQ ID NO: 75), and a CDRH3 sequence comprising GGAYGRKPMDY (SEQ ID NO: 76), and a variable light chain comprising a CDRL1 sequence comprising KASQNVGPNVA (SEQ ID NO: 77), a CDRL2 sequence comprising SASYRYS (SEQ ID NO: 78), and a CDRL3 sequence comprising QQYNSYPYT (SEQ ID NO: 79), according to the Kabat numbering scheme.

[0102] In certain embodiments, the FOLR1 binding domain comprises huFR1-65. In certain embodiments, the sequence that binds to human FOLR1 comprises the following sequence: QVQLVQSGAEVAKPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLAWIGYINPISGYTNYNQKFQGKATLTADKSSSTAYMQLNSLTSEDSAVYYCASGGAYGRKPMDYWGQGTSVTVSS (SEQ ID NO: 80), and the following sequence: The light chain region comprises: EIVMTQSPATMSTSPGDRVSVTCKASQNVGPNVAWYQQKPGQSPRALIYSASYRYSGVPARFTGSGSGTDFTLTISNMQSEDLAEYFCQQYNSYPYTFGQGTKLEIKR (SEQ ID NO: 81).

[0103] In certain embodiments, the FOLR1-binding domain comprises a sequence having at least 90% sequence identity to SEQ ID NOs: 22 to 81. In certain embodiments, the FOLR1-binding domain comprises a sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NOs: 22 to 81. In certain embodiments, the FOLR1-binding domain is an antibody and / or a polypeptide that specifically binds to FOLR1.

[0104] The multiple EGF-like domain 10 (MEGF10) protein is encoded by the MEGF10 gene. In certain embodiments, the binding domain binds to MEGF10. In certain embodiments, the amino acid sequence of human MEGF10 comprises the following sequence:

[0105] In certain embodiments, the binding domain that binds MEGF10 comprises the LS-C678634, LS-C668447, LSC497216, or PA5-76556 antibody or binding fragment thereof.

[0106] The heparinase-2 (HPSE2) enzyme is encoded by the HPSE2 gene. In certain embodiments, the binding domain binds to HPSE2. In certain embodiments, the amino acid sequence of human HPSE2 comprises the following sequence: (Sequence number 83).

[0107] In certain embodiments, the binding domain that binds HPSE2 comprises the LS-B14593, LS-C322089, LS-C378319, or HPA044603 antibody or binding fragment thereof.

[0108] The killer cell lectin-like receptor F2 (KLRF2) protein is encoded by the KLRF2 gene. In certain embodiments, the binding domain binds to KLRF2. In certain embodiments, the amino acid sequence of human KLRF2 comprises the following sequence: MENEDGYMTLSFKNRCKSKQKSKDFSLYPQYYCLLLIFGCIVILIFIMTGIDLKFWHKKMDFSQNVNVSSLSGHNYLCPNDWLLNEGKCYWFSTSFKTWKESQRDCTQLQAHLLVIQNLDELEFIQNSLKPGHFGWIGLYVTFQGNLWMWIDEHFLVPELFSVIGPTDDRSCAVITGNWVYSEDCSSTFKGICQRDAILTHNGTSGV (sequence number 84).

[0109] In certain embodiments, the binding domain that binds to KLRF2 comprises the LS-C329740, LS-C203747, SAB2108513, SAB2108684, HPA055964, SAB2108320, or SAB2108355 antibody or binding fragment thereof.

[0110] The protocadherin-19 (PCDH19) protein is encoded by the PCDH19 gene. In certain embodiments, the binding domain binds to PCDH19. In certain embodiments, the amino acid sequence of human PCDH19 comprises the following sequence:

[0111] In certain embodiments, the binding domain that binds to PCDH19 comprises the LS-C676224, LS-C496779, LS-C761991, HPA027533, HPA001461 antibody or binding fragments thereof.

[0112] The Fraser extracellular matrix complex subunit 1 (FRAS1) protein is encoded by the FRAS1 gene. In certain embodiments, the binding domain binds to FRAS1. In certain embodiments, the amino acid sequence of human FRAS1 comprises the following sequence: MGVLKVWLGLALALAEFAVLPHHSEGACVYQGSLLADATIWKPDSCQSCRCHGDIVICKPAVCRNPQCAFEKGEVLQIAANQCCPECVLRTPGSCHHEKKIHEHGTEWASSPCSVCSCNHGEVRCTPQPCPPLSCGHQELAFIPEGSCCPVCVGLGKPCSYEGHVFQDGEDWRLSRCAKCLCRNGVAQCFTAQCQPLFCNQDETVVRVPGKCCPQCSARSCSAAGQVYEHGEQWSENACTTCICDRGEVRCHKQACLPLRCGKGQSRARRHGQCCEECVSPALASQSVGIAGMSHHAQSLLGPFLTQIKKPHFSCLE (sequence number 86).

[0113] In certain embodiments, the binding domain that binds to FRAS1 comprises the LS-C763132, LS-B5486, LS-C754337, HPA011281, or HPA051601 antibody or binding fragment thereof.

[0114] In some cases, additional scFvs for use in CARs based on the binding domains described herein can be prepared according to methods known in the art (see, for example, Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). scFv molecules can be produced by linking the VH and VL regions of an antibody using a flexible polypeptide linker. When a short polypeptide linker (e.g., 5-10 amino acids) is used, intrachain folding is prevented. Interchain folding is also necessary to bring the two variable regions together to form a functional epitope binding site. For examples of linker orientation and size, see, for example, Hollinger et al. 1993 Proc Natl Acad.Sci.USA 90:6444-6448, US 2005 / 0100543, US 2005 / 0175606, US 2007 / 0014794, and WO2006 / 020258 and WO2007 / 024715. More specifically, the linker sequence used to connect the VL and VH of the scFv is generally 5-35 amino acids in length. In certain embodiments, the VL-VH linker comprises 5-35, i.e., 10-30 amino acids or 15-25 amino acids. Variation in the length of the linker can preserve or enhance activity, resulting in superior performance in activity testing. scFvs are commonly used as binding domains for CARs.

[0115] Other binding fragments, such as Fv, Fab, Fab', F(ab')2, can also be used in the CARs disclosed herein. Further examples of antibody-based binding domain configurations for use in CARs include scFv-based grababodies and soluble VH domain antibodies. These antibodies use only heavy chain variable regions to form the binding region. See, for example, Jespers et al., Nat. Biotechnol. 22:1161, 2004; Cortez-Retamozo et al., Cancer Res. 64:2853, 2004; Baral et al., Nature Med. 12:580, 2006; and Barthelemy et al., J. Biol. Chem. 283:3639, 2008.

[0116] In certain embodiments, the binding domain comprises a humanized antibody or an engineered fragment thereof. In certain embodiments, a non-human antibody is humanized, in which one or more amino acid residues of the antibody are modified to increase similarity to an antibody or fragment thereof that is naturally produced in humans. These non-human amino acid residues are often referred to as "import" residues, which are usually taken from an "import" variable domain. As provided herein, a humanized antibody or antibody fragment comprises one or more CDRs and framework regions from a non-human immunoglobulin molecule, and the amino acid residues that comprise the framework are derived entirely or predominantly from human germline.Humanized antibodies can be produced by techniques such as CDR grafting (see, e.g., European Patent No. EP 239,400, WO 91 / 09967, and US 5,225,539, US 5,530,101, and US 5,585,089), veneering or resurfacing (see, e.g., EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6):805-814, and Roguska et al., 1994, PNAS, 91:969-973), chain shuffling (see, e.g., US 5,565,332), and other techniques such as those described in, e.g., US 2005 / 0042664, US 2005 / 0048617, US 6,407,213, US 5,766,886, WO 9317105, Tan et al., J. Immunol.,169:1119-25(2002), Caldas et al., Protein Eng.,13(5):353-60(2000), Morea et al. al.,Methods,20(3):267-79(2000),Baca et al.,J.Biol.Chem.,272(16):10678-84(1997),Roguska et al.,Protein Eng.,9(10):895-904(1996),Couto et al.,Cancer Res.,55(23 Supp):5973s-5977s (1995), Couto et al., Cancer Res., 55(8):1717-22 (1995), Sandhu JS, Gene, 150(2):409-10 (1994), and Pedersen et al., J. Mol. Biol., 235(3):959-73 (1994). Often, framework residues in the framework regions are replaced with the corresponding residues from the CDR donor antibody to alter, e.g., improve, binding of the cell marker.These framework substitutions are identified by methods well known in the art, for example, by modeling the interactions of the CDRs and framework residues to identify framework residues important for cell marker binding and sequence comparison, and by identifying framework residues that are distinct at particular positions (see, e.g., US 5,585,089, and Riechmann et al., 1988, Nature, 332:323).

[0117] A functional variant includes one or more residue additions or substitutions that do not substantially affect the physiological effect of the protein. A functional fragment includes one or more deletions or truncations that do not substantially affect the physiological effect of the protein. The lack of substantial effect can be confirmed by observing experimentally similar results in activation or binding tests. Functional variants and functional fragments of intracellular domains (e.g., intracellular signaling domains) transmit activation or inhibition signals comparable to the wild-type reference when in the activation state of the present disclosure. Functional variants and functional fragments of binding domains bind to their cognate antigens or ligands at levels comparable to the wild-type reference.

[0118] In certain embodiments, the VL region of the binding domain of the present disclosure is derived from or based on the VL of an antibody disclosed herein and comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g., conservative amino acid substitutions) compared to the VL of an antibody disclosed herein, or a combination of the above changes. The insertions, deletions or substitutions may be anywhere in the VL region, including at the amino or carboxy termini or both termini of this region, provided that each CDR comprises zero changes or at most one, two or three changes, and that a binding domain comprising the modified VL region is still capable of specifically binding to its target with an affinity similar to that of the wild-type binding domain.

[0119] In certain embodiments, the VH region of the binding domain of the present disclosure may be derived from or based on the VH of an antibody disclosed herein and may comprise one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g., conservative or non-conservative amino acid substitutions) compared to the VH of an antibody disclosed herein, or a combination of the above changes. The insertions, deletions or substitutions may be anywhere in the VH region, including at the amino or carboxy termini or both termini of the region, provided that each CDR comprises zero changes or at most one, two or three changes, and that a binding domain comprising the modified VH region is still capable of specifically binding to its target with an affinity similar to that of the wild-type binding domain.

[0120] In certain embodiments, the binding domain comprises or is a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100% identical to the amino acid sequence of the light chain variable region (VL) or heavy chain variable region (VH), or both, where each CDR contains zero changes or at most one, two, or three changes from an antibody or fragment or derivative thereof disclosed herein that specifically binds to a cell marker of interest.

[0121] (iii-b-ii) Spacer region. The spacer region is used to create appropriate distance and / or flexibility from other CAR subcomponents. In certain embodiments, the length of the spacer region is customized for binding and mediating destruction of target cells. In certain embodiments, the length of the spacer region can be selected based on the location of the cell marker epitope, the affinity of the binding domain for the epitope, and / or the ability of the targeting agent to mediate destruction of cells after target binding.

[0122] Spacer regions typically include those having 10 to 250 amino acids, 10 to 200 amino acids, 10 to 150 amino acids, 10 to 100 amino acids, 10 to 50 amino acids, or 10 to 25 amino acids.

[0123] In certain embodiments, the spacer region is 5 amino acids, 8 amino acids, 10 amino acids, 12 amino acids, 14 amino acids, 20 amino acids, 21 amino acids, 26 amino acids, 27 amino acids, 45 amino acids, or 50 amino acids. These lengths are considered short spacer regions.

[0124] In certain embodiments, the spacer region is 100 amino acids, 110 amino acids, 120 amino acids, 125 amino acids, 128 amino acids, 131 amino acids, 135 amino acids, 140 amino acids, 150 amino acids, 160 amino acids, or 170 amino acids. These lengths are considered intermediate spacer regions.

[0125] In certain embodiments, the spacer region is 180 amino acids, 190 amino acids, 200 amino acids, 210 amino acids, 212 amino acids, 214 amino acids, 216 amino acids, 218 amino acids, 220 amino acids, 230 amino acids, 240 amino acids, or 250 amino acids. These lengths are considered long spacer regions.

[0126] Exemplary spacer regions include all or a portion of an immunoglobulin hinge region. The immunoglobulin hinge region may be a wild-type or modified wild-type immunoglobulin hinge region. In certain embodiments, the immunoglobulin hinge region is a human immunoglobulin hinge region. As used herein, "wild-type immunoglobulin hinge region" refers to the naturally occurring upper and middle hinge amino acid sequences located between and connecting the CH1 and CH2 domains (in the case of IgG, IgA, and IgD) or between and connecting the CH1 and CH3 domains (in the case of IgE and IgM) found in the heavy chain of an antibody.

[0127] The immunoglobulin hinge region can be an IgG, IgA, IgD, IgE, or IgM hinge region. The IgG hinge region can be an IgG1, IgG2, IgG3, or IgG4 hinge region. Sequences from IgG1, IgG2, IgG3, IgG4, or IgD can be used alone or in combination with all or part of the CH2 region, all or part of the CH3 region, or all or part of the CH2 region and all or part of the CH3 region.

[0128] In certain embodiments, the spacer is a short spacer comprising an IgG4 hinge region. In certain embodiments, the short spacer is encoded by either SEQ ID NO: 1 or 2. In certain embodiments, the spacer is an IgG4 hinge S10P. In certain embodiments, the IgG4 hinge S10P is encoded by SEQ ID NO: 135. In certain embodiments, the spacer is an intermediate spacer comprising an IgG4 hinge region and an IgG4 hinge CH3 region. In certain embodiments, the intermediate spacer is encoded by SEQ ID NO: 3. In certain embodiments, the spacer is a hinge and intermediate spacer (DS). In certain embodiments, the hinge and intermediate spacer (DS) is encoded by SEQ ID NO: 136. In certain embodiments, the spacer is a long spacer comprising an IgG4 hinge region, an IgG4 CH3 region, and an IgG4 CH2 region. In certain embodiments, the long spacer is encoded by SEQ ID NO: 4.

[0129] Other examples of hinge regions that may be used in the CARs described herein include the hinge regions present in the extracellular domains of type 1 membrane proteins, such as CD8α, CD4, CD28, and CD7, either wild-type or variants thereof.

[0130] In certain embodiments, the spacer region comprises a hinge region, which comprises a type II C-lectin interdomain (stalk) region or a stalk region of a cluster of differentiation (CD) molecule. The "stalk region" of a type II C-lectin or CD molecule refers to a portion of the extracellular domain (ECD) of a type II C-lectin or CD molecule, which is located between the C-type lectin-like domain (CTLD, e.g., similar to the CTLD of the natural killer cell receptor) and the hydrophobic portion (the transmembrane domain). For example, the ECD of human CD94 (GenBank Accession No. AAC50291.1) corresponds to amino acid residues 34-179, while the CTLD corresponds to amino acid residues 61-176, so that the stalk region of the human CD94 molecule includes amino acid residues 34-60, which are located between the hydrophobic portion (transmembrane domain) and the CTLD (see Boyington et al., Immunity 10:15, 1999; for descriptions of other stalk regions, see also Beavil et al., Proc. Nat'l. Acad. Sci. USA 89:153, 1992, and Figdor et al., Nat. Rev. Immunol. 2:11, 2002). These type II C-lectin or CD molecules may also have junction amino acids (below) between the stalk region and the transmembrane domain or the CTLD. In another example, the 233 amino acid human NKG2A protein (GenBank Accession No. P26715.1) has a hydrophobic portion (transmembrane domain) spanning amino acids 71-93 and an ECD spanning amino acids 94-233. The CTLD includes amino acids 119-231, the stalk region includes amino acids 99-116, and may be flanked by additional junction amino acids. Other type II C-lectin or CD molecules, as well as their extracellular ligand binding domains, stalk regions, and CTLDs, are known in the art (see, e.g., GenBank Accession Nos. NP 001993.2, AAH07037.1, NP 001773.1, AAL65234.1, CAA04925.1 for sequences and descriptions of human CD23, CD69, CD72, NKG2A, and NKG2D, respectively).

[0131] (iii-b-iii) Transmembrane domain. As shown, the transmembrane domain in the CAR serves to link extracellular and intracellular components through the cell membrane. The transmembrane domain can anchor the molecule expressed in the membrane of the engineered cell.

[0132] The transmembrane domain may be derived from either natural and / or synthetic sources. If the source is natural, the transmembrane domain may be derived from any membrane-bound or transmembrane protein. The transmembrane domain may include at least the transmembrane region(s) of the α, β or ζ chain of the T cell receptor, CD28, CD27, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154. In certain embodiments, the transmembrane domain comprises at least one of the following proteins: e.g., KIRDS2, OX40, CD2, CD27, LFA-1 (CD 11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2Rβ, IL2Rγ, IL7R a, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDl ld, ITGAE, CD103, ITGAL, CDl la, ITGAM, CDl lb, ITGAX, CDl It may include the transmembrane domain(s) of lc, ITGB1, CD29, ITGB2, CD18, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​PAG / Cbp, NKG2D, or NKG2C. In certain embodiments, various human hinges may be used, including human Ig (immunoglobulin) hinges (e.g., IgG4 hinges, IgD hinges), GS linkers (e.g., GS linkers described herein), KIR2DS2 hinges, or CD8a hinges.

[0133] In certain embodiments, the transmembrane domain has a thermodynamically stable three-dimensional structure in the cell membrane and generally ranges from 15 to 30 amino acids in length. The structure of the transmembrane domain may include an α-helix, a β-barrel, a β-sheet, a β-helix, or any combination thereof.

[0134] A transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, for example, one or more amino acids in the extracellular region of the CAR (e.g., up to 15 amino acids of the extracellular region) and / or one or more additional amino acids in the intracellular region of the CAR (e.g., up to 15 amino acids of the intracellular component). In one aspect, the transmembrane domain is derived from the same protein as the signaling domain, the costimulatory domain, or the hinge domain is derived from. In another aspect, the transmembrane domain is not derived from the same protein as the other domains of the CAR are derived from. In some cases, the transmembrane domain may be selected or modified by amino acid substitutions to avoid such domains binding to transmembrane domains of the same or different surface membrane proteins and to minimize interactions with other unintended members of the receptor complex. In certain embodiments, the transmembrane domain is encoded by a nucleic acid sequence encoding the transmembrane domain of CD28 (SEQ ID NOs: 12-14). In a specific embodiment, the transmembrane domain comprises the amino acid sequence of the transmembrane domain of CD28 (SEQ ID NOs: 15 and 16).

[0135] (iii-b-iv) Intracellular effector domain. The intracellular effector domain of a CAR is involved in the activation of the cell in which the CAR is expressed. Thus, the term "effector domain" is intended to include any portion of the intracellular domain sufficient to introduce an activation signal. An effector domain can directly or indirectly promote a biological or physiological response in a cell upon receiving an appropriate signal. In certain embodiments, the effector domain is part of a protein or protein complex that receives a signal when bound, or directly binds to a target molecule, which triggers a signal from the effector domain. An effector domain can directly promote a cellular response if it contains one or more signaling domains or motifs, such as immunoreceptor tyrosine-based activation motifs (ITAMs). In other embodiments, an effector domain indirectly promotes a cellular response by associating with one or more other proteins that directly promote the cellular response, such as a costimulatory domain.

[0136] The effector domain can activate at least one function of the engineered cell upon binding to a cell marker expressed by a cancer cell. The activation of the engineered cell can include one or more of differentiation, proliferation and / or activation or other effector functions. In certain embodiments, the effector domain can include intracellular signaling components, including T cell receptor and costimulatory domains, which can include cytoplasmic sequences from co-receptors or costimulatory molecules.

[0137] The effector domain may comprise one, two, three, or more intracellular signaling components (e.g., receptor signaling domains, cytoplasmic signaling sequences), costimulatory domains, or combinations thereof. Exemplary effector domains include signaling and stimulatory domains selected from 4-1BB (CD137), CARD11, CD3γ, CD3δ, CD3ε, CD3ζ, CD27, CD28, CD79A, CD79B, DAP10, FcRα, FcRβ (FcεR1b), FcRγ, Fyn, HVEM (LIGHTR), ICOS, LAG3, LAT, Lck, LRP, NKG2D, NOTCH1, pTα, PTCH2, OX40, ROR2, Ryk, SLAMF1, Slp76, TCRα, TCRβ, TRIM, Wnt, Zap70, or any combination thereof. In certain embodiments, exemplary effector domains include CD86, FcγRIIa, DAP12, CD30, CD40, PD-1, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds to CD83, CDS, ICAM-1, GITR, BAFFR, SLAMF7, NKp80 (KLRF1), CD127, CD160, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, ITGAM , CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, ITGB7, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​GADS, PAG / Cbp, NKp44, NKp30, or NKp46.

[0138] The sequence of intracellular signaling components that act in a stimulatory manner may include iTAM. Examples of iTAMs that include primary cytoplasmic signaling sequences include those derived from CD3γ, CD3δ, CD3ε, CD3ζ, CD5, CD22, CD66d, CD79a, CD79b, and the common FcRγ (FCER1G), FcγRlla, FcRβ (Fcε Rib), DAP10, and DAP12. In certain embodiments, variants of CD3ζ retain at least one, two, three, or all of the ITAM regions.

[0139] In certain embodiments, the effector domain comprises a cytoplasmic portion that associates with a cytoplasmic signaling protein, the cytoplasmic signaling protein being a lymphocyte receptor or signaling domain thereof, a protein containing multiple ITAMs, a costimulatory domain, or any combination thereof.

[0140] Further examples of intracellular signaling components include cytoplasmic sequences of the CD3 ζ chain and / or co-receptors that act in concert to initiate signal transduction following engagement of the binding domains.

[0141] A costimulatory domain is a domain whose activation may be necessary for efficient lymphocyte response to binding of a cell marker. Several molecules are interchangeable as intracellular signaling components or costimulatory domains. Examples of costimulatory domains include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83. For example, costimulation of CD27 has been shown to enhance proliferation, effector function, and survival of human CART cells in vitro, and enhances persistence and anticancer activity of human T cells in vivo (Song et al. Blood. 2012; 119(3): 696-706). Further examples of such costimulatory domain molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDlld, ITGAE, CD103, ITGAL, CDlla, ITGAM, CDl lb, ITGAX, CDllc, ITGB1, CD29, ITGB2, CD18, ITGB7, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), NKG2D, CEACAM1, CRTAM, Ly9 (CD229), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, and CD19a.

[0142] In certain embodiments, the nucleic acid sequences encoding the intracellular signaling components include sequences encoding CD3ζ (SEQ ID NO:5) and sequences encoding 4-1BB signaling (SEQ ID NOs:8 and 9). In certain embodiments, the amino acid sequences of the intracellular signaling components include CD3ζ (SEQ ID NOs:6 and 7) and the intracellular signaling components of a portion of 4-1BB (SEQ ID NOs:10 and 11).

[0143] In certain embodiments, the intracellular signaling component comprises (i) all or a portion of the signaling domain of CD3ζ, (ii) all or a portion of the signaling domain of 4-1BB, or (iii) all or a portion of the signaling domains of CD3ζ and 4-1BB.

[0144] Intracellular components may also be proteins of the Wnt signaling pathway (e.g., LRP, Ryk, or ROR2), proteins of the NOTCH signaling pathway (e.g., NOTCH1, NOTCH2, NOTCH3, or NOTCH4), proteins of the Hedgehog signaling pathway (e.g., PTCH or SMO), receptor tyrosine kinases (RTKs) (e.g., epidermal growth factor (EGF) receptor family, fibroblast growth factor (FGF) receptor family, hepatocyte growth factor (HGF) receptor family, insulin receptor (IR) family, platelet-derived growth factor (PDGF) receptor family, vascular endothelial growth factor (VEGF) receptor family, tropomyosin receptor kinase (Trk) receptor family, ephrin (Eph) receptor family, AXL receptor family, leukocyte tyrosine kinase (LTK) receptor family, tyrosine kinase with immunoglobulin-like and EGF-like domains (Trk ... The receptor may also include one or more of the following: a G-protein coupled receptor, a GPCR (Frizzled or Smoothened), a serine / threonine kinase receptor (BMPR or TGFR), or a cytokine receptor (IL1R, IL2R, IL7R, or IL15R), a G-protein coupled receptor, a GPCR (Frizzled or Smoothened), a serine / threonine kinase receptor (BMPR or TGFR), or a cytokine receptor (IL1R, IL2R, IL7R, or IL15R).

[0145] (iii-bv) Linker. As used herein, a linker can include any chemical moiety that serves to connect two other subcomponents of the molecule. Some linkers do not serve any purpose other than linking components, but many linkers serve additional purposes. A linker can, for example, link the VL and VH of the antibody-derived binding domain of an scFv, and can serve as an interface amino acid between the subcomponent portions of a CAR.

[0146] Linkers can be flexible, rigid, or semi-rigid, depending on the desired function of the linker. Linkers can include junction amino acids. For example, in certain embodiments, linkers provide space for CAR flexibility and conformational movement between different components. Commonly used flexible linkers include Gly-Ser linkers. In certain embodiments, the linker sequence is a set of glycine and serine repeats, such as (Gly x Ser y ) n (x and y are independently integers from 0 to 10, with the proviso that x and y are not both 0, and n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). Specific examples include (Gly4Ser) n (SEQ ID NO: 87), (Gly3Ser) n (Gly4Ser) n (SEQ ID NO: 88), (Gly3Ser) n (Gly2Ser) n(SEQ ID NO: 89), or (Gly3Ser)n(Gly4Ser)1 (SEQ ID NO: 90). In certain embodiments, the linker is (Gly4Ser)4 (SEQ ID NO: 91), (Gly4Ser)3 (SEQ ID NO: 92), (Gly4Ser)2 (SEQ ID NO: 93), (Gly4Ser)1 (SEQ ID NO: 94), (Gly3Ser)2 (SEQ ID NO: 95), (Gly3Ser)1 (SEQ ID NO: 96), (Gly2Ser)2 (SEQ ID NO: 97), or (Gly2Ser)1, GGSGGGSGGSG (SEQ ID NO: 98), GGSGGGSGSG (SEQ ID NO: 99), or GGSGGGSG (SEQ ID NO: 100). In certain embodiments, the (Gly4Ser)4 linker is encoded by the sequence set forth in SEQ ID NO: 91.

[0147] In certain embodiments, the linker region is (GGGGS) n (SEQ ID NO: 87), where n is an integer including 1, 2, 3, 4, 5, 6, 7, 8, 9, or more. In certain embodiments, the spacer region is n (SEQ ID NO:101), where n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or more, inclusive.

[0148] In some cases, flexible linkers may not be able to maintain the spacing or position of CARs required for a particular use. In these cases, rigid or semi-rigid linkers may be useful. Examples of rigid or semi-rigid linkers include proline-rich linkers. In certain embodiments, proline-rich linkers are peptide sequences that have more proline residues than would be expected based on chance alone. In certain embodiments, proline-rich linkers have at least 30%, at least 35%, at least 36%, at least 39%, at least 40%, at least 48%, at least 50%, or at least 51% proline residues. Specific examples of proline-rich linkers include fragments of proline-rich salivary proteins (PRPs).

[0149] The linker may be susceptible to cleavage, such as acid cleavage, light cleavage, peptidase cleavage, esterase cleavage, and disulfide bond cleavage (cleavable linker). Alternatively, the linker may be substantially resistant to cleavage (e.g., stable linker or non-cleavable linker). In some embodiments, the linker is a pro-charged linker, a hydrophilic linker, or a dicarboxylic acid-based linker.

[0150] Junction amino acids may be linkers that can be used to connect sequences when the distance provided by a spacer region is not required and / or preferred. For example, junction amino acids may be short amino acid sequences that can be used to connect costimulatory intracellular signaling components. In certain embodiments, junction amino acids are 9 amino acids or less (e.g., 2, 3, 4, 5, 6, 7, 8, or 9 amino acids). In certain embodiments, glycine-serine doublets may be used as suitable junction amino acid linkers. In certain embodiments, single amino acids, e.g., alanine, glycine, may be used as suitable junction amino acids.

[0151] (iii-b-vi) Control mechanisms including tag cassettes, transduction markers, and / or suicide switches. In certain embodiments, the CAR construct may include one or more tag cassettes and / or transduction markers. The tag cassettes and transduction markers may be used to activate, promote, detect, enrich, isolate, track, deplete, and / or remove engineered cells in vitro, in vivo, and / or ex vivo. A "tag cassette" refers to a unique synthetic peptide sequence that is fixed to, fused to, or part of a CAR, to which a cognate binding molecule (e.g., a ligand, antibody, or other binding partner) can specifically bind, and whose binding properties may be used to activate, promote, detect, enrich, isolate, track, deplete, and / or remove the tagged protein and / or cells expressing the tagged protein. Transduction markers can serve the same purpose, but are derived from naturally occurring molecules and are often expressed using a skipping element that separates the transduction marker from the rest of the CAR molecule.

[0152] In certain embodiments, the CAR comprises a T2A ribosomal skipping element, which separates the expressed CAR from the truncated CD19 (tCD19) transduction marker. In certain embodiments, the T2A ribosomal skipping element is encoded by SEQ ID NO: 137.

[0153] Examples of tag cassettes that bind to cognate binding molecules include His tag (HHHHHH, SEQ ID NO: 102), Flag tag (DYKDDDDK, SEQ ID NO: 103), Xpress tag (DLYDDDDK, SEQ ID NO: 104), Avi tag (GLNDIFEAQKIEWHE, SEQ ID NO: 105), calmodulin tag (KRRWKKNFIAVSAANRFKKISSSGAL, SEQ ID NO: 106), polyglutamic acid tag, HA tag (YPYDVPDYA, SEQ ID NO: 107), Myc tag (EQKLISEEDL, SEQ ID NO: 108), Strep tag (which refers to the original STREP® tag (WRHPQFGG, SEQ ID NO: 109), STREP® tag II (WSHPQFEK, SEQ ID NO: 110 (IBA Institut fur Bioanalytik, Germany). See, e.g., US 7,981,632), Softag 1 (SLAELLNAGLGGS, SEQ ID NO:111), Softag 3 (TQDPSRVG, SEQ ID NO:112), and V5 tag (GKPIPNPLLGLDST, SEQ ID NO:113).

[0154] Homologous binding molecules that specifically bind to the tag cassette sequences disclosed herein are commercially available. For example, His tag antibodies are commercially available from suppliers including Life Technologies, Pierce Antibodies, and GenScript. Flag tag antibodies are commercially available from suppliers including Pierce Antibodies, GenScript, and Sigma-Aldrich. Xpress tag antibodies are commercially available from suppliers including Pierce Antibodies, Life Technologies, and GenScript. Avi tag antibodies are commercially available from suppliers including Pierce Antibodies, IsBio, and Genecopoeia. Calmodulin tag antibodies are commercially available from suppliers including Santa Cruz Biotechnology, Abcam, and Pierce Antibodies. HA tag antibodies are commercially available from suppliers including Pierce Antibodies, Cell Signal, and Abcam. Myc tag antibodies are commercially available from suppliers including Santa Cruz Biotechnology, Abcam, and Cell Signal. Strep tag antibodies are commercially available from suppliers including Abcam, Iba, and Qiagen.

[0155] The transduction marker may be selected from at least one of truncated CD19 (tCD19, see Budde et al., Blood 122:1660, 2013), truncated human EGFR (tEGFR, see Wang et al., Blood 118:1255, 2011), the ECD of human CD34, and / or RQR8, which combines target epitopes from the CD34 (see Fehse et al., Mol. Therapy 1(5 Pt 1);448-456, 2000) and CD20 antigens (see Philip et al., Blood 124:1277-1278).

[0156] In certain embodiments, a polynucleotide encoding an iCaspase 9 construct (iCasp9) can be inserted into the CAR construct as a suicide switch.

[0157] Regulatory mechanisms may be present in multiple copies of the CAR and expressed as distinct molecules using skipping elements (SEQ ID NOs: 17-20). For example, the CAR may have 1, 2, 3, 4, or 5 tag cassettes, and / or 1, 2, 3, 4, or 5 transduction markers may also be expressed. For example, embodiments may include CAR constructs with two Myc tag cassettes, or a His tag and an HA tag cassette, or an HA tag and a Softag 1 tag cassette, or a Myc tag and an SBP tag cassette. Exemplary transduction markers and cognate pairs are described in US 13 / 463,247.

[0158] One benefit of including at least one control mechanism in a CAR is that cells expressing the CAR administered to a subject can be increased or depleted using a cognate binding molecule for the tag cassette. In certain embodiments, the present disclosure provides a method for depleting engineered cells expressing a CAR by using an antibody specific for the tag cassette, using a cognate binding molecule specific for the control mechanism, or using a second engineered cell that expresses a CAR and has specificity for the control mechanism. Removal of engineered cells can be achieved using a depleting agent specific for the control mechanism. For example, when tEGFR is used, an anti-tEGFR binding domain (e.g., antibody, scFv) fused or conjugated to a cytotoxic agent (e.g., toxin, radioactive metal) can be used, or an anti-tEGFR / anti-CD3 bispecific scFv, or an anti-tEGFR CAR T cell can be used.

[0159] In certain embodiments, engineered cells expressing the chimeric molecule may be detected or tracked in vivo by using antibodies (e.g., anti-Tag antibodies) that bind with specificity to the regulatory mechanism, or by other cognate binding molecules that specifically bind to the regulatory mechanism, and these binding partners to the regulatory mechanism are conjugated to fluorescent dyes, radioactive tracers, iron oxide nanoparticles, or contrast agents for detection by X-ray, CT scan, MRI scan, PET scan, ultrasound, flow cytometry, near-infrared imaging systems, or other imaging methods known in the art (see, e.g., Yu, et al., Theranostics 2:3, 2012).

[0160] Thus, engineered cells expressing at least one regulatory mechanism equipped with a CAR can, for example, be much easier to identify, isolate, sort, induce growth, track, and / or eliminate compared to engineered cells lacking the tag cassette.

[0161] (iv) Cell activation culture conditions. The cell population can be incubated in culture start medium to grow the genetically engineered cell population. The incubation can be performed in a culture vessel, such as a bag, cell culture plate, flask, chamber, chromatography column, cross-linked gel, cross-linked polymer, column, culture dish, hollow fiber, microtiter plate, silica-coated glass plate, tube, tubing set, well, vial, or other culture or cell culture vessel.

[0162] Culture conditions may include one or more of a particular medium, temperature, oxygen content, carbon dioxide content, time, agents such as nutrients, amino acids, antibiotics, ions, and / or stimuli such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and other agents designed to activate the cells.

[0163] In some embodiments, the incubation is performed according to techniques such as those described in US 6,040,177, Klebanoff et al. (2012) J Immunother. 35(9):651-660, Terakura et al. (2012) Blood. 1:72-82, and / or Wang et al. (2012) J Immunother. 35(9):689-701.

[0164] Exemplary media for culturing T cells include: (i) RPMI supplemented with non-essential amino acids, sodium pyruvate, and penicillin / streptomycin; (ii) RPMI with HEPES, 5-15% human serum, 1-3% L-glutamine, 0.5-1.5% penicillin / streptomycin, and 0.25×10-4 to 0.75×10-4 M β-mercaptoethanol; (iii) RPMI with 10% fetal bovine serum albumin; (iv) DMEM medium supplemented with 10% FBS, 2 mM L-glutamine, 10 mM HEPES, 100 U / ml penicillin, and 100 μg / mL streptomycin; and (v) X-Vivo 15 medium (Lonza, Walkersville, MD) supplemented with 5% human AB serum (Gemcell, West Sacramento, CA), 1% HEPES (Gibco, Grand Island, NY), 1% Pen-Strep (Gibco), 1% GlutaMax (Gibco), and 2% N-acetylcysteine ​​(Sigma-Aldrich, St. Louis, MO). Media for culturing T cells are also commercially available from Hyclone (Logan, UT). Additional T cell activation components that may be added to such media are described in more detail below.

[0165] In some embodiments, the T cells are expanded by adding feeder cells to the culture initiation medium (e.g., such that the resulting cell population contains at least 5, 10, 20, or 40 or more feeder cells per T lymphocyte in the initial population to be expanded) and incubating the culture (e.g., for a time sufficient to expand the number of T cells). In some aspects, the non-dividing feeder cells can include gamma-irradiated feeder cells. In some embodiments, the feeder cells are irradiated with gamma radiation ranging from 3000 to 3600 rads to prevent cell division. In some aspects, the feeder cells are added to the medium prior to addition of the T cell population. In certain embodiments, the time sufficient to expand the number of T cells includes 24 hours. In certain embodiments, the ratio of T cells to feeder cells is 1:1, 2:1, or 1:2. In certain embodiments, the feeder cells include cells expressing FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1. In certain embodiments, the feeder cells comprise cancer cells, hi certain embodiments, the feeder cells comprise AML feeder cells.

[0166] In some embodiments, the stimulatory conditions include a temperature suitable for the growth of human T lymphocytes, for example, at least 25°C, at least 30°C, or at least 37°C.

[0167] Activation culture conditions for T cells include conditions under which T cells in the culture initiation medium proliferate or expand. T cell activation conditions can include one or more cytokines, such as interleukin (IL)-2, IL-7, IL-15, and / or IL-21. IL-2 can be included in the range of 10-100 ng / ml (e.g., 40, 50, or 60 ng / ml). IL-7, IL-15, and / or IL-21 can be included individually in the range of 0.1-50 ng / ml (e.g., 5, 10, or 15 ng / ml).

[0168] In certain embodiments, the T cell activating culture conditions may include T cell stimulatory epitopes, including CD3, CD27, CD2, CD4, CD5, CD7, CD8, CD28, CD30, CD40, CD56, CD83, CD90, CD95, 4-1BB (CD 137), B7-H3, CTLA-4, Frizzled-1 (FZD1), FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, FZD10, HVEM, ICOS, IL-1R, LAT, LFA-1, LIGHT, MHCI, MHCII, NKG2D, OX40, ROR2, and RTK.

[0169] CD3 is the primary signaling element of the T cell receptor. As mentioned above, CD3 is expressed on all mature T cells. In certain embodiments, the CD3 stimulatory molecule (i.e., CD3 binding domain) can be derived from the OKT3 antibody (see US 5,929,212, US 4,361,549, ATCC® CRL-8001™, and Arakawa et al., J. Biochem. 120, 657-662 (1996)), the 20G6-F3 antibody, the 4B4-D7 antibody, the 4E7-C9 antibody, or the 18F5-H10 antibody.

[0170] In certain embodiments, the CD3 stimulatory molecule may be included in the medium at a concentration of at least 0.25 or 0.5 ng / ml, or at a concentration of 2.5-10 μg / ml. Certain embodiments use a CD3 stimulatory molecule (e.g., OKT3) at 5 μg / ml.

[0171] In certain embodiments, the activation molecule associated with an avi tag can be biotinylated and bound to streptavidin beads. This approach can be used, for example, to create a removable T cell epitope stimulated activation system.

[0172] Exemplary binding domains for CD28 may include or be derived from TGN1412, CD80, CD86 or 9D7 antibodies. Additional antibodies that bind to CD28 include 9.3, KOLT-2, 15E8, 248.23.2, EX5.3D10, and CD28.3 (deposited as a synthetic single chain Fv construct under GenBank accession number AF451974.1, see also Vanhove et al., BLOOD, 15 Jul. 2003, Vol. 102, No. 2, pages 564-570). Additionally, 1YJD provides a crystal structure of human CD28 in complex with a Fab fragment of a mitogenic antibody (5.11A1). In certain embodiments, an antibody that does not compete with 9D7 is selected.

[0173] The 4-1BB binding domain may be derived from LOB12, IgG2a, LOB12.3, or IgG1, as described in Taraban et al. Eur J Immunol. 2002 December; 32(12): 3617-27. In certain embodiments, the 4-1BB binding domain is derived from a monoclonal antibody described in US 9,382,328. Further 4-1BB binding domains are described in US 6,569,997, US 6,303,121, and Mittler et al. Immunol Res. 2004; 29(1-3): 197-208.

[0174] OX40 (CD134) and / or ICOS activation may also be used. OX40 binding domains are described in US20100196359, US 20150307617, WO 2015 / 153513, WO2013 / 038191 and Melero et al. Clin Cancer Res. 2013 Mar. 1; 19(5): 1044-53. Exemplary binding domains capable of binding and activating ICOS are described, for example, in US20080279851 and Deng et al. Hybrid Hybridomics. 2004 June; 23(3): 176-82.

[0175] When in soluble form, the T cell stimulator can be conjugated with another molecule, for example, a polyethylene glycol (PEG) molecule. Any suitable PEG molecule can be used. Usually, PEG molecules with molecular weights up to 1000 Da are soluble in water or medium. In some cases, such PEG-based reagents can be prepared using commercially available activated PEG molecules (e.g., PEG-NHS derivatives available from NOF North America Corporation, Irvine, Calif., USA, or activated PEG derivatives available from Creative PEGWorks, Chapel Hills, NC, USA).

[0176] In certain embodiments, the cell stimulant is fixed to a solid phase in the medium.In certain embodiments, the solid phase is the surface of a culture vessel (e.g., a bag, a cell culture plate, a chamber, a chromatography column, a cross-linked gel, a cross-linked polymer, a column, a culture dish, a hollow fiber, a microtiter plate, a silica-coated glass plate, a tube, a tubing set, a well, a vial, or other structure or vessel for cell culture or cultivation).

[0177] In certain embodiments, a solid phase can be added to the medium, such as, for example, beads, hollow fibers, resins, membranes, and polymers.

[0178] Exemplary beads include magnetic, polymeric, and resin beads (e.g., Strep-Tactin® Sepharose, Strep-Tactin® Superflow, and Strep-Tactin® MacroPrep IBA GmbH, Göttingen). Anti-CD3 / anti-CD28 beads are commercially available reagents for T cell proliferation (Invitrogen). These beads are uniform, 4.5 μm superparamagnetic, sterile, non-pyrogenic polystyrene beads coated with a mixture of affinity-purified monoclonal antibodies against CD3 and CD28 cell surface molecules of human T cells. Hollow fibers are available from TerumoBCT Inc. (Lakewood, Colo., USA). Resins include metal affinity chromatography (IMAC) resins (e.g., TALON® resins (Westburg, Leusden)). Membranes include paper and chromatographic matrix membrane substrates (e.g., nitrocellulose or polyvinylidene fluoride (PVDF) membranes).

[0179] Exemplary polymers include polysaccharides, such as polysaccharide matrices. Such matrices include agarose gels (e.g., Superflow™ agarose or Sepharose® materials, such as Superflow™ Sepharose®, which are commercially available in different bead and pore sizes) or gels of cross-linked dextran(s). A further illustrative example is commercially available as Sephadex® or Superdex® (in various bead and pore sizes), both available from GE Healthcare, which are particulate cross-linked agarose matrices to which dextran is covalently attached.

[0180] Synthetic polymers that can be used include polyacrylamides, polymethacrylates, copolymers of polysaccharides and agarose (e.g., polyacrylamide / agarose complexes), or copolymers of polysaccharides and N,N'-methylenebisacrylamide. Examples of copolymers of dextran and N,N'-methylenebisacrylamide are the Sephacryl® (Pharmacia Fine Chemicals, Inc., Piscataway, NJ) series of materials.

[0181] Certain embodiments may use silica particles bound to synthetic or natural polymers, such as polysaccharide-grafted silica, polyvinylpyrrolidone-grafted silica, polyethylene oxide-grafted silica, poly(2-hydroxyethylaspartamide) silica, and poly(N-isopropylacrylamide)-grafted silica.

[0182] The cell stimulant may be immobilized on the solid phase via covalent bonds or reversibly immobilized via non-covalent bonds.

[0183] In certain embodiments, T cells are activated with anti-CD3 / CD28 beads in Retronectin coated plates (beads:cells 3:1, Gibco, 11131D). In certain embodiments, CAR T cells are selected with CD19 microbeads 8-10 days after activation. In certain embodiments, selected cells are further expanded in CTL (+50 U / mL IL-2) medium.

[0184] Culture conditions for HSC / HSP may include Notch agonist proliferation (see, e.g., US 7,399,633, US 5,780,300, US 5,648,464, US 5,849,869, and US 5,856,441), and the following growth factors present in the culture conditions: 25-300 ng / ml SCF, 25-300 ng / ml Flt-3L, 25-100 ng / ml TPO, 25-100 ng / ml IL-6, and 10 ng / ml IL-3. In further specific embodiments, 50, 100, or 200 ng / ml SCF, 50, 100, or 200 ng / ml Flt-3L, 50 or 100 ng / ml TPO, 50 or 100 ng / ml IL-6, and 10 ng / ml IL-3 may be used.

[0185] (v) Cell preparations produced ex vivo. In certain embodiments, genetically engineered cells may be harvested from culture medium, washed, and concentrated in a carrier in a therapeutically effective amount. Exemplary carriers include saline, buffered saline, saline, water, Hank's solution, Ringer's solution, Nonnosol-R (Abbott Labs), PLASMA-LYTE A® (Baxter Laboratories, Inc., Morton Grove, IL), glycerol, ethanol, and combinations thereof.

[0186] In certain embodiments, carriers can be supplemented with human serum albumin (HSA) or other serum components or fetal bovine serum.In certain embodiments, carriers for injection include buffered saline containing 5% HSA or dextrose.Additional isotonicity agents include polyhydric sugar alcohols, including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol.

[0187] Carriers can include buffers, such as citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers, and / or trimethylamine salts.

[0188] Stabilizers refer to a broad category of excipients that can range in function, from bulking agents to additives that help prevent cell adhesion to the container wall. Exemplary stabilizers include polyhydric sugar alcohols, amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, and threonine, organic sugars or sugar alcohols such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinositol, galactitol, glycerol, and cyclitols such as inositol, PEG, amino acid polymers, sulfur-containing reducing agents such as urea, glutamine, and glycerol. Examples of suitable sugars include thiones, thioctic acid, sodium thioglycolate, thioglycerol, alpha-monothioglycerol, and sodium thiosulfate, low molecular weight polypeptides (i.e., <10 residues), proteins such as HSA, bovine serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, monosaccharides such as xylose, mannose, fructose, and glucose, disaccharides such as lactose, maltose, and sucrose, trisaccharides such as raffinose, and polysaccharides such as dextran.

[0189] Where necessary or beneficial, the compositions and / or preparations may include a local anesthetic such as lidocaine to ease pain at the site of the injection.

[0190] Exemplary preservatives include phenol, benzyl alcohol, meta-cresol, methylparaben, propylparaben, octadecyldimethylbenzylammonium chloride, benzalkonium halides, hexamethonium chloride, alkylparabens, such as methyl or propylparaben, catechol, resorcinol, cyclohexanol, and 3-pentanol.

[0191] The therapeutically effective amount of cells in the composition and / or formulation is 10 2 More than 10 cells 3 More than 10 cells 4 More than 10 cells 5 More than 10 cells 6 More than 10 cells 7 More than 10 cells 8 More than 10 cells 9 More than 10 cells 10 More than 10 cells, or 11 There may be more than one.

[0192] In the compositions and formulations disclosed herein, the cells are generally contained in a volume of 1 liter or less, 500 ml or less, 250 ml or less, or 100 ml or less. Thus, the density of cells administered is typically less than 10 4 >10 cells / ml 7 cells / ml or 10 8 cells / ml.

[0193] As discussed above, the preparation includes at least one type of engineered cell (e.g., engineered T cells, NK cells, or stem cells). The preparation can include different types of engineered cells (e.g., a combination of T cells, NK cells, and / or stem cells).

[0194] Different types of engineered cells or cell subsets (e.g., engineered T cells, NK cells, and / or stem cells) can be provided in different ratios, such as 1:1:1 ratio, 2:1:1 ratio, 1:2:1 ratio, 1:1:2 ratio, 5:1:1 ratio, 1:5:1 ratio, 1:1:5 ratio, 10:1:1 ratio, 1:10:1 ratio, 1:1:10 ratio, 2:2:1 ratio, 1:2:2 ratio, 2:1:2 ratio, 5:5:1 ratio, 1:5:5 ratio, 5:1:5 ratio, 10:10:1 ratio, 1:10:10 ratio, 10:1:10 ratio, etc. These ratios can also be applied to cell numbers expressing the same or different CAR components. When only two of the cell types are combined, or when only two combinations of expressed CAR components are included in the formulation, the ratios can include any two number combinations that can be created from the combinations of the three numbers above. In embodiments, the combined cell populations are tested for efficacy and / or cell proliferation in vitro, in vivo and / or ex vivo, and the ratio of cells that conferred efficacy and / or cell proliferation is selected.

[0195] The cell-based formulations disclosed herein can be prepared for administration, for example, by injection, infusion, perfusion, or lavage. The formulations can further be formulated for bone marrow, intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intratumoral, intravesical, and / or subcutaneous injection.

[0196] (vi) Antibody conjugate. An antibody conjugate refers to a binding domain as disclosed herein linked to another entity. The other entity may be, for example, a toxin, a drug, a label, a radioisotope, or a nanoparticle. In certain examples, the antibody conjugate is an immunotoxin, an antibody drug conjugate (ADC), an antibody radioisotope conjugate, or an antibody nanoparticle conjugate.

[0197] Immunotoxins include the binding domains disclosed herein (e.g., antibodies or binding fragments thereof) conjugated to one or more cytotoxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof). A toxin can be any agent that is harmful to cells. Frequently used plant toxins are divided into two classes: (1) holotoxins (or class II ribosome-inactivating proteins), such as ricin, abrin, mistletoe lectin, and modeccin, and (2) hemitoxins (class I ribosome-inactivating proteins), such as pokeweed antiviral protein (PAP), saporin, Bryodin 1, bouganin, and gelonin. Commonly used bacterial toxins include diphtheria toxin (DT) and Pseudomonas aeruginosa exotoxin (PE). Kreitman, Current Pharmaceutical Biotechnology 2:313-325 (2001). The toxins can be from essentially any source and can be synthetic or natural.

[0198] Immunotoxins with multiple (e.g., four) cytotoxins per binding domain can be prepared by partially reducing the binding domain with an excess of reducing reagent, such as dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP), for 30 minutes at 37°C, and then the buffer can be exchanged by eluting through SEPHADEX G-25 resin with Dulbecco's phosphate buffered saline (DPBS) containing 1 mM DTPA (diethylenetriaminepentaacetic acid). The eluate can be further diluted with DPBS, and the thiol concentration of the binding domain can be measured using 5,5'-dithiobis(2-nitrobenzoic acid) [Ellman's reagent]. An excess, e.g., 5-fold, of linker-cytotoxin conjugate can be added for 1 hour at 4°C, and the conjugation reaction can be quenched by adding a large excess, e.g., 20-fold, of cysteine. The resulting immunotoxin mixture can be purified with SEPHADEX G-25 equilibrated with PBS to remove unreacted linker-cytotoxin conjugates, desalted if necessary, and purified by size exclusion chromatography. The resulting immunotoxin can then be sterile filtered, for example through a 0.2 μm filter, and, if necessary, lyophilized for storage.

[0199] In certain embodiments, the immunotoxin may comprise a binding domain conjugated to a toxin for target cell killing.

[0200] Antibody drug conjugates (ADCs) allow for targeted delivery of a drug moiety to cells expressing a target cell marker. In certain embodiments, the drug moiety may comprise a cytotoxic or therapeutic drug or agent.

[0201] In certain embodiments, ADC refers to targeted chemotherapy molecules that combine the properties of both a binding domain and a cytotoxic drug to target a potent cytotoxic drug to cancer cells expressing an antigen (Teicher, BA (2009) Current Cancer Drug Targets 9:982-1004), thereby enhancing the therapeutic index by maximizing efficacy and minimizing off-target toxicity (Carter, PJ and Senter PD (2008) The Cancer Jour. 14(3):154-169; Chari, RV (2008) Acc. Chem. Res. 41:98-107). See also Kamath & Iyer (Pharm Res. 32(11):3470-3479, 2015), which describes considerations for the development of ADCs.

[0202] The cytotoxic drug moieties of the ADCs may include any compound, moiety, or group that has cytotoxic or cytostatic activity. Cytotoxic drug moieties may impart their cytotoxic and cytostatic effects by mechanisms including tubulin binding, DNA binding or intercalation, and inhibition of RNA polymerase, protein synthesis, and / or topoisomerase. Exemplary drugs include actinomycin D, anthracyclines, auristatins, calicheamicin, camptothecin, CC1065, colchicine, cytochalasin B, daunorubicin, 1-dehydrotestosterone, dihydroxyanthracenedione, dolastatins, doxorubicin, duocarmycin, elinafide, emetine, ethidium bromide, etoposide, gramicidin D, glucocorticoids, lidocaine, maytansinoids (monomethyl ether, methyltransferase ... Statin E [MMAE], including vedotin), mithramycin, mitomycin, mitoxantrone, nemorubicin, PNU-159682, procaine, propranolol, puromycin, pyrrolobenzodiazepines (PBDs), taxanes, taxol, teniposide, tetracaine, trichothecenes, vinblastine, vinca alkaloids, vincristine, and their stereoisomers, isosteres, analogs, and derivatives that have cytotoxic activity.

[0203] In certain embodiments, the ADC compound comprises a binding domain conjugated, i.e., covalently linked, to the drug moiety. In certain embodiments, the binding domain is covalently linked to the drug moiety via a linker. The linker can include any chemical moiety capable of linking a binding domain, an antibody, an antibody fragment (e.g., an antigen-binding fragment) or a functional equivalent to another moiety, e.g., a drug moiety. The linker can be susceptible to cleavage, e.g., acid cleavage, light cleavage, peptidase cleavage, esterase cleavage, and disulfide bond cleavage (cleavable linker), under conditions in which the compound or binding domain remains active. Alternatively, the linker can be substantially resistant to cleavage (e.g., stable linker or non-cleavable linker). In some aspects, the linker is a pro-charged linker, a hydrophilic linker, or a dicarboxylic acid-based linker. Such ADCs selectively deliver an effective dose of drug to cancer cells, thereby allowing greater selectivity, i.e., lower effective doses, to be achieved while increasing the therapeutic index ("therapeutic window").

[0204] To prepare ADC, linker-drug conjugates can be prepared by conventional methods similar to those described by Doronina et al. (Bioconjugate Chem.17:114-124,2006). Antibody-drug conjugates with multiple (e.g., 4) drugs per binding domain can be prepared by partially reducing the binding domain with excess reducing reagent, such as dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP), at 37°C for 30 minutes, and then buffer exchange can be performed by eluting through SEPHADEX G-25 resin with Dulbecco's phosphate buffered saline (DPBS) containing 1 mM DTPA. The eluate can be further diluted with DPBS, and the thiol concentration of the binding domain can be measured using 5,5'-dithiobis(2-nitrobenzoic acid) [Ellman's reagent]. An excess of, for example, 5 times, the linker-drug conjugate can be added for 1 hour at 4°C, and the conjugation reaction can be quenched by adding a large excess of, for example, 20 times, cysteine. The resulting ADC mixture can be purified with SEPHADEX G-25 equilibrated with PBS to remove unreacted linker-drug conjugate, desalted as required, and purified by size exclusion chromatography. The resulting ADC can then be sterile filtered, for example, through a 0.2 μm filter, and lyophilized for storage as required.

[0205] Antibody-radioisotope conjugates contain a binding domain linked to a radioisotope for use in nuclear medicine. Nuclear medicine refers to the diagnosis and / or treatment of conditions by administering a radioactive isotope (radioisotope or radionuclide) to a subject. Therapeutic nuclear medicine is often referred to as radiation therapy or radioimmunotherapy (RIT).

[0206] Examples of radioisotopes that can be conjugated to the binding domains of the present disclosure include actinium-225, iodine-131, arsenic-211, iodine-131, indium-111, yttrium-90, and lutetium-177, as well as alpha-decay nuclides, such as astatine-211 or bismuth-212 or bismuth-213. Methods for preparing radioimmunoconjugates are established in the art. Examples of radioimmunoconjugates are commercially available, including Zevalin™ (DEC Pharmaceuticals), and similar methods can be used to prepare radioimmunoconjugates using the binding domains of the present disclosure.

[0207] Examples of radionuclides useful in radiation therapy include: 225 Ac and 227 Examples include Th. 225 Ac is a radioactive nuclide with a half-life of 10 days. 225 As Ac decays, the daughter nuclide 221 Fr, 213 Bi, and 209 Pb is produced. 227 Th has a half-life of 19 days and is the daughter nuclide 223 This results in Ra.

[0208] Further examples of useful radioisotopes include: 228 Ac, 111 Ag, 124 Am, 74 As, 211 As, 209 At, 194 Au, 128 Ba, 7 Be, 206 Bi, 245 Bk, 246 Bk, 76 Br, 11 C. 47 Ca, 254 Cf, 242 Cm, 51 Cr, 67 Cu, 153 Dy, 157 Dy, 159 Dy, 165 Dy, 166 Dy,171 Do, 250 Es、 254 Es、 147 Eu、 157 Eu、 52 Fe、 59 Fe、 251 Fm、 252 Fm、 253 Fm、 66 Won't, 72 Won't, 146 Gd、 153 Gd、 68 Here、 170 Hf、 171 Hf、 193 Hg、 193 mHg、 160 mHo、 130 I、 131 I、 135 I、 114 mIn、 185 They、 42 K、 43 K、 76 Kr、 79 Kr、 81 mKr、 132 That, 262 Lr、 169 Is, 174 I was, 176 I was, 257 Md、 260 Md、 28 Mg、 52 Mn、 90 I, 24 Provide, 95 Nb、 138 Nd、 57 Ni、 66 Ni、 234 Np、 15 O、 182 Os、 189 mOs、 191 Os、 32 P、 201 Pb、 101 Pd、 143 Pr、 191 Pt、 243 Pu、 225 Ra、 81 Rb、 188 Re、 105 Rh、 211 Rn、 103 Ru、 35S, 44 Sc, 72 Se, 153 Sm, 125 Sn, 91 Sr, 173 Ta, 154 Tb, 127 Te, 234 Th, 45 Ti, 166 Tm, 230 U, 237 U, 240 U, 48 V, 178 W, 181 W, 188 W, 125 Xe, 127 Xe, 133 Xe, 133 mXe, 135 Xe, 85 mY, 86 Y, 90 Y, 93 Y, 169 Yb, 175 Yb, 65 Zn, 71 mZn, 86 Zr, 95 Zr, and / or 97 Zr is an example.

[0209] In certain embodiments, the antibody complex comprises an antibody nanoparticle complex. The antibody nanoparticle complex can function in the targeted delivery of payload (e.g., small molecule or genetically engineered moiety) to cells expressing the target cell marker, ex vivo or in vivo. For example, scFv or other binding fragments can be linked to the surface of nanoparticles to guide delivery to target cells. The linkage can be, for example, via covalent bond.

[0210] Examples of nanoparticles include metal nanoparticles (eg, gold, platinum, or silver), liposomes, and polymer-based nanoparticles.

[0211] Methods for forming liposomes are described, for example, in U.S. Patent Nos. 4,229,360, 4,224,179, 4,241,046, 4,737,323, 4,078,052, 4,235,871, 4,501,728, and 4,837,028, as well as Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980) and Hope et al., Chem. Phys. Lip. 40:89 (1986). For more information on nanoparticles, see Yetisgin et al., Molecules 2020, 25, 2193.

[0212] Examples of polymers that can be used within the nanoparticles include polyglutamic acid (PGA), poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), poly-D-lactic acid (PDLA), PLGA-dimethacrylate, polyamines, polyorganoamines (e.g., polyethyleneimine (PEI), polyethyleneimine cellulose), poly(amidoamine) (PAMAM), polyamino acids (e.g., polylysine (PLL), polyarginine), polysaccharides (e.g., cellulose, dextran, DEAE dextran, starch), spermine, spermidine, poly(vinylbenzyltrialkylammonium), poly(4-vinyl-N-alkyl-pyridiumiun), poly(acryloyl-trialkylammonium), and Tat protein.

[0213] In certain embodiments, the nanoparticles may include a coating, particularly when used in vivo. The coating may serve to protect the encapsulated cargo and / or reduce or prevent off-target binding. Off-target binding is reduced or prevented by reducing the surface charge of the nanoparticle to neutral or negative. The coating may include a neutral or negatively charged polymer-based and / or liposome-based coating. In certain embodiments, the coating is a dense surface coating of hydrophilic and / or hydrophilic polymers with a neutral charge sufficient to prevent the encapsulated cargo from being exposed to the environment before release into the target cell. In certain embodiments, the coating covers at least 80% or at least 90% of the surface of the nanoparticle.

[0214] Examples of polymers with a neutral charge that can be used as nanoparticle coatings include polyethylene glycol (PEG), poly(propylene glycol), and polyalkylene oxide copolymers, (PLURONIC®, BASF Corp., Mount Olive, NJ).

[0215] Particle size can vary widely and can be measured in a variety of ways. In a preferred embodiment, the nanoparticles are less than 130 nm in diameter. However, the nanoparticles can also have a minimum dimension of 500 nm or less, less than 150 nm, less than 140 nm, less than 120 nm, less than 110 nm, less than 100 nm, less than 90 nm, less than 80 nm, less than 70 nm, less than 60 nm, less than 50 nm, less than 40 nm, less than 30 nm, less than 20 nm, or less than 10 nm. In a particular embodiment, the nanoparticles are 90-130 nm in diameter.

[0216] The size of the particles can be measured, for example, using conventional techniques such as dynamic light scattering and / or electron microscopy.

[0217] (vii) Compositions. The compositions described herein comprise (i) an antibody or antibody-binding fragment, (ii) an antibody conjugate, and / or (iii) a nanoparticle (hereinafter collectively referred to as "active ingredient"), and a pharma- ceutically acceptable carrier. Any of the active ingredients described herein, in any exemplary configuration or complex form, can be formulated into a composition, alone or in combination, for administration to a subject. Salts and / or prodrugs of the active ingredients can also be used.

[0218] Pharmaceutically acceptable salts include any salt that retains the activity of the active ingredient and is applicable for pharmaceutical use. Pharmaceutically acceptable salts also refer to any salt that may be formed in vivo as a result of administering an acid, another salt, or a prodrug that is converted into an acid or salt.

[0219] Suitable pharma- ceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid. Suitable organic acids can be selected from the aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.

[0220] Suitable pharma- ceutically acceptable base addition salts include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc, or organic salts made from N,N'-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine), lysine, arginine, and procaine.

[0221] Prodrugs include active ingredients that are converted into therapeutically active compounds after administration, for example, by cleavage or hydrolysis of biologically labile groups.

[0222] Exemplary commonly used pharma- ceutically acceptable carriers include any and all absorption retarders, antioxidants, binders, buffers, bulking agents or fillers, chelating agents, coatings, disintegrants, dispersion media, gels, isotonic agents, lubricants, preservatives, salts, solvents or cosolvents, stabilizers, surfactants, and / or delivery vehicles. Exemplary carriers include saline, buffered saline, saline, water, Hank's solution, Ringer's solution, Nonnosol-R (Abbott Labs), Plasma-Lyte A® (Baxter Laboratories, Inc., Morton Grove, IL), glycerol, ethanol, and combinations thereof.

[0223] Exemplary antioxidants include ascorbic acid, methionine, and vitamin E.

[0224] Exemplary buffers include citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers, and / or trimethylamine salts.

[0225] An exemplary chelating agent is EDTA (ethylenediaminetetraacetic acid).

[0226] Exemplary isotonicity agents include polyhydric sugar alcohols, including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol.

[0227] Exemplary preservatives include phenol, benzyl alcohol, meta-cresol, methylparaben, propylparaben, octadecyldimethylbenzylammonium chloride, benzalkonium halides, hexamethonium chloride, alkylparabens, such as methyl or propylparaben, catechol, resorcinol, cyclohexanol, and 3-pentanol.

[0228] Stabilizers refer to a broad category of excipients that can range in function, from bulking agents to additives that help solubilize the active ingredient or prevent denaturation or adhesion to the container wall. Exemplary stabilizers include polyhydric sugar alcohols, amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, and threonine, organic sugars or sugar alcohols such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinositol, galactitol, glycerol, and cyclitols such as inositol, PEG, amino acid polymers, sulfur-containing reducing agents such as urea, glutathione, glycerol ... Examples of suitable stabilizers include thioctic acid, sodium thioglycolate, thioglycerol, α-monothioglycerol, and sodium thiosulfate, low molecular weight polypeptides (i.e., <10 residues), proteins such as human serum albumin, bovine serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, monosaccharides such as xylose, mannose, fructose, and glucose, disaccharides such as lactose, maltose, and sucrose, trisaccharides such as raffinose, and polysaccharides such as dextran. Stabilizers are typically present in the range of 0.1 to 10,000 parts by weight based on the weight of the therapeutic agent.

[0229] The compositions disclosed herein may be formulated for administration, for example, by injection, inhalation, infusion, perfusion, lavage, or ingestion. The compositions disclosed herein may further be formulated for intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesical, oral, sublingual, and / or subcutaneous administration.

[0230] For injection, the composition may be formulated as an aqueous solution, for example in a buffer solution including Hank's solution, Ringer's solution, or physiological saline. The aqueous solution may contain formulatory agents such as suspending agents, stabilizing agents and / or dispersing agents. Alternatively, the composition may be in lyophilized and / or powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.

[0231] Composition can be formulated as aerosol.In certain embodiments, said aerosol is provided as part of anhydrous, liquid or dry powder inhaler.Aerosol spray from pressurized pack or nebulizer can also be used with suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.

[0232] Additionally, the compositions can be formulated as a sustained-release system using semipermeable matrices of solid polymers containing at least one type of antibody conjugate or nanoparticles.

[0233] In certain embodiments, the composition comprises the active ingredient in at least 0.1% w / v or w / w of the composition, at least 1% w / v or w / w of the composition, at least 10% w / v or w / w of the composition, at least 20% w / v or w / w of the composition, at least 30% w / v or w / w of the composition, at least 40% w / v or w / w of the composition, at least 50% w / v or w / w of the composition, at least 60% w / v or w / w of the composition, at least 70% w / v or w / w of the composition, at least 80% w / v or w / w of the composition, at least 90% w / v or w / w of the composition, at least 95% w / v or w / w of the composition, or at least 99% w / v or w / w of the composition.

[0234] Any composition disclosed herein can advantageously contain any other pharma- ceutically acceptable carrier, including those that do not cause significant side effects, allergic reactions, or other adverse reactions that outweigh the benefits of administration.Exemplary pharma-ceutically acceptable carriers are disclosed in Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990.Furthermore, the composition can be prepared to meet the sterility, pyrogenicity, general safety, and purity standards required by the biological standards of the U.S. Food and Drug Administration and / or other relevant foreign regulatory agencies.

[0235] (viii) Methods of Use. The methods disclosed herein include treating subjects (humans, veterinary animals (dogs, cats, reptiles, birds, etc.), livestock (horses, cows, goats, pigs, chickens, etc.), and research animals (monkeys, rats, mice, fish, etc.) with the formulations and / or compositions disclosed herein. Treating a subject includes delivering a therapeutically effective amount. A therapeutically effective amount includes an amount that provides an effective amount, prophylactic treatment, and / or therapeutic treatment.

[0236] An "effective amount" is the amount of the formulation and / or composition required to produce a desired physiological change in the subject. For example, an effective amount can produce an immunogenic anti-cancer effect. An effective amount is often administered for research purposes. An effective amount disclosed herein can produce a statistically significant effect in an animal model or in vitro assay for evaluating the development or progression of cancer. An amount that induces an immune response can be produced in an effective amount, and the effective amount stimulates the immune response.

[0237] "Prophylactic treatment" includes treatment administered to a subject who does not show signs or symptoms of cancer, or who only shows early signs or symptoms of cancer, such that the treatment is administered with the intent of reducing or lowering the risk of further development of the cancer. Thus, prophylactic treatment serves as a preventative treatment against cancer.

[0238] "Therapeutic treatment" includes treatment administered to a subject who exhibits symptoms or signs of cancer, for the purpose of reducing or eliminating the signs or symptoms of the cancer. The therapeutic treatment may reduce, control, or eliminate the presence or activity of the cancer, and / or reduce, control, or eliminate the side effects of the cancer.

[0239] As a function of the effective amount, prophylactic or therapeutic treatments are not mutually exclusive, and in certain embodiments, more than one type of treatment may be achieved by an administered dose.

[0240] In certain embodiments, the therapeutically effective amount provides an anti-cancer effect, including reducing cancer cell count, reducing tumor size, increasing life expectancy, inducing chemo- or radio-sensitivity in cancer cells, inhibiting the proliferation of cancer cells, increasing the lifespan of a subject, reducing cancer-related pain, and / or reducing the relapse or re-occurrence of cancer following treatment.

[0241] In certain embodiments, the therapeutically effective amount induces an immune response, which can be against cancer cells.

[0242] In certain embodiments, the cancer cells express FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and / or FRAS1. In certain embodiments, the cancer includes leukemia, peritoneal cancer, fallopian tube cancer, ovarian cancer (e.g., epithelial ovarian cancer), endometrial cancer, cervical cancer, breast cancer (e.g., triple-negative breast cancer, HER2-breast cancer), bladder cancer, renal cell carcinoma, pituitary tumor, lung cancer (e.g., lung adenocarcinoma or epithelial lung cancer, e.g., non-small cell lung cancer), uterine cancer, squamous cell carcinoma, ureteral cancer, urethral cancer, osteosarcoma, transitional cell carcinoma. In certain embodiments, the leukemia is acute myeloid leukemia (AML). In certain embodiments, the AML is CBFA2T3 / GLIS2(C / G) AML. In certain embodiments, the cancer cells are C / G AML cells that express FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and / or FRAS1. In certain embodiments, the cancer cells are leukemia, peritoneal cancer, fallopian tube cancer, ovarian cancer, endometrial cancer, cervical cancer, breast cancer, bladder cancer, renal cell carcinoma, pituitary tumor, lung cancer, uterine cancer, squamous cell carcinoma, ureteral cancer, urethral cancer, osteosarcoma, or transitional cell carcinoma cells that express FOLR1.

[0243] Clinical trials with the following trial identification numbers further support the efficacy of FOL1R binding in the treatment of various cancer types: GDCT0356356: Indications: Peritoneal Carcinoma (PC), Fallopian Tube Carcinoma (FTC), Epithelial Ovarian Carcinoma (EOC), GDCT0374537: Indications: Ovarian Carcinoma (OC), EOC, FTC, PC, GDCT0429750: Indications: OC, Solid Tumors, Endometrial Carcinoma (EC), Non-Small Cell Lung Cancer (NSCLC), FTC, PC, EOC, Triple Negative Breast Cancer (TNBC), GDCT0026391: Indications: FTC, PC, OC, EOC, GDCT044720 4: Indications: EOC, PC, FTC, GDCT0232423: Indications: EOC, PC, FTC, OC, GDCT0229058: Indications: NSCLC, GDCT0445760: Indications: OC, GDCT0001547: Indications: EOC, OC, PC, FTC, GDCT0198047: Indications: NSCLC, GDCT0201658: Indications: TNBC, breast cancer (BC), human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer (HER2-BC)), GDCT0043006: Indications: OC, GDCT0423171: Indications: OC, GDCT0002756: Indications: EOC, GDCT0011290: Indications: Solid tumors, GDCT0198051: Indications: OC, GDCT0286303: Indications: Metastatic BC, TNBC, BC, HER2-BC, GDCT0227787: Indications: OC, EOC, PC, FTC, GDCT0403589: Indications: FTC, PC, EOC, GDCT0004066: Indications: OC, GDCT0007040: Indications: Metastatic renal cell carcinoma (RCC), RCC, GDCT0007042: Indications: OC, EC, GDCT0445900: Indications: OC, GDCT0041274: Indications: Adenoma, Pituitary Tumor, GDCT0016528: Indications: Lung adenocarcinoma, GDCT0346710: Indications: EC, Uterine cancer (UC), GDCT0347063: Indications: EC, GDCT0347076: Indications: EC, GDCT0014731: Indications: EOC, FTC, PC, OC, GDCT0144078: Indications: OC, GDCT0048904: Indications: Lung adenocarcinoma, NSCLC, GDCT0152905: Indications: NSCLC, Squamous cell carcinoma, GDCT0010332: Indications: PC, EOC, FTC, OC, GDCT0380005: Indications: EOC, OC, FTC, PC, Metastatic OC,GDCT0433366: Indications: OC, PC, FTC, EOC, GDCT0291846: Indications: Bladder cancer, transitional cell carcinoma (urothelial cell carcinoma), RCC, ureteral cancer, urethral cancer, metastatic transitional (urinary ductal carcinoma, bladder cancer, GDCT0381573: Indications: TNBC, EC, OC, NSCLC, PC, FTC, EOC, GDCT0232424: Indications: EOC, PC, FTC, EC, O C, GDCT0325007: Indications: EC, OC, FTC, PC, carcinoma, UC, metastatic BC, GDCT0401603: Indications: BC, Lung cancer (LC), GDCT0405347: Indications: OC, GDCT0429611: Indications: EOC, EC, solid tumors, PC, FTC, NSCLC, GDCT0209078: Indications: solid tumors, GDCT0158131: Indications: solid tumors, EC, EOC, NSCLC, OC, FTC, PC, transitional cell carcinoma (urothelial cell carcinoma), cervical cancer, RCC, GDCT0301058: Indication: Osteosarcoma, GDCT0456860: Indication: NSCLC, RCC, EOC, solid tumor, FTC, PC, EC, squamous non-small cell lung cancer, GDCT0450501: Indication: PC, NSCLC, GDCT0284998: Indication: OC, EOC, Carcinoma, GDCT0005507: Indications: OC, EOC, GDCT0006565: Indications: Metastatic cancer Advanced malignancies, GDCT0250249: Indications: Unspecified cancer, GDCT0006477: Indications: Metastatic cancer, GDCT0291176: Indications: Osteosarcoma, GDCT0429953: Indications: OC, GDCT0002840: Indications: Solid tumors, GDCT0017012: Indications: Solid tumors Lymphoma, GDCT0007464: Indications: Advanced malignancies, solid tumors, metastatic OC, unspecified cancer, GDCT0205391: Indications: Solid tumors, OC, EC, NSCLC, TNBC, GDCT0452526: Indications: Osteosarcoma, GDCT0198062: Indications: Metastatic RCC, OC, GDCT0281679: Indications: TNBC, GDCT0243737: Indications: OC, FTC, solid tumors, malignant mesothelioma, EC, GDCT0170283: indications: EC, advanced malignancies, metastatic cancer, solid tumors, GDCT0162335: indications: solid tumors, GDCT0289943: indications: solid tumors, EC, TNBC, OC, FTC, NSCLC, PC, GDCT0279766: indications: OC, GDCT0278064: indications: FTC, OC, PC, UC,EC, Carcinoma, TNBC, BC, GDCT0250120: Indications: TNBC, GDCT0295131: Indications: OC, LC, TNBC, GDCT0391284: Indications: FTC, EC, EOC, Peritoneal tumors, OC, PC, GDCT0003999: Indications: Metastatic cancer, Metastatic RCC, GDCT0011743: Indications: FTC, PC, EOC, GDCT0232969: Indications: Solid tumors, Hodgkin lymphoma (B-cell Hodgkin lymphoma), Non-Hodgkin lymphoma, OC, EC, GDCT0327878: Indications: OC, FTC, PC, EOC, GDCT0434405: Indications: Solid tumors, GDCT0319681: Indications: OC, EC, EOC, FTC, PC, Gynecologic cancer.,

[0244] The formulations and / or compositions disclosed herein can also be used to treat complications or diseases associated with C / G AML. For example, complications associated with AML may include the aforementioned myelodysplastic syndromes (MDS, previously known as "preleukemia"), secondary leukemia, particularly secondary AML, leukocytosis, and Auer rod defects. Leukostasis and central nervous system (CNS) disorders, leukocytosis, residual disease, among others, are also considered complications or diseases associated with AML.

[0245] With regard to administration, a therapeutically effective amount (also referred to herein as a dosage) can be initially estimated based on the results of in vitro assays and / or animal model tests. Such information can be used to more accurately determine a dosage useful for a subject of interest. The actual dosage administered to a particular subject can be determined by a physician, veterinarian, or researcher, taking into account parameters such as the target, body weight, severity of the condition, stage of cancer, previous or concurrent therapeutic interventions, physical and physiological factors including the subject's idiopathic disease, and route of administration.

[0246] The therapeutically effective amount of the cell line preparation is 10 4 ~10 9 cells / kg body weight, or 10 3 ~10 11 The therapeutically effective amount administered may comprise 10 cells / kg body weight. 2More than 10 cells 3 More than 10 cells 4 More than 10 cells 5 More than 10 cells 6 More than 10 cells 7 More than 10 cells 8 More than 10 cells 9 More than 10 cells 10 More than 10 cells, or 11 It may include more than one.

[0247] The therapeutically effective amount of the composition may include 0.1 μg / kg to 5 mg / kg body weight, 0.5 μg / kg to 2 mg / kg, or 1 mg / kg to 4 mg / kg. The therapeutically effective amount administered may include greater than 0.1 μg / kg, greater than 0.6 μg / kg, greater than 1 mg / kg, greater than 2 mg / kg, greater than 3 mg / kg, greater than 4 mg / kg, or greater than 5 mg / kg.

[0248] A therapeutically effective amount can be achieved by administration once or multiple times during the course of a treatment regimen (e.g., daily, every other day, every 3rd, 4th, 5th, 6th, weekly, every 2nd, 3rd week, monthly, every 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th month, or yearly). In certain embodiments, the treatment protocol can be determined by a clinical trial protocol or an FDA approved treatment protocol.

[0249] A therapeutically effective amount may be administered, for example, by injection, infusion, perfusion, or lavage. Routes of administration may include intravenous bolus, intradermal, intraarterial, intraparenteral, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intrathecal, intratumor, intravesical, and / or subcutaneous.

[0250] In certain embodiments, the formulations and / or compositions are administered to a patient in combination with (e.g., prior to, concurrently with, or subsequent to) any number of relevant therapies. In certain embodiments, the cells may be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytotoxins, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation.

[0251] (ix) Reference levels obtained from a control population. The values ​​obtained for the parameters associated with the treatment described herein can be compared to the reference levels obtained from a control population, which can indicate whether the treatment described herein is effective for a subject in need thereof. The reference levels can be obtained from one or more relevant datasets from a control population. As used herein, a "dataset" is a set of values ​​obtained from evaluating a sample (or a population of samples) under desired conditions. The values ​​of the dataset can be obtained, for example, by experimentally obtaining measurements from the samples and constructing a dataset from those measurements. As will be understood by those skilled in the art, the reference levels can be based on any mathematical or statistical formula that is useful and known in the art, for example, to arrive at a meaningful population reference value, such as the mean, median, median of the mean, etc., from a collection of individual data points. Alternatively, the reference levels or the datasets for creating the reference levels can be obtained from a service provider, such as a laboratory, or from a database or server on which the datasets are stored.

[0252] The reference levels from the dataset can be obtained from previous measurements obtained from a control population. A "control population" is any grouping of subjects or samples that are comparable in certain characteristics. The grouping can be according to, for example, clinical parameters, clinical assessments, treatment regimens, disease state, severity of condition, etc. In certain embodiments, the grouping is based on age range and absence of immune dysfunction. In certain embodiments, the normal control population includes individuals without immune dysfunction that are age-matched to the test subjects. In certain embodiments, age-matching includes ages that are clinically relevant in the context, such as 0-1 years, 1-2 years, 2-4 years, 4-5 years, 5-18 years, 18-25 years, 25-50 years, 50-80 years, etc. In certain embodiments, the control population can include a population that has cancer with cancer cells that express FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and / or FRAS1 and has never been administered a therapeutically effective amount of a composition or formulation described herein.

[0253] In certain embodiments, an associated reference level for the value of a particular parameter associated with a treatment described herein is obtained based on the value of the particular corresponding parameter associated with the treatment in a control population to determine whether the treatment disclosed herein is therapeutically effective in a subject in need thereof.

[0254] In certain embodiments, conclusions are drawn based on whether a sample value has a statistically significant difference or does not have a statistically significant difference from a reference level. A measurement does not have a statistically significant difference if the difference is within the level expected to occur based on chance alone. In contrast, a statistically significant difference or increase is greater than what is expected to occur simply by chance. Statistical significance or lack thereof can be determined by any of a variety of methods well known to those skilled in the art. An example of a commonly used measure of statistical significance is the p-value. The p-value represents the probability of obtaining a given result equivalent to a particular data point, which data point is the result of chance alone. A result is often considered significant (not by chance) at a p-value of 0.05 or less. In certain embodiments, a sample value is "comparable" to a reference level obtained from a normal control population if the sample value and the reference level are not statistically significantly different.

[0255] (x) Methods of transforming cells. The present disclosure also provides methods and assays for further investigating the cancer biology of C / G AML. A model of C / G AML cells is provided by expressing the C / G fusion construct in cells by any suitable protein expression technology. In certain embodiments, the method includes inserting the C / G fusion construct into a vector, producing viral particles, and transducing a target cell type with the viral particles. In certain embodiments, the transduced cell type is co-cultured with endothelial cells to reconstitute the microenvironment of the C / G AML cells.

[0256] In certain embodiments, the C / G fusion construct can be inserted into a lentiviral vector. In certain embodiments, the C / G fusion construct is a MSCV-CBFA2T3-GLIS2-IRES-mCherry construct. In certain embodiments, the C / G fusion gene and the MND promoter can be inserted into a lentiviral vector. In certain embodiments, the lentiviral vector is a pRRLhPGK-GFP lentiviral vector.

[0257] In certain embodiments, the transduced cells include cord blood (CB) hematopoietic stem and progenitor cells (HSPCs). These cells are referred to herein as C / G-CB cells. In certain embodiments, the transduced cells are grown with Notch ligand at 37° C. in 5% CO2. In certain embodiments, the transduced cells are implanted into animals or grown in monoculture under conditions that stimulate the microenvironment. In certain embodiments, the conditions that stimulate the microenvironment include coculture with endothelial cells. In certain embodiments, the conditions that stimulate the microenvironment include bone marrow promoting conditions. In certain embodiments, the cells are in monoculture at 75,000 cells per well in 6-well plates. In certain embodiments, the cells are in monoculture at 300,000 cells per well in 12-well plates.

[0258] Co-culture with endothelial cells or EC co-culture includes culturing with endothelial cells in serum-free growth medium (SFEM) II supplemented with 50 ng / mL SCF, 50 ng / mL TPO, 50 ng / mL FLT3L, and 100 U / mL penicillin / streptomycin. In certain embodiments, the endothelial cells include human umbilical vein endothelial cells (HUVEC). In certain embodiments, the endothelial cells are transduced with an E4ORF1 construct and expanded. In certain embodiments, the endothelial cells are seeded in 6-well plates at 800,000 cells per well. In certain embodiments, the endothelial cells are seeded in 12-well plates at 300,000 cells per well. The endothelial cells may be cultured in medium 199 supplemented with FBS, endothelial mitogen, heparin, HEPES, L-glutamine, and penicillin / streptomycin. Prior to co-culture, the endothelial cells may be washed with a buffer (e.g., phosphate-buffered saline). In EC co-culture, the endothelial cells may be replaced weekly. In certain embodiments, 3-20% of the culture is replaced weekly.

[0259] Bone marrow promoting conditions or MC comprise Iscove's Modified Dulbecco's Medium (IMDM, Gibco 12-440-053) supplemented with 15% fetal bovine serum (FBS, Corning, 35-010-CV), 100 U / mL penicillin-streptomycin (Pen / Strep, Gibco, 15-140-122), 10 ng / mL SCF, 10 ng / mL TPO, 10 ng / mL FLT3L, 10 ng / mL IL-6 (Shenandoah Biotechnology, Catalog No. 100-10), and 10 ng / mL IL3 (Shenandoah, Catalog No. 100-80).

[0260] The following illustrative embodiments and examples are included to demonstrate specific, non-limiting embodiments of the present disclosure. Those of skill in the art will, in light of the present disclosure, appreciate that many changes can be made to the specific embodiments disclosed herein and still obtain the same or similar results without departing from the spirit and scope of the present disclosure.

[0261] (xi) Exemplary embodiments 1. A targeted therapeutic molecule that contains a binding domain that binds to folate receptor 1 (FOLR1), multiple EGF-like domain 10 (MEGF10), heparinase-2 enzyme (HPSE2), killer cell lectin-like receptor F2 (KLRF2), protocadherin-19 (PCDH19), or Fraser extracellular matrix complex subunit 1 (FRAS1).

[0262] 2. When expressed by a cell, an extracellular component that comprises a binding domain that binds to FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1; an intracellular component comprising an effector domain, and The targeted therapeutic molecule of embodiment 1, which is a chimeric antigen receptor (CAR) comprising a transmembrane domain that links the extracellular component to the intracellular component.

[0263] 3. The targeted therapeutic molecule of embodiment 2, wherein said binding domain specifically binds to FOLR1.

[0264] 4. The targeted therapeutic molecule of embodiment 2 or 3, wherein the binding domain comprises a single chain variable fragment (scFv).

[0265] 5. The targeted therapeutic molecule of embodiment 4, wherein the scFv has a sequence set forth in SEQ ID NO:22 or SEQ ID NO:23, or has a sequence with at least 95% sequence identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.

[0266] 6. The targeted therapeutic molecule of any one of embodiments 3 to 5, wherein the binding domain comprises: A variable heavy chain as set forth in SEQ ID NO: 30 and a variable light chain as set forth in SEQ ID NO: 31, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 30 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 31, A variable heavy chain as set forth in SEQ ID NO: 38 and a variable light chain as set forth in SEQ ID NO: 39, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 38 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 39, A variable heavy chain as set forth in SEQ ID NO: 40 and a variable light chain as set forth in SEQ ID NO: 41, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 40 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 41, A variable heavy chain as set forth in SEQ ID NO: 48 and a variable light chain as set forth in SEQ ID NO: 49, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 48 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 49, A variable heavy chain as set forth in SEQ ID NO: 56 and a variable light chain as set forth in SEQ ID NO: 57, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 56 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 57, A variable heavy chain as set forth in SEQ ID NO: 64 and a variable light chain as set forth in SEQ ID NO: 65, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 64 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 65, A variable heavy chain as set forth in SEQ ID NO: 72 and a variable light chain as set forth in SEQ ID NO: 73, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 72 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 73, or A variable heavy chain set forth in SEQ ID NO: 80 and a variable light chain set forth in SEQ ID NO: 81, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 80 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 81.

[0267] 7. The binding domain comprises a variable heavy chain (CDRH) 1 having complementarity determining regions set forth in SEQ ID NO: 24, a CDRH2 set forth in SEQ ID NO: 25, and a CDRH3 set forth in SEQ ID NO: 26, according to the Kabat numbering scheme; Variable light chain complementarity determining region (CDRL) 1 set forth in SEQ ID NO: 27, CDRL2 set forth in SEQ ID NO: 28, and CDRL3 set forth in SEQ ID NO: 29; CDRH1 as set forth in SEQ ID NO: 32, CDRH2 as set forth in SEQ ID NO: 33, and CDRH3 as set forth in SEQ ID NO: 34, and CDRL1 set forth in SEQ ID NO: 35, CDRL2 set forth in SEQ ID NO: 36, and CDRL3 set forth in SEQ ID NO: 37; CDRH1 as set forth in SEQ ID NO: 42, CDRH2 as set forth in SEQ ID NO: 43, and CDRH3 as set forth in SEQ ID NO: 44, and CDRL1 set forth in SEQ ID NO: 45, CDRL2 set forth in SEQ ID NO: 46, and CDRL3 set forth in SEQ ID NO: 47; CDRH1 as set forth in SEQ ID NO:50, CDRH2 as set forth in SEQ ID NO:51, and CDRH3 as set forth in SEQ ID NO:52, and CDRL1 set forth in SEQ ID NO:53, CDRL2 set forth in SEQ ID NO:54, and CDRL3 set forth in SEQ ID NO:55; CDRH1 as set forth in SEQ ID NO:58, CDRH2 as set forth in SEQ ID NO:59, and CDRH3 as set forth in SEQ ID NO:60, and CDRL1 set forth in SEQ ID NO: 61, CDRL2 set forth in SEQ ID NO: 62, and CDRL3 set forth in SEQ ID NO: 63; CDRH1 as set forth in SEQ ID NO: 66, CDRH2 as set forth in SEQ ID NO: 67, and CDRH3 as set forth in SEQ ID NO: 68, and CDRL1 set forth in SEQ ID NO:69, CDRL2 set forth in SEQ ID NO:70, and CDRL3 set forth in SEQ ID NO:71, and CDRH1 as set forth in SEQ ID NO: 74, CDRH2 as set forth in SEQ ID NO: 75, and CDRH3 as set forth in SEQ ID NO: 76, and CDRL1 set forth in SEQ ID NO: 77, CDRL2 set forth in SEQ ID NO: 78, and CDRL3 set forth in SEQ ID NO: 79 7. The targeted therapeutic molecule of any one of embodiments 3 to 6, comprising:

[0268] 8. The targeted therapeutic molecule of embodiment 2, encoded by a sequence set forth in SEQ ID NO: 134 or a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 134.

[0269] 9. The targeted therapeutic molecule of embodiment 2, wherein said binding domain specifically binds to MEGF10.

[0270] 10. The targeted therapeutic molecule of embodiment 9, wherein the binding domain comprises LS-C678634, LS-C668447, LSC497216, or PA5-76556, or a binding fragment thereof.

[0271] 11. The targeted therapeutic molecule of embodiment 2, wherein the binding domain specifically binds to HPSE2.

[0272] 12. The targeted therapeutic molecule of embodiment 11, wherein the binding domain comprises LS-B14593, LS-C322089, LS-C378319, or HPA044603, or a binding fragment thereof.

[0273] 13. The targeted therapeutic molecule of embodiment 2, wherein the binding domain specifically binds to KLRF2.

[0274] 14. The targeted therapeutic molecule of embodiment 13, wherein the binding domain comprises LS-C329740, LS-C203747, SAB2108513, SAB2108684, HPA055964, SAB2108320, or SAB2108355, or a binding fragment thereof.

[0275] 15. The targeted therapeutic molecule of embodiment 2, wherein said binding domain specifically binds to PCDH19.

[0276] 16. The targeted therapeutic molecule of embodiment 15, wherein the binding domain comprises LS-C676224, LS-C496779, LS-C761991, HPA027533, or HPA001461, or a binding fragment thereof.

[0277] 17. The targeted therapeutic molecule of embodiment 2, wherein said binding domain specifically binds to FRAS1.

[0278] 18. The targeted therapeutic molecule of embodiment 17, wherein the binding domain comprises LS-C763132, LS-B5486, LS-C754337, HPA011281, or HPA051601, or a binding fragment thereof.

[0279] 19. The targeted therapeutic molecule of any of embodiments 2-18, wherein the extracellular component further comprises a spacer region.

[0280] 20. The targeted therapeutic molecule of embodiment 19, wherein the spacer region comprises a long spacer region, an intermediate spacer region, or a short spacer region.

[0281] 21. The targeted therapeutic molecule of embodiment 20, wherein said intermediate spacer region is 135 amino acids or less.

[0282] 22. The targeted therapeutic molecule of embodiment 20 or 21, wherein said intermediate spacer region is 131 amino acids or less and comprises the hinge region and CH3 domain of IgG4.

[0283] 23. The targeted therapeutic molecule of embodiment 22, wherein the intermediate spacer region is encoded by a sequence set forth in SEQ ID NO: 136 or a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 136.

[0284] 24. A targeted therapeutic molecule according to any of embodiments 20 to 23, wherein the intermediate spacer region is encoded by a sequence set forth in SEQ ID NO:3 or a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO:3.

[0285] 25. The targeted therapeutic molecule of embodiment 20, wherein said long spacer region is more than 200 amino acids and comprises an IgG4 hinge, an IgG4 CH3 region, and an IgG4 CH2 region.

[0286] 26. The targeted therapeutic molecule of embodiment 20 or 25, wherein the long spacer region is encoded by a sequence set forth in SEQ ID NO:4 or a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO:4.

[0287] 27. The targeted therapeutic molecule of embodiment 20, wherein said short spacer region is less than 50 amino acids and comprises an IgG4 hinge.

[0288] 28. The targeted therapeutic molecule of embodiment 20 or 27, wherein the short spacer region is encoded by a sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, or a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

[0289] 29. A targeted therapeutic molecule according to any of embodiments 2 to 28, wherein the intracellular effector domain comprises all or part of the signalling domains of CD3ζ and 4-1BB.

[0290] 30. The targeted therapeutic molecule of embodiment 29, wherein the signaling domain of CD3ζ is encoded by a CD3ζ coding sequence set forth in SEQ ID NO:5, or a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO:5.

[0291] 31. The targeted therapeutic molecule of embodiment 29 or 30, wherein the signaling domain of CD3ζ comprises a sequence set forth in SEQ ID NO:6 or SEQ ID NO:7, or a sequence having at least 90% sequence identity to a sequence set forth in SEQ ID NO:6 or SEQ ID NO:7.

[0292] 32. A targeted therapeutic molecule according to any of embodiments 29 to 31, wherein the 4-1BB signaling domain is encoded by SEQ ID NO: 8 or SEQ ID NO: 9, or by a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 8 or SEQ ID NO: 9.

[0293] 33. A targeted therapeutic molecule according to any of embodiments 29 to 32, wherein the 4-1BB signaling domain comprises a sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 11, or a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 11.

[0294] 34. A targeted therapeutic molecule according to any of embodiments 2 to 33, wherein said transmembrane domain comprises the transmembrane domain of CD28.

[0295] 35. The targeted therapeutic molecule of embodiment 34, wherein the transmembrane domain of CD28 is encoded by SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:14, or by a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:14.

[0296] 36. The targeted therapeutic molecule of embodiment 34 or 35, wherein the transmembrane domain of CD28 comprises SEQ ID NO: 15 or SEQ ID NO: 16, or a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 15 or SEQ ID NO: 16.

[0297] 37. A targeted therapeutic molecule according to any of embodiments 2 to 36, further comprising a control mechanism selected from a tag cassette, a transduction marker, and / or a suicide switch.

[0298] 38. The targeted therapeutic molecule of embodiment 37, wherein the transduction marker comprises a truncated CD19.

[0299] 39. The targeted therapeutic molecule of embodiment 38, wherein said truncated CD19 is encoded by SEQ ID NO: 117 or by a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 117.

[0300] 40. A targeted therapeutic molecule according to any of embodiments 2 to 39, further comprising a ribosomal skipping element.

[0301] 41. The targeted therapeutic molecule of embodiment 40, wherein the ribosomal skip element comprises T2A, P2A, E2A, or F2A.

[0302] 42. The targeted therapeutic molecule of embodiment 40 or 41, wherein the ribosomal skip element comprises T2A.

[0303] 43. The targeted therapeutic molecule of embodiment 42, wherein said T2A is encoded by SEQ ID NO: 137 or by a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 137.

[0304] 44. A genetic construct encoding a CAR according to any one of embodiments 2 to 43.

[0305] 45. Nanoparticles encapsulating a genetic construct according to embodiment 44.

[0306] 46. ​​A cell genetically engineered to express a CAR according to any of embodiments 2 to 43.

[0307] 47. The cell of embodiment 46, which is an autologous or allogeneic cell with respect to the subject.

[0308] 48. A cell according to embodiment 46 or 47, which is in vivo or ex vivo.

[0309] 49. The cell according to any of embodiments 46 to 48, which is a T cell, a B cell, a natural killer (NK) cell, an NK-T cell, a monocyte / macrophage, a hematopoietic stem cell (HSC), or a hematopoietic progenitor cell (HPC).

[0310] 50. The cell of embodiment 49, which is a T cell selected from a CD3+ T cell, a CD4+ T cell, a CD8+ T cell, a central memory T cell, an effector memory T cell, and / or a naive T cell.

[0311] 51. The cell according to embodiment 49 or 50, which is a CD8+ T cell and / or a CD4+ T cell.

[0312] 52. A targeted therapeutic molecule according to any of the preceding embodiments, wherein the binding domain is conjugated to a cytotoxic payload.

[0313] 53. The targeted therapeutic agent of any of embodiments 1-43, wherein the binding domain specifically binds to FOLR1.

[0314] 54. The targeted therapeutic agent of any of embodiments 1-43, wherein the binding domain comprises a single chain variable fragment (scFv).

[0315] 55. The targeted therapeutic agent of embodiment 54, wherein the scFv has a sequence set forth in SEQ ID NO:22 or SEQ ID NO:23, or a sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO:22 or SEQ ID NO:23.

[0316] 56. The targeted therapeutic agent of any one of embodiments 52-55, wherein the binding domain comprises: A variable heavy chain as set forth in SEQ ID NO: 30 and a variable light chain as set forth in SEQ ID NO: 31, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 30 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 31, A variable heavy chain as set forth in SEQ ID NO: 38 and a variable light chain as set forth in SEQ ID NO: 39, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 38 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 39, A variable heavy chain as set forth in SEQ ID NO: 40 and a variable light chain as set forth in SEQ ID NO: 41, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 40 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 41, A variable heavy chain as set forth in SEQ ID NO: 48 and a variable light chain as set forth in SEQ ID NO: 49, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 48 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 49, A variable heavy chain as set forth in SEQ ID NO: 56 and a variable light chain as set forth in SEQ ID NO: 57, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 56 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 57, A variable heavy chain as set forth in SEQ ID NO: 64 and a variable light chain as set forth in SEQ ID NO: 65, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 64 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 65, A variable heavy chain as set forth in SEQ ID NO: 72 and a variable light chain as set forth in SEQ ID NO: 73, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 72 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 73, or A variable heavy chain set forth in SEQ ID NO: 80 and a variable light chain set forth in SEQ ID NO: 81, or a variable heavy chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 80 and a variable light chain having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 81.

[0317] 57. The binding domain comprises a variable heavy chain (CDRH) 1 having complementarity determining regions as set forth in SEQ ID NO: 24, a CDRH2 as set forth in SEQ ID NO: 25, and a CDRH3 as set forth in SEQ ID NO: 26, according to the Kabat numbering scheme; Variable light chain complementarity determining region (CDRL) 1 set forth in SEQ ID NO: 27, CDRL2 set forth in SEQ ID NO: 28, and CDRL3 set forth in SEQ ID NO: 29; CDRH1 as set forth in SEQ ID NO: 32, CDRH2 as set forth in SEQ ID NO: 33, and CDRH3 as set forth in SEQ ID NO: 34, and CDRL1 set forth in SEQ ID NO: 35, CDRL2 set forth in SEQ ID NO: 36, and CDRL3 set forth in SEQ ID NO: 37; CDRH1 as set forth in SEQ ID NO: 42, CDRH2 as set forth in SEQ ID NO: 43, and CDRH3 as set forth in SEQ ID NO: 44, and CDRL1 set forth in SEQ ID NO: 45, CDRL2 set forth in SEQ ID NO: 46, and CDRL3 set forth in SEQ ID NO: 47; CDRH1 as set forth in SEQ ID NO:50, CDRH2 as set forth in SEQ ID NO:51, and CDRH3 as set forth in SEQ ID NO:52, and CDRL1 set forth in SEQ ID NO:53, CDRL2 set forth in SEQ ID NO:54, and CDRL3 set forth in SEQ ID NO:55; CDRH1 as set forth in SEQ ID NO:58, CDRH2 as set forth in SEQ ID NO:59, and CDRH3 as set forth in SEQ ID NO:60, and CDRL1 set forth in SEQ ID NO: 61, CDRL2 set forth in SEQ ID NO: 62, and CDRL3 set forth in SEQ ID NO: 63; CDRH1 as set forth in SEQ ID NO: 66, CDRH2 as set forth in SEQ ID NO: 67, and CDRH3 as set forth in SEQ ID NO: 68, and CDRL1 set forth in SEQ ID NO:69, CDRL2 set forth in SEQ ID NO:70, and CDRL3 set forth in SEQ ID NO:71, and CDRH1 as set forth in SEQ ID NO: 74, CDRH2 as set forth in SEQ ID NO: 75, and CDRH3 as set forth in SEQ ID NO: 76, and The targeted therapeutic agent of any of embodiments 52 to 55, comprising CDRL1 set forth in SEQ ID NO: 77, CDRL2 set forth in SEQ ID NO: 78, and CDRL3 set forth in SEQ ID NO: 79.

[0318] 58. A targeted therapeutic molecule according to any of embodiments 1-43, wherein the binding domain specifically binds to MEGF10.

[0319] 59. The targeted therapeutic molecule of embodiment 58, wherein the binding domain comprises LS-C678634, LS-C668447, LSC497216, or PA5-76556, or a binding fragment thereof.

[0320] 60. The targeted therapeutic agent of any of embodiments 1-43, wherein the binding domain specifically binds to HPSE2.

[0321] 61. The targeted therapeutic molecule of embodiment 60, wherein the binding domain comprises LS-B14593, LS-C322089, LS-C378319, or HPA044603, or a binding fragment thereof.

[0322] 62. A targeted therapeutic molecule according to any of embodiments 1-43, wherein the binding domain specifically binds to KLRF2.

[0323] 63. The targeted therapeutic molecule of embodiment 62, wherein the binding domain comprises LS-C329740, LS-C203747, SAB2108513, SAB2108684, HPA055964, SAB2108320, or SAB2108355, or a binding fragment thereof.

[0324] 64. A targeted therapeutic molecule according to any of embodiments 1-43, wherein the binding domain specifically binds to PCDH19.

[0325] 65. The targeted therapeutic molecule of embodiment 64, wherein the binding domain comprises LS-C676224, LS-C496779, LS-C761991, HPA027533, or HPA001461, or a binding fragment thereof.

[0326] 66. A targeted therapeutic molecule according to any of embodiments 1-43, wherein said binding domain specifically binds to FRAS1.

[0327] 67. The targeted therapeutic molecule of embodiment 66, wherein the binding domain comprises LS-C763132, LS-B5486, LS-C754337, HPA011281, or HPA051601, or a binding fragment thereof.

[0328] 68. A targeted therapeutic molecule according to any of embodiments 52 to 67, wherein the cytotoxic payload comprises a cytotoxin, a cytotoxic drug, a radioisotope, or a nanoparticle.

[0329] 69. The targeted therapeutic molecule of embodiment 68, wherein the cytotoxin comprises a holotoxin or a hemitoxin.

[0330] 70. The cytotoxic drug is actinomycin D, anthracycline, auristatin, calicheamicin, camptothecin, CC1065, colchicine, cytochalasin B, daunorubicin, 1-dehydrotestosterone, dihydroxyanthracenedione, dolastatin, doxorubicin, duocarmycin, elinafide, emetine, ethidium bromide, etoposide, gramicidin D, glucocorticoids, lidocaine, or maytan. 69. The targeted therapeutic molecule of embodiment 68, comprising a sinoid, mithramycin, mitomycin, mitoxantrone, nemorubicin, PNU-159682, procaine, propranolol, puromycin, pyrrolobenzodiazepine (PBD), taxane, taxol, teniposide, tetracaine, trichothecene, vinblastine, vinca alkaloid, vincristine, or a stereoisomer, isostere, analog, or derivative thereof.

[0331] 71.You have a lot of money. 228 Ac、 111 Ag、 124 Am、 74 As、 211 As、 209 And、 194 I、 128 Ba、 7 Well、 206 Bi、 245 Bk、 246 Bk、 76 Br、 11 C、 47 Ca、 254 Cf、 242 Cm、 51 Cr、 67 Cu、 153 Dy、 157 Dy、 159 Dy、 165 Dy、 166 Dy、 171 Er、 250 Es、 254 Es、 147 Eu、 157 Eu、 52 Fe、 59 Fe、 251 Fm、 252 Fm、 253 Fm、 66 Ga、 72 Ga、 146 Gd、 153 Gd、 68 Here、 170 Hf、 171 Hf、 193 Hg、 193 mHg、 160 mHo、 130 I、 131 I、 135 I、 114 mIn、 185 They、 42 K、 43 K、 76 Kr、 79 Kr、 81 mKr、 132 The、 262 Lr、 169 Ridiculous, 174 mLu、 176 mLu、 257 Md、 260 Md、 28Mg, 52 Mn, 90 Mo, 24 Na, 95 Nb, 138 Nd, 57 Ni, 66 Ni, 234 Np, 15 O. 182 Os, 189 mOs, 191 Os, 32 P, 201 Pb, 101 Pd, 143 Pr, 191 Pt, 243 Pu, 225 Ra, 81 Rb, 188 Re, 105 Rh, 211 Rn, 103 Ru, 35 S, 44 Sc, 72 Se, 153 Sm, 125 Sn, 91 Sr, 173 Ta, 154 Tb, 127 Te, 234 Th, 45 Ti, 166 Tm, 230 U, 237 U, 240 U, 48 V, 178 W, 181 W, 188 W, 125 Xe, 127 Xe, 133 Xe, 133 mXe, 135 Xe, 85 mY, 86 Y, 90 Y, 93 Y, 169 Yb, 175 Yb, 65 Zn, 71 mZn, 86 Zr, 95 Zr, and / or 97 The targeted therapeutic molecule of embodiment 68, comprising Zr.

[0332] 72. The targeted therapeutic molecule of embodiment 68, wherein the nanoparticles comprise metal nanoparticles, liposomes, or polymeric nanoparticles.

[0333] 73. A formulation comprising cells genetically engineered to express a CAR system according to any of embodiments 2 to 43.

[0334] 74. The formulation of embodiment 73, wherein the cells are T cells, natural killer cells, monocytes / macrophages, hematopoietic stem cells or hematopoietic progenitor cells.

[0335] 75. The formulation of embodiment 74, wherein the T cells are selected from CD3 T cells, CD4 T cells, CD8 T cells, central memory T cells, effector memory T cells, and / or naive T cells.

[0336] 76. The formulation of embodiment 74 or 75, wherein the T cells are CD4 T cells and / or CD8 T cells.

[0337] 77. The formulation of any of embodiments 73-76, further comprising a pharma- ceutically acceptable carrier.

[0338] 78. A composition comprising a targeted therapeutic agent according to any one of embodiments 52-72 and a pharma- ceutically acceptable carrier.

[0339] 79. A method for treating a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a formulation according to any of embodiments 73-77 and / or a composition according to embodiment 78, thereby treating the subject in need of treatment.

[0340] 80. The method of embodiment 79, wherein the subject in need of treatment has cancer.

[0341] 81. The method of embodiment 80, wherein the cancer comprises cancer cells that express FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1.

[0342] 82. The method of embodiment 81, wherein the cancer comprises leukemia.

[0343] 83. The method of embodiment 82, wherein the leukemia is acute myeloid leukemia (AML).

[0344] 84. The method of embodiment 83, wherein the AML comprises CBFA2T3 / GLIS2 AML.

[0345] 85. The method of any of embodiments 80-84, wherein the cancer comprises cancer cells that express FOLR1.

[0346] 86. The method of embodiment 85, wherein the cancer comprises leukemia, peritoneal cancer, fallopian tube cancer, ovarian cancer, endometrial cancer, cervical cancer, breast cancer, bladder cancer, renal cell carcinoma, pituitary tumor, lung cancer, uterine cancer, squamous cell carcinoma, ureteral cancer, urethral cancer, osteosarcoma, or transitional cell carcinoma.

[0347] 87. The method of embodiment 86, wherein the cancer is metastatic.

[0348] 88. The method of embodiment 86 or 87, wherein the ovarian cancer comprises epithelial ovarian cancer.

[0349] 89. The method of embodiment 86 or 87, wherein the breast cancer comprises triple-negative breast cancer or HER2 breast cancer.

[0350] 90. The method of embodiment 86 or 87, wherein the lung cancer comprises lung adenocarcinoma or epithelial lung cancer, such as non-small cell lung cancer.

[0351] 91. The method of any of embodiments 79-90, wherein the preparation comprises autologous or allogeneic cells.

[0352] 92. A method for treating a subject with CBFA2T3 / GLIS2 acute myeloid leukemia (AML), comprising administering to the subject a therapeutically effective amount of a formulation according to any one of embodiments 73 to 77 and / or a composition according to embodiment 78, thereby treating the subject with CBFA2T3 / GLIS2 AML.

[0353] 93. The method of embodiment 92, wherein the preparation comprises autologous or allogeneic cells.

[0354] (xii) Experimental Examples. Example 1. CBFA2T3-GLIS2 oncogenic fusion is sufficient for leukemic transformation.

[0355] OVERVIEW: Fusion oncoproteins are initiating events in the development of acute myeloid leukemia (AML), but additional co-mutations are thought to be required for leukemic transformation. CBFA2T3-GLIS2 (C / G) fusions occur exclusively in early childhood and are associated with highly aggressive disease (de Rooij et al., Nat Genet 49:451-456, 2017; Gruber et al., Cancer Cell 22, 683-697, 2012; Masetti et al., Blood 121:3469-3472, 2013; and Smith et al., Clin Cancer Res 26:726-737, 2020). Lentiviral transduction of C / G fusions is sufficient to induce malignant transformation of human cord blood hematopoietic stem and progenitor cells (CB HSPCs), fully recapitulating C / G AML. Co-cultured with endothelial cells, engineered CB HSPCs undergo complete malignant transformation with the same molecular, morphological, phenotypic and disease characteristics as observed in primary C / G AML. By examining the transcriptome of engineered cells, a library of C / G fusion-specific targets that are candidates for chimeric antigen receptor (CAR) T-cell therapy was identified. We developed CAR-T cells against one of the targets, FOLR1. These CAR-T cells showed preclinical efficacy against C / G AML without damaging normal hematopoiesis. These findings highlight the role of the endothelial niche in promoting leukemic transformation of C / G-transduced CB HSPCs. Furthermore, this work has far-reaching implications for the study of leukemogenesis applicable to a variety of pediatric leukemias driven by oncogenic fusions, providing a robust and tractable model system to characterize molecular mechanisms of leukemogenesis and identify biomarkers for disease diagnosis and targets for therapy.

[0356] Results: C / G expression transforms human CB HSPCs. CBFA2T3 (ETO2) is a member of the ETO family of transcription factors. Its fusion partner, GLIS2, is a zinc finger protein regulated by the Hedgehog pathway. C / G AML lacks recurrent co-mutations (Gruber et al., Cancer Cell 22, 683-697, 2012; Smith et al., Clin Cancer Res 26:726-737, 2020; and Bolouri et al., Nat Med 25:530, 2019), suggesting that this fusion may be sufficient for malignant transformation. To test this, we expressed the C / G fusion or a GFP control in CB HSPCs by lentiviral transduction (C / G-CB or GFP-CB) and transplanted the transduced cells into NSG-SGM3 mice (Figure 1A). Within 60 days of transplantation, all mice (4 / 4) injected with C / G-CB cells developed aggressive leukemia, whereas all control mice (4 / 4) survived to the study endpoint (Figure 1B). Histology of femurs from C / G-CB xenografted mice revealed extensive leukemia with bone remodeling similar to pathology observed in xenografted mice carrying C / G patient-derived leukemia cells (PDX) (Figures 1C and 2). The malignant cells had a unique pattern of focal adhesion to neighboring cells characteristic of C / G AML. Flow cytometric analysis of bone marrow C / G-CB xenograft cells revealed a malignant population (CD56 hi , CD45 dim , and CD38 dim / -, Figure 1D). Immunohistochemistry further demonstrated high expression of ERG and CD56 (markers associated with CG / AML (Pardo et al., Cytometry B Clin Cytom 98:52-56, 2020; Eidenschink Brodersen et al., Leukemia 30:2077-2080, 2016; and Thirant et al., Cancer Cell 31:452-465, 2017)) in the bone marrow of mice, indicative of malignant transformation, similar to high CD56 expression in leukemic aggregates present in bone marrow biopsies of C / G patients (Figure 1E).

[0357] To evaluate whether C / G enhances the self-renewal of leukemia-initiating cells (LICs), we performed serial transplants of C / G-CB cells. All mice from secondary (8 / 8) and tertiary (5 / 5) transplants also developed AML, with median survival times of 69 and 72 days, respectively (Figure 1F). Bone marrow engraftment of C / G-CB cells was variable in these mice at the time of symptomatic disease (5-70%, Figure 1G). Focal clusters of leukemic cells were present in the femurs of all mice, similar to the primary transplant and PDX models (Figure 2). Notably, there was an immune phenotypic evolution over the course of serial transplants with an expanded CD56+ cell population (Figure 1H). Similar observations were made in other tissues at necropsy (Figures 3A and 3B).

[0358] Acute megakaryocytic leukemia (AMKL) is a form of AML characterized by immature blasts expressing megakaryocyte markers CD41, CD42 or CD61 (Paredes-Aguilera et al., Am J Hematol 73:71-80, 2003). Because AMKL is frequently seen in C / G-positive patients (Smith et al., Clin Cancer Res 26:726-737, 2020), expression of CD41 and CD42 was evaluated in C / G-CB cells. Immunophenotypic analysis revealed that a subset of abnormal megakaryocytes (CD41 - CD42 +) was evident (Figures 1I and 3C). Bertuccio et al. previously identified a similar subpopulation whose gene expression best matched that of human C / G leukemia (Bertuccio et al., Hemasphere 4:e319, 2020). By observing CD41 and CD42 expression over the course of serial transplants, we found that CD41 - CD42 + Mature CD41 from + CD42 + Immunophenotypic evolution towards megakaryocytic subsets was noted (Figures 1I, 1J, and 3C). Taken together, these results indicate that expression of C / G induces transformation of CB HSPCs that faithfully recapitulates human C / G AMKLs.

[0359] ECs promote leukemia progression ex vivo. Mounting evidence supports the role of the microenvironment in the leukemic process. In particular, endothelial cells (ECs) of the vascular niche play a key role in both normal and malignant hematopoiesis, contributing to the maintenance and self-renewal of HSPCs and supporting leukemia progression, survival and drug resistance of leukemia precursors (Pinho et al., Nat Rev Mol Cell Biol 20, 303-320, 2019; Poulos, MGet al. Exp Hematol 42:976-986 e971-973, 2014; Walter, RBet al. Leukemia 28:1969-1977, 2014; and Le et al., Leukemia:35:601-605, 2021). Previous studies have shown that E4ORF1 virus-transduced human umbilical vein endothelial cells (E4 ECs) support the proliferation of CB HSPCs (Butler et al., Blood 120:1344-1347, 2012) and provide efficient conditions for long-term culture of primary AML precursors (Walter, RB et al. Leukemia 28:1969-1977, 2014), thus efficiently recapitulating the EC niche ex vivo. To assess whether ECs support the leukemic transformation of C / G fusions, C / G-CB cells were cultured in E4 EC cocultures (Butler et al., Blood 120:1344-1347, 2012) or in myeloid-promoting conditions (Imren et al., Blood 124:3608-3612, 2014) (MCs) (Figure 4A). C / G-CB cells proliferated faster and had extended survival in EC cocultures compared to MCs, as measured by the cumulative number of GFP+ cells (Figure 4B). In contrast, GFP-CB cells showed limited, short-lived proliferation in both conditions, reaching exhaustion after 3 weeks. Proliferation of C / G-CB cells was reduced after transfer to either EC transwell or suspension culture (Figure 4C), suggesting that the growth-promoting effect of ECs is mediated by direct contact and secreted factors.

[0360] C / G fusions have previously been shown to confer self-renewal to hematopoietic progenitor cells (Gruber et al., Cancer Cell 22, 683-697, 2012, and Thirant et al., Cancer Cell 31:452-465, 2017). This property in C / G-CB cells was further enhanced by EC coculture (i.e., culture with endothelial cells). At 6 weeks, C / G-CB cells in EC coculture formed significantly more megakaryocyte colonies than C / G-CB cells grown on MC or C / G-GFP cells grown in either condition. Strikingly, after 12 weeks, C / G-CB cells cultured in EC coculture produced numerous megakaryocyte colonies (Figure 4D), demonstrating the long-lived self-renewal of C / G-CB cells cocultured with EC.

[0361] To determine whether the EC niche promotes LIC generation and proliferation, engraftment of C / G-CB cells grown on ECs or MCs was assessed after 3, 6, 9, and 12 weeks of culture. Notably, C / G-CB cells at each time point cultured in EC coculture showed robust engraftment progressing to overt leukemia in vivo (Figures 4E and 5A-5C), demonstrating that EC coculture promotes long-term maintenance of functional LICs. C / G-CB cells grown on MCs also induced leukemia from 3 and 6 weeks of culture but subsequently senesced at 9 and 12 weeks, suggesting limited maintenance of their LICs.

[0362] To observe the evolution of leukemia, we assessed the expression of RAM immunophenotype and AMKL markers in C / G-CB cells from EC cocultures and MCs. C / G-CB cells in EC cocultures constituted a nearly homogenous population expressing RAM immunophenotype, whereas in MCs, only a subset was detected at 6 weeks (Figure 6A). A high percentage of CD56+ cells was maintained in EC cocultures from 6 to 12 weeks (Figure 4F). Abnormal CD41 - CD42 +Emergence of a subset occurred by week 3 in both culture conditions, more prominent in EC cocultures (Figures 4G and 6B), which then progressed to a more mature immunophenotype. Morphological assessment demonstrated megakaryocytic features among C / G-CB cells in both culture conditions (Figure 6C). These results were reproduced in a separate experiment with CB HSPCs from a different donor (Figures 7A-7D). Thus, EC coculture supports the development of C / G-transformed CB HSPCs that recapitulate the continuum of immunophenotypic changes associated with transformation in primary C / G AML.

[0363] Fidelity of engineered cells to C / G AML. To determine the fidelity of transformation to primary leukemia, we performed RNA sequencing of C / G-CB cells cultured with ECs or with MCs. Notably, unsupervised clustering analysis showed that C / G-CB cells from 6 and 12 weeks of EC coculture clustered with primary C / G-positive patient samples, but not with C / G-CB cells cultured with MCs or GFP controls (Figure 4H). This suggested that signaling pathways aberrantly dysregulated in primary C / G leukemia were faithfully recapitulated in C / G-CB cells cocultured with ECs. Further transcriptome analysis revealed upregulation of downstream genes ERG and BMP2, both in EC cocultures and MCs, which were previously found to be strongly upregulated in C / G AML (Gruber et al., Cancer Cell 22, 683-697, 2012; and Thirant et al., Cancer Cell 31:452-465, 2017), as well as downregulation of the erythroid-megakaryocyte differentiation gene GATA1 (Welch et al., Blood 104:3136-3147, 2004; Wang et al., EMBO J 21:5225-5234, 2002; Vyas et al., Blood 93:2867-2875, 1999; Shivdasani et al., EMBO J 16:3965-3973, 1997; and Kuhl et al., Mol Cell Biol. 2013). 25:8592-8606,2005) was similarly downregulated in C / G AML (Thirant et al,Cancer Cell 31:452-465,2017) (Figure 8A). However, there were significant differences in the overall expression profile of C / G-CB cells from EC cocultures compared to MCs (Figure 4I).

[0364] To determine the impact of ECs on malignant transformation, we assessed the status of the WNT, Hedgehog, and TGF-beta pathways, which are known to be dysregulated in C / G leukemia (Gruber et al., Cancer Cell 22, 683-697, 2012, and Smith et al., Clin Cancer Res 26:726-737, 2020). These pathways were highly enriched in C / G-CB cells grown in EC coculture, but not in MC (Figure 8A). Cell adhesion numbers and integrins have been demonstrated to be upregulated in C / G leukemia (Smith et al., Clin Cancer Res 26:726-737, 2020). The majority of these genes were upregulated in C / G-CB cells, independent of culture conditions (Figure 9A), suggesting that this pathway is determined by fusion and not the microenvironment. Cell adhesion and integrin expression likely contribute to the focal distribution and adhesion morphology identified in C / G-CB xenografted mice (FIG. 1C).

[0365] Gene set enrichment analysis (GSEA) revealed that both C / G and HSC signature genes previously identified as associated with C / G AML (Smith et al., Clin Cancer Res 26:726-737, 2020, and Thirant et al., Cancer Cell 31:452-465, 2017) were significantly enriched in C / G-CB cells grown in EC culture versus MCs (Figures 4J, 9B, and 9C).

[0366] The Hippo signaling pathway and tight junctions are other C / G-specific pathways (see Smith et al., Clin Cancer Res 26:726-737, 2020), which were also significantly enriched in C / G-CB cells in EC cocultures compared to MC (Figure 8B). Overall, these results suggest that ECs induce a transcriptional program that synergizes with fusion to recapitulate primary leukemia.

[0367] Upregulation of FOLR1 therapeutic targets. CAR T therapy has demonstrated success in treating B-cell acute lymphoblastic leukemia (B-ALL), but immunotherapeutic targeting for AML remains a challenge given the high overlap of target antigens expressed in AML and normal hematopoietic cells. Extensive target discovery efforts by TARGET and Target Pediatric AML (TpAML) have identified a library of AML-restricted genes (expressed in AML, silent in normal hematopoiesis) in one or more AML subtypes, including C / G AML (607 genes, Figures 10A and 11). Of these, 42 were upregulated in both C / G AML and C / G-CB cells cultured with ECs, representing C / G fusion-associated genes. Eighteen of these encode proteins that localize to the plasma membrane, and seven of these C / G fusion-specific CAR targets (FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and FRAS1) were identified as being highly expressed in C / G patients and C / G-CB cells but completely silent in normal hematopoiesis (Figures S10B and S10C).

[0368] FOLR1 was prioritized for further development given its existing record as a target in solid tumors (Scaranti et al., Nat Rev Clin Oncol 17:349-359, 2020). FOLR1 transcript expression was confirmed by qPCR (Figure 12). Flow cytometry analysis of primary AML cells revealed that FOLR1 is expressed in AML blasts but not in normal lymphocytes, monocytes, and myeloid cells from individual patients (Figures 10D and 10E). Surface FOLR1 protein was detected on C / G-CB cells as early as 6 weeks of EC coculture, progressing to near uniform expression by week 12 (Figures 10f and 10G).

[0369] Targeting C / G AML with FOLR1 CAR T. Evidence that FOLR1 is causally associated with C / G fusions and uniquely expressed in AML blasts suggested that targeting FOLR1 may provide a specific strategy to eliminate C / G leukemia without affecting normal hematopoiesis. To evaluate the therapeutic potential of targeting FOLR1, FOLR1-directed CARs were generated using an anti-FOLR1 binder (farletuzumab), an IgG4 intermediate spacer, and the signaling domain of 41-BB / CD3 zeta (see Methods). The targeting specificity of FOLR1-directed CAR T cells was examined against FOLR1-positive (C / G-CB, WSU-AML, Kasumi-1 FOLR1+) and FOLR1-negative (Kasumi-1) cells. CD8 FOLR1 CAR T cells showed cytolytic activity against FOLR1-positive cells but not against FOLR1-negative cells (Figure 13A). Furthermore, both CD8 and CD4 FOLR1 CAR T cells produced higher levels of IL-2, IFN-γ, and TNF-α than unengineered T cells and proliferated robustly when incubated with FOLR1-positive but not FOLR1-negative cells (Figures 13B and 13C). These results demonstrate the highly specific reactivity of FOLR1 CAR T cells to FOLR1-expressing AML cells.

[0370] The in vivo efficacy of FOLR1-directed CAR T cells was next examined. In C / G-CB, WSU-AML, and Kasumi-1 FOLR1+ xenograft models, treatment with FOLR1 CAR T cells induced leukemia clearance, whereas disease progression occurred in all mice receiving unmanipulated T cells (Figures 13D and 14A). Leukemia clearance was associated with the expansion of CAR T cells in the peripheral blood of C / G-CB and WSU-AML xenografts (Figure 14B). Importantly, treatment with FOLR1 CAR T cells significantly extended the median survival time in mice bearing C / G-CB, WSU-AML, and Kasumi-1 FOLR1+ leukemia, respectively (Figure 14C). The in vivo activity of FOLR1 CAR T cells was target-specific and did not limit leukemia progression or extend survival of Kasumi-1 xenografts (Figures 13D and 14C).

[0371] To determine whether FOLR1 is expressed in normal HSPCs, FOLR1 expression was characterized in CB CD34+ samples from three healthy donors. FOLR1 expression was completely silent in a subset of HSPCs (Figures 15A-15c). Consistent with the lack of expression, no cytolytic activity was detected against HPSCs after 4 h of co-incubation with CAR T cells (Figure 15D). Furthermore, FOLR1 CAR T cells did not affect the self-renewal and multipotency of normal HSPCs compared to unmanipulated control T cells (Figure 15E), whereas significant eradication of colonies was detected in C / G-CB cells (Figure 15F). Taken together, these results suggest that FOLR1 CAR T can eradicate C / G AML cells without harming normal HSPCs and may be a promising treatment for C / G AML.

[0372] Discussion: Previous attempts to generate overt leukemias from bone marrow hematopoietic cells of C / G-transduced mice were unsuccessful (Gruber et al., Cancer Cell 22, 683-697, 2012, and Dang et al., Leukemia 31:2228-2234, 2017), leading to the notion that co-mutations are required for leukemic transformation. This example demonstrates that C / G oncogenic fusions are sufficient to transform human CB HSPCs that faithfully recapitulate the transcriptome, morphology, and immunophenotype of C / G AML observed in early childhood and highly aggressive leukemias in xenograft models. Furthermore, it is demonstrated that direct interaction with the EC niche is necessary for malignant transformation by this fusion protein. These results indicate that, given the appropriate developmental environment (CB HSPCs) and permissive microenvironment (EC niche), oncogenic fusions may be sufficient to induce an overt AML phenotype. This contrasts with the widely accepted "cooperative" model of AML (Gilliland et al., Curr Opin Hematol 8:189-191, 2001), which requires synergy between class II (fusion) and class I (SNV) variants to recapitulate the AML phenotype.

[0373] Progress in elucidating disease pathogenesis and developing novel therapies for C / G AML cohorts is currently limited by the lack of a relevant model system that accurately recapitulates the human disease. The EC coculture platform overcomes this obstacle and recapitulates the vascular EC niche that supports malignant transformation, self-renewal and LIC proliferation in vitro. This platform is therefore suitable to investigate AML-niche interactions and identify novel therapeutic targets for C / G and should be extended to studies with other oncogenic fusions.

[0374] Finally, the results presented herein address a fundamental challenge in immunotherapy for AML, as AML-specific targets remain elusive. By integrating the transcriptomics of primary C / G AML and engineered CB cells, seven C / G fusion-specific genes were identified that represent potential high-value targets. The present disclosure provides validation for FOLR1 by showing that FOLR1-directed CAR T efficiently eradicates C / G AML cells without damaging normal HSPCs. These results provide a preclinical rationale for further development of FOLR-directed CAR T in clinical trials for the treatment of C / G AML.

[0375] Materials and Methods.

[0376] animal. NOD / SCID / γc - / - (NSG) and NOD.CG-Prkdc scid Il2rg tm1Wjl Tg(CMV-IL3, CSF2, KITLG)1Eav / MloySzJ(NSG-SGM3) mice were obtained from Jackson Laboratory. In all experiments, age-matched females aged 6–10 weeks were randomly assigned to experimental groups. Mice engrafted with engineered CB or AML cell lines were observed and euthanized when they showed symptomatic leukemia (tachypnea, kyphosis, persistent weight loss, fatigue or hind limb paralysis). Experiments were performed in accordance with institutional and national guidelines and regulations after approval by the Animal Care and Use Committee (Protocol No. 51068).

[0377] Primary specimens. Human umbilical cord blood samples were obtained from normal deliveries at Swedish Medical Center (Seattle, WA). Frozen aliquots of diagnostic bone marrow samples for AML were obtained from the Children's Oncology Group. Cells were thawed in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 20% fetal bovine serum (FBS) and 100 U / mL DNase I (Sigma, catalog number D5025). Bone marrow biopsies from C / G patients were obtained from patients treated at the University of Minnesota Masonic Children's Hospital. Healthy donor T cells were obtained from Bloodworks Northwest (Seattle, WA). The cells were confirmed to be free of infectious agents (Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), hepatitis A, hepatitis B, hepatitis C, human herpes virus (HHV) 6, HHV 8, human immunodeficiency virus (HIV) 1, HIV2, human papillomavirus (HPV) 16, HPV 18, herpes simplex virus (HSV) 1, HSV2, human T-lymphotropic virus (HTLV) 1, HTLV 2, and Mycoplasma sp) through IDEXX Bioanalytics (West Sacramento, CA). All specimens used in this example were obtained after written informed consent from patients and donors. This study was performed after approval by the Institutional Review Board of the FHCRC (protocol number 9950). This study was performed in accordance with the Declaration of Helsinki.

[0378] Cell lines. M07e (DSMZ, Cat. No. ACC104), WSU-AML (BioIVT, Cat. No. HCL-WSUAML-AC), and Kasumi-1 (ATCC, Cat. No. CRL-2724) cell lines were maintained according to the manufacturer's instructions. Kasumi-1 FOLR1+ cell line was engineered by transducing Kasumi-1 cells with a lentivirus (Genecopoeia, Cat. No. LPP-C0250-Lv156-050) containing a FOLR1 transgene driven by the EF1a promoter. Jurkat Nur77 reporter cells (Rosskopf et al., Oncotarget 9:17608-17619, 2018) were maintained in RPMI supplemented with 20% FBS and 2 mM L-glutamine.

[0379] Constructs and lentivirus production. The MSCV-CBFA2T3-GLIS2-IRES-mCherry construct was a kind gift from Dr. Tanja Gruber (Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tn, (Gruber et al., Cancer Cell 22, 683-697, 2012)). The C / G fusion gene and MND promoter from this construct were inserted into the pRRLhPGK-GFP lentiviral vector (Dull et al., J Virol 72:8463-8471, 1998) as described by Smith et al. (Clin Cancer Res 26:726-737, 2020).

[0380] CAR constructs containing IgG4 short, medium and long spacers have been previously described by Turtle et al. (Sci Transl Med 8:355ra116,2016). Farletuzumab VL and VH sequences were used to construct anti-FOLR1 scFv in VL / VH orientation using a G4SX4 linker. This anti-FOLR1 scFv DNA fragment was human codon optimized and synthesized by IDT gBlock gene fragment and cloned into a CAR vector with NheI and RsrII restriction enzyme sites upstream of the IgG4 spacer.

[0381] Farletuzumab scFv: [ka]

[0382] Lentiviral particles were produced in 293T cells (ATCC, Cat. No. CRL-3216). 293T cells were transfected with a 4:2:1 ratio of transfer vector, viral packaging vector (psPAX2), and viral envelope vector (pMD2G) using Mirus 293Trans-IT transfection agent (Mirus, Cat. No. MIR2700) as instructed by the manufacturer's protocol. Viral particles were harvested daily for 4 days after transfection, filtered through a 0.45 μm membrane (Thermo Fisher, Cat. NAL-166-0045), and concentrated (rotating at 4° C. overnight, 5000 rpm) before use.

[0383] Transduction of cord blood CD34+ cells. CB samples were treated with red blood cell lysis buffer and enriched for CD34+ cells using CliniMACS CD34 MicroBeads (Miltenyi Biotec, Cat. No. 130-017-501). CB CD34+ cells were then seeded onto Retronectin (5ug / mL, Takara, Cat. No. T100A) + Notch ligand delta1 (2.5ug / mL, (Delaney et al., Nat Med 16:232-236, 2010)) coated plates in SFEM II medium (StemCell Technologies, Cat. No. 09650FH) containing 50ng / mL stem cell factor (SCF, StemCell Technologies, Cat. No. 78062), 50ng / mL thrombopoietin (TPO, StemCell Technologies, Cat. No. 78210) and 50ng / mL Fms-like tyrosine kinase 3 ligand (FLT3L, StemCell Technologies, Cat. No. 78009). Cells were transduced the following day with the C / G construct at an MOI of 200 or the GFP control construct at a multiplicity of infection (MOI) of 50. Transduced cells were grown with Notch ligand for 6 days at 37°C, 5% CO2 before sorting for GFP+ cells. Sorted GFP+ cells were transplanted into NSG-SGM3 mice at 200,000 cells per mouse, or plated for long-term culture in EC co-culture or bone marrow-promoting conditions (MC, Imren et al. (Blood 124:3608-3612,2014) and see below) at 75,000 cells per 6 wells. In subsequent experiments using a CB CD34+ sample from a different donor (CB2, see Figures 7A-7D), transduced cells were grown with Notch ligand for 2 days before sorting for 100,000 cells per 12 wells in EC co-culture or MC plating.

[0384] Long-term culture of transduced cord blood CD34+ cells. Transduced cells were cultured in serum-free growth medium (SFEM) II medium supplemented with 50 ng / mL SCF, 50 ng / mL TPO, 50 ng / mL FLT3L, and 100 U / mL penicillin / streptomycin, or in Iscove's modified Dulbecco's medium (IMDM, Gibco) supplemented with 15% fetal bovine serum (FBS, Corning, 35-010-CV), 100 U / mL penicillin / streptomycin (Pen / Strep, Gibco, 15-140-122), 10 ng / mL SCF, 10 ng / mL TPO, 10 ng / mL FLT3L, 10 ng / mL IL-6 (Shenandoah Biotechnology, Cat. No. 100-10), and 10 ng / mL IL3 (Shenandoah, Cat. No. 100-80). For EC coculture, human umbilical vein endothelial cells (HUVECs) transduced with the E4ORF1 construct (E4 ECs) were grown as previously described (Walter, RB et al. Leukemia 28:1969-1977, 2014, and Butler et al., Cell Stem Cell 6:251-264, 2010). One day before co-culture, E4 ECs were seeded in 6-well or 12-well plates at 800,000 or 300,000 cells per well, respectively, and cultured in medium 199 (Biowhittaker #12-117Q) supplemented with FBS (20%, Hyclone, Cat. No. SH30088.03), endothelial mitogen (Biomedical Technologies, Cat. No. BT203), heparin (Sigma, Cat. No. H3149), HEPES (Gibco, Cat. No. 15630080), L-glutamine (Gibco, Cat. No. 25030), and penicillin / streptomycin. After 24 hours, E4 ECs were washed with phosphate-buffered saline (PBS) and cultured with the transduced CB cells in the above medium. Transduced CB cells in both culture conditions were grown in fresh medium and E4 EC replaced weekly until the cells stopped growing. Three to 20 percent of the cultures were replated weekly for long-term culture.

[0385] Expression of C / G and FOLR1 in engineered cells over several weeks in culture was confirmed using RT-PCR (Figure 16). Transduced CB cells were sorted for GFP+ cells on a FACSAria II using FACSDiva software (BD Biosciences). DNA and RNA were extracted from sorted cells with the AllPrep DNA / RNA / miRNA Universal Kit using the QIAcube platform (QIAGEN). Expression of this fusion transcript in GFP+ cells was confirmed by RT-qPCR TaqMan assay and QuantStudio 5 real-time PCR system using primers: forward 5-CCCTGACGGTCATCAACCA-3 (SEQ ID NO: 114), reverse 5-CACCATCCAAATAGCGCAGTG-3 (SEQ ID NO: 115), and TaqMan probe 5-[FAM]-CAGCGAGGACTTCCAG-[MGB]-3 (SEQ ID NO: 116). FOLR1 expression was measured using an RT-qPCR TaqMan assay (Hs01124177_m1, catalog no. 4331182).

[0386] Cell surface analysis. For xenografted CB cells, mouse bone marrow, peripheral blood, spleen, and liver were collected at necropsy and treated with red blood cell lysis buffer. Spleen and liver were processed into cell suspension on glass slides and passed through a 70 μm cell strainer. CB cells in EC co-cultures and MC were collected after vigorous shaking to resuspend the CB cells. CB cells from treated mouse tissues and cultures were washed with PBS containing 2% FBS, blocked with PBS containing 2% human AB serum, and then stained with a cocktail of fluorescently labeled monoclonal antibodies for 20 minutes on ice (see FIG. 18). Labeled cells were washed with PBS and resuspended in 2% FBS / PBS before flow cytometry analysis. Cell surface expression was assessed using a FACSymphony (BD Biosciences) with FACSDiva software, and FlowJo software was used for this analysis. Dead cells were excluded based on LIVE / DEAD™ Fixable Violet Dead Cell Stain (FVD, Invitrogen, Cat. No. L34955). In the case of EC co-cultures, ECs were excluded by gating on CD45+ cells or CD45+CD144- cells.

[0387] Fractions at various time points of C / G-CB cells isolated from the xenograft model or cultured in EC coculture or MC were sent to Hematologics, Inc. (Seattle, WA) along with C / G patient samples for evaluation of RAM immunophenotype.

[0388] Histology and immunocytochemistry. Sample tissues were fixed in 10% formalin, processed into paraffin sections, and stained with hematoxylin and eosin (H&E). Immunohistochemistry was performed using antibodies against ERG (EP111, Cell Marque) and CD56 (MRQ-42, Cell Marque) after citrate pretreatment and visualized with 3,3'-diaminobenzidine (DAB) on a Ventana Bench Mark Ultra.

[0389] All tissues were reviewed by a board-certified hematopathologist. Bone marrow core biopsy specimens were fixed in zinc acetate-formalin (AZF), decalcified, embedded in paraffin, and sections were stained for CD56 (clone MRQ-42, Cell Marque, Rockin, California).

[0390] RNA-seq analysis. Construction of RNA-sequencing libraries. For diagnostic pediatric AML samples from peripheral blood or bone marrow, as well as bulk healthy bone marrow and healthy CD34+ peripheral blood samples, total RNA was extracted with the AllPrep DNA / RNA / miRNA universal kit using a QIAcube automated system (QIAGEN, Valencia, CA, #80224). Total RNA from C / G-CB and GFP-CB cells in EC co-cultures and MCs at the indicated time points was purified as described above. 75 bp strand-specific paired-end mRNA libraries were prepared using the ribodepletion 2.0 protocol by British Columbia Genome Sciences Center (BCGSC, Vancouver, BC) and sequenced on an Illumina HiSeq 2000 / 2500. Sequenced reads were quantified using Kallisto v0.45.0 (Bray et al., Nat Biotechnol 34:525-527, 2016) on the GRCh38 transcriptome standard prepared using annotations of coding and non-coding transcripts in Gencode v29 and RepBase v24.01, and gene-level counts and abundances were presented using tximport v1.16.1 (Soneson et al., F1000Res 4:1521, 2015).

[0391] Screening of C / G fusions in patient samples. C / G fusion transcripts were detected by fragment length analysis or the fusion detection algorithms STAR-fusion v1.1.0 and TransAbyss v1.4.10 (Haas et al., Genome Biol 20:213, 2019, and Robertson et al., Nat Methods 7:909-912, 2010). Details of the procedure have been described previously (Smith et al., Clin Cancer Res 26:726-737, 2020).

[0392] Transcriptome analysis: Differentially expressed genes between C / G-CB and GFP-CB cells were identified using trimmed mean of M values ​​(TMM) normalized gene counts using limma voom (v3.44.3 R package) (Ritchie et al., Nucleic Acids Res 43:e47,2015). Genes with absolute log2 fold change >1 and Benjamini-Hochberg adjusted p-value <0.05 were retained. Unsupervised hierarchical clustering was completed using ComplexHeatmap R package (v2.4.3) utilizing Euclidean distance with the ward.D2 linkage algorithm. Log2-transformed TMM-normalized counts per million (CPM) were used as input, and a count of 1 was added to avoid taking the logarithm of zero. Hierarchical clustering was performed using the C / G transcriptome signatures of primary C / G AML samples and C / G-CB cells. Signature genes (N=1,116 genes) were defined as those with absolute log2 fold changes within the 75th percentile and adjusted p-value <0.001 when comparing C / G fusion-positive patients (N=39) against a heterogeneous AML reference cohort (N=1,355). The 85th percentile of this signature (N=167 genes) was used to define the C / G gene set for GSEA.

[0393] Gene set enrichment scores were calculated using the single sample gene set enrichment (ssGSEA) method (GSVA v1.32.0), which converts normalized count data from genes by sample matrix to gene sets by sample matrix (Hanzelmann et al., BMC Bioinformatics 14:7, 2013). Counts were TMM normalized and log2(x+1) transformed prior to gene set analysis. Signal transduction and metabolism related gene sets curated from the KEGG database were included in this analysis (gageData v2.26.0). Gene sets significantly associated with C / G-CB cells (Benjamini-Hochberg adjusted p-value < 0.05) were identified using limma v3.44.3 with GSVA-transformed gene sets by sample matrix as input.

[0394] GSEA was performed using "unpaired" comparisons in the GAGE ​​R package (v2.38.3), examining the differential expression of gene sets by contrasting C / G-CB versus GFP-CB cells in each condition, to define pathways enriched in EC coculture versus MC. Non-redundant gene sets were extracted for further analysis, and then core genes contributing to pathway enrichment were identified. Gene sets from the Molecular Signatures Database (MSigDB) and KEGG pathway databases were used. Enrichment score plots for HSC and C / G signatures were generated using the R package fgsea (v1.14.0). Log fold change values ​​obtained from limma (C / G-CB EC 6 weeks versus C / G-CB MC 6 weeks) were used as ranking metrics for genes in the two signatures.

[0395] Unsupervised clustering of C / G-CB cells with pediatric AML primary diagnostic samples (N = 1,033) and healthy normal bone marrow (N = 68) was performed by uniform manifold approximation and projection (UMAP) using the uwot v0.1.8 R package (Leland McInnes and Melville. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. arXiv:1802.03426, 2020). For UMAP clustering, gene counts underwent a variance-stabilizing transformation (VST) using the DESeq2 v1.28.1 package. Input genes for clustering (N = 6,678 genes) were selected using a mean-versus-variance parametric model trend (SeqGlue v0.1) to identify genes with high variance.

[0396] Identification of fusion-specific CAR targets involves three main steps: 1) Identifying the ratio of expression between AML primary samples and healthy normal hematopoietic tissue samples (combination of bulk normal bone marrow, N=68, and selected peripheral blood samples of CD34+, N=16) as transcripts per million (TPM) from log10-transformed normalized expression. Normalization was completed on a total gene expression matrix, followed by a ratio analysis of 19,901 annotated protein-coding genes for identification of therapeutic targets. The ratio is calculated for each gene from the mean AML expression and the mean normal tissue expression, where the mean expression of normal healthy hematopoietic tissue is the divisor, providing a measure of above or below expression. A normal curve was fitted to these ratio values, and genes with ratios above +2 standard deviations were retained. This process was performed for all heterogeneous AML samples (N=1483) as a group, and then repeated within mutation subtypes, including AML fusions and C / G, to ensure that the inherent variability in gene expression in different fusion classes was picked up and all actionable targets were identified in every given subtype. Genes were then further narrowed down to include those with maximal expression <1.0 TPM in normal healthy hematopoietic tissue samples, and thus considered to have expression restricted to AML when compared to healthy controls. 2) If AML-restricted genes were found by RNA-seq to be significantly overexpressed in bulk fusion-positive patient samples compared to bulk healthy bone marrow, they were further selected, yielding several candidate targets, as they were similarly overexpressed in C / G-CB at weeks 6 and 12 in EC co-cultures, and not expressed in GFP-CB controls (<1.0 TPM).3) Final selection of optimal CAR-T targets was determined by identification of candidate genes with moderate to high expression in C / G patient samples (maximum expression ≥ 10 TPM), expressed in the majority (> 75%) of patient samples, and with cell surface localization potential as annotated by the Human Protein Atlas (www.proteinatlas.org / ) or the Jensen Lab compartments database (https: / / compartments.jensenlab.org / ), in addition to being expressed in healthy hematopoietic tissues as described in step 1 above.

[0397] Generation of human FOLR1 CAR T cells. CAR T cells were generated by transducing healthy donor T cells (Bloodworks Northwest) with lentivirus carrying the FOLR1 CAR vector. Peripheral blood mononuclear cells from healthy donors were isolated with Lymphoprep (StemCell Technologies, Catalog No. 07851). CD4 or CD8 T cells were isolated by negative magnetic selection using the Easy Sep Human CD4+ T Cell Isolation Kit II (StemCell Technologies, Catalog No. 17952) and Easy Sep Human CD8+ T Cell Isolation Kit II (StemCell Technologies, Catalog No. 17953).

[0398] Purified T cells were cultured in CTL medium [RPMI medium supplemented with 10% human serum (Bloodworks Northwest), 2% L-glutamine (Gibco, Cat. No. 25030-081), 1% pen-strep (Gibco, Cat. No. 15140-122), 0.5 M beta-mercaptoethanol (Gibco, Cat. No. 21985-023), and 50 U / ml IL-2 (aldesleukin, Prometheus)] at 37°C with 5% CO2. T cells were activated with anti-CD3 / CD28 beads (beads:cells 3:1, Gibco, 11131D) on Retronectin-coated plates (5 μg / mL, coated overnight at 4°C, Takara, Cat. No. T100B) and 1 day after activation, 8 ug / ml T cells were added to the plate. Cells were transduced with CAR lentivirus by spinoculation at 800g for 90 min at 25°C in CTL medium (+50U / mL IL-2) supplemented with 1L protamine sulfate (MOI=50). Transductions were performed in 24-well plates, with 200,000 cells per well. Transduced cells were grown in CTL medium (+50U / mL IL-2) and detached from beads on day 5. A truncated CD19 was co-expressed with CAR by the T2A ribosomal skip element and was used to select transduced cells. Transduced cells were screened 8-10 days after activation by CD19 expression [anti-human CD19 microbeads (Miltenyi)] in an Automacs. Cells were then sorted using a 30-mL ELISA kit (Biotec, Cat. No. 130-050-301). Sorted cells were expanded for an additional 4-6 days in CTL (+50 U / mL IL-2) medium before in vitro and in vivo cytotoxicity assays.

[0399] In vitro cytotoxicity tests. Target cells (C / G-CB, M07e, WSU-AML, Kasumi-1 FOLR1+ and Kasumi-1 parental over 9 weeks in EC coculture) were split 1-2 days before cytotoxicity assays. Target leukemia cells were labeled with 2.5 μM carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, Cat. No. C34554) according to the manufacturer's protocol, washed with 1× PBS, and resuspended in CTL medium (without IL-2). For T cell proliferation assays, effector cells (unengineered or CAR T cells) were labeled with 2.5 μM Violet Cell Proliferation Dye (Invitrogen, Cat. No. C34557), washed with 1× PBS, serially diluted in CTL medium (without IL-2), and mixed with target cells at various effector:target (E:T) ratios in 96-well U-bottom plates. Cytotoxicity (at the indicated time points) and T cell proliferation (4 days) were assessed by flow cytometry after staining with live / dead fixable viability dyes [FVD, Invitrogen, Cat. No. L34964 (cytotoxicity) or L10120 (T cell proliferation)]. Percent dead among target cells was assessed by gating on FVD+ among CFSE+ target cells. Percent specific lysis was calculated by subtracting the average of three replicate wells containing only target cells from each well containing target and effector cells at each E:T ratio. After 24 hours of coculture, culture supernatants were assessed for IL-2, IFN-γ, and TNF-α production by Luminex microbead technology (provided by the FHCRC Immune Monitoring Core).

[0400] Optimization of the IgG4 spacer region for efficient CAR T activity. To evaluate the therapeutic potential of FOLR1 targeting, FOLR1-directed CARs were generated by fusing single-chain variable fragments (scFv) from the anti-FOLR1 antibody farletuzumab to the IgG4 spacer, CD28 transmembrane, 4-1BB costimulatory, and CD3z signaling domains (Figure 17A). The IgG4 spacer region was optimized for fusion-positive cell lines (M0-7e and WSU-AML), C / G-CB cells, Kasumi-1 cells engineered to express FOLR1 (Kasumi-1 FOLR1+), and Kasumi-1 parental cells (Figure 17B). All constructs produced similar cytotoxicity against FOLR1+ cells, but the intermediate spacer CAR produced higher levels of inflammatory cytokines (IL-2, IFN-γ, and TNF-α) compared to the short and long IgG4 spacers (Figures 17C and 17D). Expression of NFAT, NFkB, and AP-1 was assayed in Jurkat Nur77 reporter cells (Rosskopf et al., Oncotarget 9:17608-17619, 2018) transduced with CAR constructs, cultured alone or in coculture with Kasumi-1 FOLR1+ cells. None of the FOLR1 CAR constructs showed tonic signaling in the absence of target binding (Figures 17E and 17F).

[0401] In vivo cytotoxicity test. Target leukemia cells were transduced with mCherry / ffluciferase (C / G-CB at 9–12 weeks in EC coculture, plasmid no. 104833, Addgene) or eGFP / ffluciferase constructs (WSU-AML, Kasumi-1 FOLR1+ and Kasumi-1 parent, plasmid no. 104834, Addgene) and sorted for mCherry+ or GFP+ cells, respectively. Luciferase expressing cells were transduced into NSG-SGM3(C / G-CB) at 5 × 10 per mouse. 6 cells, or NSG (WSU-AML, Kasumi-1 FOLR1+ and Kasumi-1 parental) mice, 6One week after leukemia cell injection, mice were treated with FOLR1 CAR T or non-engineered T cells by intravenous injection via the tail vein.

[0402] Leukemia burden was measured weekly by bioluminescence imaging. Leukemia burden and T cell proliferation were monitored by flow cytometry analysis of mouse peripheral blood drawn from the retro-orbital plexus for the indicated time points starting from the first week of T cell injection. Flow cytometry analysis of peripheral blood and tissues was performed as described elsewhere herein (Figure 18).

[0403] Colony forming cell assay. After 6 and 12 weeks of culture, cells were plated in Megacult (Megacult-C, collagen and medium with cytokines, Stemcell Technologies, Vancouver, Canada, Cat. No. 04961) and incubated at 37°C with 5% CO2 for 10-14 days. Colonies from megacult cultures were fixed with 3.7% formaldehyde, washed with PBS and stained with CFU-Mk's MegaCult™-C staining kit (StemCell Technologies, Vancouver, Canada, Cat. No. 04962) according to the manufacturer's instructions or fixed with 0.1% Triton X-100 for 10 min, permeabilized and blocked with 1% BSA in PBST (PBS + 0.1% Tween-20) for 30 min and then stained with biotin-conjugated mouse anti-human CD41 (Biolegend, Cat. No. 303734) and FITC-conjugated goat anti-GFP (abcam, Cat. No. ab6662) followed by secondary staining with Alexa 647-labeled streptavidin (Biolegend, Cat. No. 405237) according to the manufacturer's instructions. Colonies were stained with DAPI and then imaged using a TissueFAX microscope. Mk colonies were counted and enumerated based on positive staining for CD41.

[0404] C / G-CB and normal HPSCs, either unmanipulated or after 4 h of coculture with CAR T cells, were plated onto Methocult H4034 Optimum (Stemcell Technologies, catalog no. 04034). Colonies derived from erythroid (E), granulocyte-macrophage (G, M, and GM) and multipotent granulocyte, erythroid, macrophage, and megakaryocyte (GEMM) progenitors were counted and enumerated after 7–10 days as directed by the manufacturer's instructions.

[0405] Statistical analysis for in vitro and in vivo studies. Statistical significance was determined for all in vitro studies using an unpaired two-tailed Student's t-test. Kaplan-Meier survival curves between experimental groups were compared using the log-rank (Mantel-Cox) test. Statistical significance was defined for p<0.05.

[0406] Availability of data and code. RNA-seq data of primary patient samples will be deposited in GDC, SRA and Target Data Matrix. RNA-seq data of engineered CB will be deposited in GEO. All codes used for this will be made publicly available.

[0407] Example 2. Development and preclinical evaluation of FOLR1-directed chimeric antigen receptor T cells in CBF2AT3-GLIS2 / RAM AML

[0408] Background: A rare but highly aggressive form of acute myeloid leukemia (AML) found exclusively in young children with a unique immunophenotype (RAM phenotype characterized by positive CD56 expression, negative CD45 expression, negative CD38 expression, and negative HLA-DR expression) is caused by a latent CBFA2T3-GLIS2 (CBF / GLIS) fusion. This infantile AML is highly refractory to conventional chemotherapy and remains largely lethal despite highly aggressive, myeloablative therapy (Gruber et al., Cancer Cell. 22(5):683-97, 2012). Transcriptomic profiling of CBF / GLIS AML has revealed new insights into the pathogenesis of this fusion and uncovered fusion-specific molecular biomarkers that can be used to inform risk stratification and treatment (Masetti et al., Br J Haematol. 184(3):337-47, 2019). Examination of the largest cohort of these high-risk infants demonstrated several alterations in gene expression and transcriptional networks with potential therapeutic targets in these CBF / GLIS-positive patient samples (Smith et al., Clin Cancer Res. 26(3):726-737, 2020). FOLR1, encoding folate receptor alpha, was highly and uniquely expressed in CBF / GLIS AML but completely absent in AML with other cytogenetic abnormalities and in normal hematopoietic cells. Furthermore, it was demonstrated that forced expression of CBF / GLIS enhanced proliferation and altered differentiation of cord blood (CB) CD34+ early precursors to the megakaryocytic lineage, which recapitulated acute megakaryocytic leukemia seen in infants (Smith et al., Clin Cancer Res. 26(3):726-737, 2020). Importantly, surface expression of FOLR1 was found to be causally associated with CBF / GLIS-induced malignant transformation, making it an attractive antigen for targeted therapy against CBF / GLIS AML cells.Considering that chimeric antigen receptor (CAR) T cells are highly effective in eradicating relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL) malignancies, FOLR1-directed CAR T cells were developed for preclinical evaluation in CBF / GLIS AML.

[0409] Methods. FOLR1-directed CARs were generated using an anti-FOLR1 binder (farletuzumab), an IgG4 intermediate spacer, and the signaling domain of 41BB / CD3 zeta. Preclinical efficacy of FOLR1 CAR T cells was evaluated in vitro and in vivo against CBF / GLIS AML cell lines. CBF / GLIS AML models include CB CD34+ cells transduced with a CBF / GLIS expression construct (CBF / GLIS-CB) and the WSU-AML cell line. The Kasumi-1 cell line was also engineered to express FOLR1 (Kasumi-1 FOLR1+) to assess target specificity (Figure 17B).

[0410] Results. The target specificity of FOLR1-directed CAR T cells was examined against FOLR1-positive (CBF / GLIS-CB, WSU-AML, Kasumi-1 FOLR1+) and FOLR1-negative (Kasumi-1) cells. CD8 FOLR1 CAR T cells exhibited cytolytic activity against FOLR1-positive cells, but not against FOLR1-negative cells (Figure 13A). Furthermore, both CD8 and CD4 FOLR1 CAR T cells produced higher levels of IL-2, IFN-γ, and TNF-α than unengineered T cells and proliferated robustly when incubated with FOLR1-positive cells but not with FOLR1-negative cells (Figure 13B). These results indicate the highly specific reactivity of FOLR1 CAR T against AML cells expressing FOLR1. Next, the in vivo efficacy of FOLR1-directed CAR T cells was examined. In CBF / GLIS-CB, WSU-AML, and Kasumi-1 FOLR1+ xenograft models, treatment with FOLR1 CAR T cells induced leukemia clearance, whereas disease progression occurred in all mice receiving unmanipulated T cells (Figure 13D). The in vivo activity of FOLR1 CAR T cells was target-specific and did not limit leukemia progression or extend survival of Kasumi-1 xenografts (Figure 13D).

[0411] To determine whether FOLR1 is expressed in normal hematopoietic stem and progenitor cells (HSPCs), FOLR1 expression was characterized in normal CB CD34+ samples. FOLR1 expression was completely silent in a subset of HSPCs (Figure 15C). Consistent with the lack of expression, no cytolytic activity was detected against HSPCs. Furthermore, FOLR1 CAR T cells did not affect the self-renewal and multipotency of normal HSPCs compared to unmanipulated control T cells (Figure 15E), whereas significant eradication of colonies was detected in CBF / GLIS-CB cells (Figure 15F).

[0412] Conclusion: This example demonstrates that FOLR1 CAR T efficiently eradicates CBF / GLIS AML cells without damaging normal HSPCs, providing a promising approach for the treatment of high-risk CBF / GLIS AML. The transition of this CAR T into clinical development for pediatric AML is ongoing.

[0413] (xiii) Conjunctions. The nucleic acid and amino acid sequences provided herein are shown using the letter abbreviations for nucleotide bases and amino acid residues as defined in 37 CFR 1.822 and as set forth in the tables in WIPO Standard ST.25 (1998), Appendix 2, Tables 1 and 3. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included in the embodiments, where appropriate.

[0414] To the extent not explicitly provided herein, the coding sequences of the proteins disclosed herein and the protein sequences of the coding sequences disclosed herein can be readily obtained by one of skill in the art.

[0415] Variants of sequences disclosed and referenced herein are also included. Guidance for determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological activity can be found using computer programs known in the art, such as DNASTAR™ (Madison, Wisconsin) software. Preferably, the amino acid changes in the protein variants disclosed herein are conservative amino acid changes, i.e., substitution of similarly charged or uncharged amino acids. Conservative amino acid changes include substitution of one of a family of amino acids whose side chains are related.

[0416] In peptides or proteins, conservative substitutions of suitable amino acids are known to those skilled in the art and can generally be made without altering the biological activity of the resulting molecule.Those skilled in the art generally recognize that a single amino acid substitution in a non-essential region of a polypeptide does not substantially alter biological activity (see, for example, Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin / Cummings Pub.Co., p.224). Naturally occurring amino acids are generally classified into the following conservative substitution families: Group 1: alanine (Ala), glycine (Gly), serine (Ser), and threonine (Thr); Group 2: (acidic): aspartic acid (Asp) and glutamic acid (Glu); Group 3: (also classified as acidic, polar, negatively charged residues and their amides): asparagine (Asn), glutamine (Gln), Asp, and Glu; Group 4: Gln and Asn; Group 5: (also classified as basic, polar, positively charged residues): arginine (Arg), lysine (Lys), and histidine (His); Group 6 (large aliphatic, non-polar residues): isoleucine ( Group 10 (small aliphatic, non-polar or slightly polar residues): Ala, Ser, Thr, Pro, and Gly; and Group 12 (sulfur-containing): Met and Cys. Further information can be found in Creighton (1984) Proteins, W.H. Freeman and Company.

[0417] In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, 1982, J. Mol. Biol. 157(1), 105-32). Each amino acid has been assigned a hydropathic index based on its hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values ​​are: Ile (+4.5), Val (+4.2), Leu (+3.8), Phe (+2.8), Cys (+2.5), Met (+1.9), Ala (+1.8), Gly (-0.4), Thr (-0.7), Ser (-0.8), Trp (-0.9), Tyr (-1.3), Pro (-1.6), His (-3.2), Glutamic acid (-3.5), Gln (-3.5), Aspartic acid (-3.5), Asn (-3.5), Lys (-3.9), and Arg (-4.5).

[0418] It is known in the art that certain amino acids may be substituted by other amino acids with similar hydropathic index or score and still result in proteins with similar biological activity, i.e., proteins with the same biological function are still obtained. When making such changes, amino acid substitutions with hydropathic index within ±2 are preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred. It is also understood in the art that similar amino acid substitutions can be effectively made based on hydrophilicity.

[0419] As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values ​​have been assigned to amino acid residues: Arg (+3.0), Lys (+3.0), Aspartic acid (+3.0±1), Glutamic acid (+3.0±1), Ser (+0.3), Asn (+0.2), Gln (+0.2), Gly (0), Thr (-0.4), Pro (-0.5±1), Ala (-0.5), His (-0.5), Cys (-1.0), Met (-1.3), Val (-1.5), Leu (-1.8), Ile (-1.8), Tyr (-2.3), Phe (-2.5), Trp (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular an immunologically equivalent, protein. Of such changes, amino acid substitutions within a hydrophilicity value of ±2 are preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.

[0420] As discussed above, amino acid substitutions can be made on the basis of the relative similarity of the amino acid side-chain substituents, for example, hydrophobicity, hydrophilicity, charge, size, and the like.

[0421] As noted elsewhere, variants of a gene sequence can include codon-optimized variants, sequence polymorphisms, splice variants, and / or mutations that do not affect the function of the encoded product to any statistically significant degree.

[0422] Variants of the protein, nucleic acid, and gene sequences disclosed herein also include sequences having at least 70% sequence identity, 80% sequence identity, 85% sequence identity, 90% sequence identity, 95% sequence identity, 96% sequence identity, 97% sequence identity, 98% sequence identity, or 99% sequence identity to the protein, nucleic acid, or gene sequences disclosed herein.

[0423] "Percent sequence identity" refers to a relationship between two or more sequences, as determined by comparing those sequences. In the art, "identity" also means the degree of sequence relatedness between protein, nucleic acid, or gene sequences, as determined by the match between strings of such sequences. "Identity" (often referred to as "similarity") can be readily calculated by known methods, including, but not limited to, those described in Computational Molecular Biology (Lesk, AM, ed.) Oxford University Press, NY (1988), Biocomputing: Informatics and Genome Projects (Smith, DW, ed.) Academic Press, NY (1994), Computer Analysis of Sequence Data, Part I (Griffin, AM, and Griffin, HG, eds.) Humana Press, NJ (1994), Sequence Analysis in Molecular Biology (Von Heijne, G., ed.) Academic Press (1987), and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Oxford University Press, NY (1992). Preferred methods for determining identity are designed to give the best match between the sequences examined. Methods for determining identity and similarity are codified in publicly available computer programs. Sequence alignment and percent identity calculations can be performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR, Inc., Madison, Wisconsin). Multiple alignment of sequences can also be performed using the Clustal alignment method (Higgins and Sharp CABIOS, 5, 151-153 (1989) with default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10).Related programs include the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wisconsin), BLASTP, BLASTN, BLASTX (Altschul, et al., J. Mol. Biol. 215:403-410 (1990)), DNASTAR (DNASTAR, Inc., Madison, Wisconsin), and the FASTA program incorporating the Smith-Waterman algorithm (Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Publisher: Plenum, New York, 1999). Also included are the University of New York, NY. As part of this disclosure, when sequence analysis software is used for the analysis, it will be understood that the results of the analysis will be based on the "default values" of the program referenced. As used herein, "default values" refers to any set of values ​​or parameters that are originally loaded by the software when first initialized.

[0424] Variants also include nucleic acid molecules that hybridize to the sequences disclosed herein under stringent hybridization conditions, resulting in the same function as the reference sequences. Exemplary stringent hybridization conditions include 50% formamide, 5XSSC (750mM NaCl, 75mM trisodium citrate), 50mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20μg / ml denatured salmon sperm DNA, incubated overnight at 42°C, followed by washing the filter with 0.1x SSC at 50°C. The change in stringency of hybridization and signal detection is mainly achieved through the manipulation of formamide concentration (lower percentage of formamide results in lower stringency), salt conditions, or temperature. For example, moderately high stringency conditions include 6xSSPE (20xSSPE=3M NaCl, 0.2M NaH2PO4, 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 μg / ml salmon sperm blocking DNA, followed by a wash at 50°C with 1xSSPE, 0.1% SDS. Additionally, to achieve even lower stringency, washes performed after stringent hybridization can be performed with higher salt concentrations (e.g., 5xSSC). Variations in the above conditions can be achieved through the inclusion or substitution of alternative blocking reagents used to suppress background in hybridization experiments. Exemplary blocking reagents include Denhardt's Reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available preparations. The inclusion of certain blocking reagents may require modification of the hybridization conditions described above due to compatibility issues.

[0425] "Bind" refers to a binding domain (e.g., a CAR binding domain or that of a selected cell targeting ligand of a nanoparticle) that binds to its cognate binding molecule with affinity or K a (i.e., the equilibrium binding constant for a particular binding interaction in units 1 / M) is 105 M -1 A binding domain may be classified as "high affinity" or "low affinity." In certain embodiments, a "high affinity" binding domain is one that binds to a target molecule at or above the K a But at least 10 7 M -1 , at least 10 8 M -1 , at least 10 9 M -1 , at least 10 10 M -1 , at least 10 11 M -1 , at least 10 12 M -1 , or at least 10 13 M -1 In certain embodiments, a "low affinity" binding domain refers to a binding domain of a But up to 10 7 M -1 , up to 10 6 M -1 , up to 10 5 M -1 Alternatively, affinity is the equilibrium dissociation constant (K) of a particular binding interaction in units M. d ) (e.g., 10 -5 M~10 -13 In certain embodiments, a binding domain may have a "high affinity," which refers to a selected or engineered binding domain having stronger binding to a cognate binding molecule than a wild-type (or parent) binding domain. For example, high affinity may be defined as a higher KM than a reference binding domain for the cognate binding molecule. a (equilibrium binding constant) or a lower K d (dissociation constant) also has a lower off-rate (K offA variety of assays, such as Western blots, ELISAs, and BIACORE® analyses, are known for detecting binding domains that specifically bind to a particular cognate binding molecule and for determining binding affinity (see, e.g., Scatchard, et al., 1949, Ann. NY Acad. Sci. 51:660, and U.S. Pat. Nos. 5,283,173, 5,468,614, or equivalents).

[0426] Unless otherwise indicated, the practice of the present disclosure may employ conventional techniques of immunology, molecular biology, microbiology, cell biology, and recombinant DNA. These methods are described in, for example, Sambrook, et al. Molecular Cloning: A Laboratory Manual, 2nd Edition (1989), FM Ausubel, et al. eds., Current Protocols in Molecular Biology, (1987), the series Methods IN Enzymology (Academic Press, Inc.), M. MacPherson, et al., PCR: A Practical Approach, IRL Press at Oxford University Press (1991), MacPherson et al., eds. PCR 2: Practical Approach, (1995), Harlow and Lane, eds. Antibodies, A Laboratory Manual, (1988), and R.I. Freshney, ed. Animal Cell Culture (1987).

[0427] As will be appreciated by those skilled in the art, each embodiment disclosed herein can comprise, consist essentially of, or consist of the specified stated elements, steps, components, or ingredients. Thus, the term "include" or "including" should be interpreted as reciting "comprise, consist of, or consist essentially of." The transitional term "comprise" or "comprises" refers to and allows for the inclusion of, but not limited to, any unspecified elements, steps, components, or ingredients, even in amounts that are greater than or equal to the specified elements, steps, components, or ingredients. The transitional phrase "consisting of" also excludes all unspecified elements, steps, components, or ingredients. The transitional phrase "consisting essentially of" limits the scope of the embodiment to the specified elements, steps, components, or ingredients and those that do not substantially affect the embodiment. A substantial effect is one that causes a statistically significant decrease in the ability to treat cancer as described herein.

[0428] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and the like used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and appended claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Where further clarity is needed, the term "about," when used in conjunction with a stated numerical value or range, has the meaning that would be reasonably ascribed to it by one of ordinary skill in the art, i.e., slightly more or slightly less than the stated value or range, up to within ±20% of the stated value, ±19% of the stated value, ±18% of the stated value, ±17% of the stated value, ±16% of the stated value, ±15% of the stated value, ±14% of the stated value, ±13% of the stated value, ±12% of the stated value, ±11% of the stated value, ±10% of the stated value, ±9% of the stated value, ±8% of the stated value, ±7% of the stated value, ±6% of the stated value, ±5% of the stated value, ±4% of the stated value, ±3% of the stated value, ±2% of the stated value, or ±1% of the stated value.

[0429] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values ​​set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[0430] The terms "a," "an," "the," and similar referents as used in the context of describing the present invention (particularly in the context of the claims below) should be construed to include both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values ​​herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated herein as if it were individually recited herein. All methods described herein may be performed in any suitable order, unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "for example, etc.") provided herein is intended merely to better elucidate the invention and does not limit the scope of the invention as otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0431] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limiting. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in or deleted from a group for convenience and / or patentability. When such inclusion or deletion occurs, the specification shall be deemed to include the group as modified and thus fulfill the specification of all Markush groups used in the appended claims.

[0432] Certain embodiments of the invention have been described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations of those described embodiments will become apparent to those of skill in the art after reading the foregoing description. The inventors anticipate that those of skill in the art will employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or clearly contradicted by context.

[0433] Additionally, throughout this specification, numerous references are made to patents, publications, journal articles, and other writings ("reference materials"). Each of such reference materials is individually incorporated herein by reference in its entirety for the teachings referenced thereto.

[0434] Finally, it is to be understood that the embodiments of the invention disclosed herein are examples of the principles of the invention. Other modifications that may be used are within the scope of the invention. Thus, by way of example, and not of limitation, alternative constructions of the invention may be used in accordance with the teachings herein. Thus, the invention is not limited to that precisely as shown and described.

[0435] The details shown in this specification are by way of example and are for the sole purpose of illustrative discussion of preferred embodiments of the present invention, and are shown to provide what is believed to be the most useful, as well as a readily understood description of the principles and conceptual aspects of various embodiments of the present invention. In this regard, no attempt has been made to show the structural details of the present invention in more detail than is necessary for a fundamental understanding of the present invention, and the description taken together with the figures and / or examples will make clear to those skilled in the art how various forms of the present invention may be embodied in practice.

[0436] The definitions and explanations used in this disclosure are meant and intended to govern any future constructions, unless clearly and unambiguously amended in the examples, or unless application of the meaning would render any construction meaningless or essentially meaningless. In the event that construction of the term renders it meaningless or essentially meaningless, the definition shall be taken from Webster's Dictionary, 3rd Edition, or dictionaries known to those skilled in the art, such as the Oxford Dictionary of Biochemistry and Molecular Biology (Eds. Attwood T et al., Oxford University Press, Oxford, 2006).

Claims

1. When expressed by a cell, An extracellular component comprising a binding domain having the sequence set forth in SEQ ID NO: 22 or SEQ ID NO: 23; an intracellular component comprising an effector domain, and A transmembrane domain that links the extracellular component to the intracellular component A chimeric antigen receptor comprising:

2. A targeted therapeutic molecule comprising a binding domain that binds to folate receptor 1 (FOLR1), multiple EGF-like domain 10 (MEGF10), heparinase-2 enzyme (HPSE2), killer cell lectin-like receptor F2 (KLRF2), protocadherin-19 (PCDH19), or Fraser extracellular matrix complex subunit 1 (FRAS1).

3. When expressed by a cell, an extracellular component comprising a binding domain that binds to FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1; an intracellular component comprising an effector domain, and A transmembrane domain that links the extracellular component to the intracellular component 3. The targeted therapeutic molecule of claim 2, which is a chimeric antigen receptor (CAR) comprising:

4. The targeted therapeutic molecule of claim 3 , wherein the binding domain specifically binds to FOLR1.

5. The targeted therapeutic molecule of claim 3 , wherein the binding domain comprises a single chain variable fragment (scFv).

6. The targeted therapeutic molecule of claim 5 , wherein the scFv has the sequence set forth in SEQ ID NO:22 or SEQ ID NO:

23.

7. 5. The targeted therapeutic molecule of claim 4, wherein the binding domain comprises a variable heavy chain set forth in SEQ ID NO: 30 and a variable light chain set forth in SEQ ID NO: 31, a variable heavy chain set forth in SEQ ID NO: 38 and a variable light chain set forth in SEQ ID NO: 39, a variable heavy chain set forth in SEQ ID NO: 40 and a variable light chain set forth in SEQ ID NO: 41, a variable heavy chain set forth in SEQ ID NO: 48 and a variable light chain set forth in SEQ ID NO: 49, a variable heavy chain set forth in SEQ ID NO: 56 and a variable light chain set forth in SEQ ID NO: 57, a variable heavy chain set forth in SEQ ID NO: 64 and a variable light chain set forth in SEQ ID NO: 65, a variable heavy chain set forth in SEQ ID NO: 72 and a variable light chain set forth in SEQ ID NO: 73, or a variable heavy chain set forth in SEQ ID NO: 80 and a variable light chain set forth in SEQ ID NO:

81.

8. The binding domain is, according to the Kabat numbering scheme: A variable heavy chain (CDRH) 1 having a complementarity determining region as set forth in SEQ ID NO: 24, a CDRH2 as set forth in SEQ ID NO: 25, and a CDRH3 as set forth in SEQ ID NO: 26, a variable light chain complementarity determining region (CDRL) 1 set forth in SEQ ID NO: 27, a CDRL 2 set forth in SEQ ID NO: 28, and a CDRL 3 set forth in SEQ ID NO: 29; CDRH1 set forth in SEQ ID NO: 32, CDRH2 set forth in SEQ ID NO: 33, and CDRH3 set forth in SEQ ID NO: 34, and CDRL1 set forth in SEQ ID NO: 35, CDRL2 set forth in SEQ ID NO: 36, and CDRL3 set forth in SEQ ID NO: 37; CDRH1 set forth in SEQ ID NO: 42, CDRH2 set forth in SEQ ID NO: 43, and CDRH3 set forth in SEQ ID NO: 44, and CDRL1 set forth in SEQ ID NO: 45, CDRL2 set forth in SEQ ID NO: 46, and CDRL3 set forth in SEQ ID NO: 47; CDRH1 set forth in SEQ ID NO:50, CDRH2 set forth in SEQ ID NO:51, and CDRH3 set forth in SEQ ID NO:52, and CDRL1 set forth in SEQ ID NO:53, CDRL2 set forth in SEQ ID NO:54, and CDRL3 set forth in SEQ ID NO:55; CDRH1 set forth in SEQ ID NO:58, CDRH2 set forth in SEQ ID NO:59, and CDRH3 set forth in SEQ ID NO:60, and CDRL1 set forth in SEQ ID NO:61, CDRL2 set forth in SEQ ID NO:62, and CDRL3 set forth in SEQ ID NO:63; CDRH1 set forth in SEQ ID NO:66, CDRH2 set forth in SEQ ID NO:67, and CDRH3 set forth in SEQ ID NO:68, and CDRL1 set forth in SEQ ID NO:69, CDRL2 set forth in SEQ ID NO:70, and CDRL3 set forth in SEQ ID NO:71, and CDRH1 set forth in SEQ ID NO: 74, CDRH2 set forth in SEQ ID NO: 75, and CDRH3 set forth in SEQ ID NO: 76, and CDRL1 set forth in SEQ ID NO:77, CDRL2 set forth in SEQ ID NO:78, and CDRL3 set forth in SEQ ID NO:79 The targeted therapeutic molecule of claim 4 .

9. The targeted therapeutic molecule of claim 3, encoded by the sequence set forth in SEQ ID NO:

134.

10. The targeted therapeutic molecule of claim 3 , wherein the binding domain specifically binds to MEGF10.

11. The targeted therapeutic molecule of claim 10, wherein the binding domain comprises LS-C678634, LS-C668447, LSC497216, or PA5-76556, or a binding fragment thereof.

12. The targeted therapeutic molecule of claim 3 , wherein the binding domain specifically binds to HPSE2.

13. 13. The targeted therapeutic molecule of claim 12, wherein the binding domain comprises LS-B14593, LS-C322089, LS-C378319, or HPA044603, or a binding fragment thereof.

14. The targeted therapeutic molecule of claim 3 , wherein the binding domain specifically binds to KLRF2.

15. 15. The targeted therapeutic molecule of claim 14, wherein the binding domain comprises LS-C329740, LS-C203747, SAB2108513, SAB2108684, HPA055964, SAB2108320, or SAB2108355, or a binding fragment thereof.

16. 4. The targeted therapeutic molecule of claim 3, wherein the binding domain specifically binds to PCDH19.

17. 17. The targeted therapeutic molecule of claim 16, wherein the binding domain comprises LS-C676224, LS-C496779, LS-C761991, HPA027533, or HPA001461, or a binding fragment thereof.

18. The targeted therapeutic molecule of claim 3 , wherein the binding domain specifically binds to FRAS1.

19. 20. The targeted therapeutic molecule of claim 18, wherein the binding domain comprises LS-C763132, LS-B5486, LS-C754337, HPA011281, or HPA051601, or a binding fragment thereof.

20. The targeted therapeutic molecule of claim 3 , wherein the extracellular component further comprises a spacer region.

21. The targeted therapeutic molecule of claim 20 , wherein the spacer region comprises a long spacer region, an intermediate spacer region, or a short spacer region.

22. 22. The targeted therapeutic molecule of claim 21, wherein the intermediate spacer region is 135 amino acids or less.

23. 22. The targeted therapeutic molecule of claim 21, wherein the intermediate spacer region is 131 amino acids or less and comprises the hinge region and CH3 domain of IgG4.

24. The targeted therapeutic molecule of claim 23 , wherein the intermediate spacer region is encoded by the sequence set forth in SEQ ID NO:

136.

25. The targeted therapeutic molecule of claim 21 , wherein the intermediate spacer region is encoded by the sequence set forth in SEQ ID NO:

3.

26. 22. The targeted therapeutic molecule of claim 21, wherein the long spacer region is greater than 200 amino acids and includes an IgG4 hinge, an IgG4 CH3 region, and an IgG4 CH2 region.

27. The targeted therapeutic molecule of claim 21 , wherein the long spacer region is encoded by the sequence set forth in SEQ ID NO:

4.

28. 22. The targeted therapeutic molecule of claim 21 , wherein the short spacer region is less than 50 amino acids and comprises an IgG4 hinge.

29. The targeted therapeutic molecule of claim 21 , wherein the short spacer region is encoded by the sequence set forth in SEQ ID NO:1 or SEQ ID NO:

2.

30. The targeted therapeutic molecule of claim 3, wherein the intracellular effector domain comprises all or part of the signaling domains of CD3ζ and 4-1BB.

31. The targeted therapeutic molecule of claim 30, wherein the signaling domain of CD3ζ is encoded by the CD3ζ coding sequence set forth in SEQ ID NO:

5.

32. The targeted therapeutic molecule of claim 30, wherein the signaling domain of CD3ζ comprises the sequence set forth in SEQ ID NO:6 or SEQ ID NO:

7.

33. The targeted therapeutic molecule of claim 30, wherein the signaling domain of 4-1BB is encoded by SEQ ID NO:8 or SEQ ID NO:

9.

34. The targeted therapeutic molecule of claim 30, wherein the signaling domain of 4-1BB comprises the sequence set forth in SEQ ID NO:10 or SEQ ID NO:

11.

35. The targeted therapeutic molecule of claim 3 , wherein the transmembrane domain comprises the transmembrane domain of CD28.

36. The targeted therapeutic molecule of claim 35, wherein the transmembrane domain of CD28 is encoded by SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO:

14.

37. The targeted therapeutic molecule of claim 35, wherein the transmembrane domain of CD28 comprises SEQ ID NO: 15 or SEQ ID NO:

16.

38. The targeted therapeutic molecule of claim 3, further comprising a control mechanism selected from a tag cassette, a transduction marker, and / or a suicide switch.

39. 39. The targeted therapeutic molecule of claim 38, wherein the transduction marker comprises a truncated CD19.

40. The targeted therapeutic molecule of claim 39, wherein the truncated CD19 is encoded by SEQ ID NO:

117.

41. The targeted therapeutic molecule of claim 3 , further comprising a ribosomal skipping element.

42. 40. The targeted therapeutic molecule of claim 39, wherein the ribosomal skip element comprises T2A, P2A, E2A, or F2A.

43. The targeted therapeutic molecule of claim 41 , wherein the ribosomal skip element comprises T2A.

44. The targeted therapeutic molecule of claim 43, wherein the T2A is encoded by SEQ ID NO:

137.

45. A gene construct encoding the CAR according to claim 3.

46. 46. ​​A nanoparticle encapsulating a genetic construct according to claim 45.

47. A cell genetically engineered to express the CAR of claim 3.

48. 48. The cell of claim 47, which is an autologous or allogeneic cell with respect to the subject.

49. 48. The cell of claim 47, which is in vivo or ex vivo.

50. 48. The cell of claim 47, which is a T cell, a B cell, a natural killer (NK) cell, an NK-T cell, a monocyte / macrophage, a hematopoietic stem cell (HSC), or a hematopoietic progenitor cell (HPC).

51. 51. The cell of claim 50, which is a T cell selected from a CD3+ T cell, a CD4+ T cell, a CD8+ T cell, a central memory T cell, an effector memory T cell, and / or a naive T cell.

52. The cell of claim 50, which is a CD8+ T cell and / or a CD4+ T cell.

53. The targeted therapeutic molecule of claim 2 , wherein the binding domain is conjugated to a cytotoxic payload.

54. The targeted therapeutic agent of claim 2 , wherein the binding domain specifically binds to FOLR1.

55. The targeted therapeutic of claim 2 , wherein the binding domain comprises a single chain variable fragment (scFv).

56. The targeted therapeutic agent of claim 55, wherein the scFv has the sequence set forth in SEQ ID NO:22 or SEQ ID NO:

23.

57. 55. The targeted therapeutic agent of claim 54, wherein the binding domain comprises a variable heavy chain set forth in SEQ ID NO: 30 and a variable light chain set forth in SEQ ID NO: 31, a variable heavy chain set forth in SEQ ID NO: 38 and a variable light chain set forth in SEQ ID NO: 39, a variable heavy chain set forth in SEQ ID NO: 40 and a variable light chain set forth in SEQ ID NO: 41, a variable heavy chain set forth in SEQ ID NO: 48 and a variable light chain set forth in SEQ ID NO: 49, a variable heavy chain set forth in SEQ ID NO: 56 and a variable light chain set forth in SEQ ID NO: 57, a variable heavy chain set forth in SEQ ID NO: 64 and a variable light chain set forth in SEQ ID NO: 65, a variable heavy chain set forth in SEQ ID NO: 72 and a variable light chain set forth in SEQ ID NO: 73, or a variable heavy chain set forth in SEQ ID NO: 80 and a variable light chain set forth in SEQ ID NO:

81.

58. The binding domain is, according to the Kabat numbering scheme: A variable heavy chain (CDRH) 1 having a complementarity determining region as set forth in SEQ ID NO: 24, a CDRH2 as set forth in SEQ ID NO: 25, and a CDRH3 as set forth in SEQ ID NO: 26, a variable light chain complementarity determining region (CDRL) 1 set forth in SEQ ID NO: 27, a CDRL 2 set forth in SEQ ID NO: 28, and a CDRL 3 set forth in SEQ ID NO: 29; CDRH1 set forth in SEQ ID NO: 32, CDRH2 set forth in SEQ ID NO: 33, and CDRH3 set forth in SEQ ID NO: 34, and CDRL1 set forth in SEQ ID NO: 35, CDRL2 set forth in SEQ ID NO: 36, and CDRL3 set forth in SEQ ID NO: 37; CDRH1 set forth in SEQ ID NO: 42, CDRH2 set forth in SEQ ID NO: 43, and CDRH3 set forth in SEQ ID NO: 44, and CDRL1 set forth in SEQ ID NO: 45, CDRL2 set forth in SEQ ID NO: 46, and CDRL3 set forth in SEQ ID NO: 47; CDRH1 set forth in SEQ ID NO:50, CDRH2 set forth in SEQ ID NO:51, and CDRH3 set forth in SEQ ID NO:52, and CDRL1 set forth in SEQ ID NO:53, CDRL2 set forth in SEQ ID NO:54, and CDRL3 set forth in SEQ ID NO:55; CDRH1 set forth in SEQ ID NO:58, CDRH2 set forth in SEQ ID NO:59, and CDRH3 set forth in SEQ ID NO:60, and CDRL1 set forth in SEQ ID NO:61, CDRL2 set forth in SEQ ID NO:62, and CDRL3 set forth in SEQ ID NO:63; CDRH1 set forth in SEQ ID NO:66, CDRH2 set forth in SEQ ID NO:67, and CDRH3 set forth in SEQ ID NO:68, and CDRL1 set forth in SEQ ID NO:69, CDRL2 set forth in SEQ ID NO:70, and CDRL3 set forth in SEQ ID NO:71, and CDRH1 set forth in SEQ ID NO: 74, CDRH2 set forth in SEQ ID NO: 75, and CDRH3 set forth in SEQ ID NO: 76, and CDRL1 set forth in SEQ ID NO:77, CDRL2 set forth in SEQ ID NO:78, and CDRL3 set forth in SEQ ID NO:79 The targeted therapeutic agent of claim 54 .

59. The targeted therapeutic molecule of claim 2 , wherein the binding domain specifically binds to MEGF10.

60. 60. The targeted therapeutic molecule of claim 59, wherein the binding domain comprises LS-C678634, LS-C668447, LSC497216, or PA5-76556, or a binding fragment thereof.

61. The targeted therapeutic agent of claim 2 , wherein the binding domain specifically binds to HPSE2.

62. 62. The targeted therapeutic molecule of claim 61 , wherein the binding domain comprises LS-B14593, LS-C322089, LS-C378319, or HPA044603, or a binding fragment thereof.

63. The targeted therapeutic molecule of claim 2 , wherein the binding domain specifically binds to KLRF2.

64. 64. The targeted therapeutic molecule of claim 63, wherein the binding domain comprises LS-C329740, LS-C203747, SAB2108513, SAB2108684, HPA055964, SAB2108320, or SAB2108355, or a binding fragment thereof.

65. 3. The targeted therapeutic molecule of claim 2, wherein the binding domain specifically binds to PCDH19.

66. 66. The targeted therapeutic molecule of claim 65, wherein the binding domain comprises LS-C676224, LS-C496779, LS-C761991, HPA027533, or HPA001461, or a binding fragment thereof.

67. The targeted therapeutic molecule of claim 2 , wherein the binding domain specifically binds to FRAS1.

68. 68. The targeted therapeutic molecule of claim 67, wherein the binding domain comprises LS-C763132, LS-B5486, LS-C754337, HPA011281, or HPA051601, or a binding fragment thereof.

69. 54. The targeted therapeutic molecule of claim 53, wherein the cytotoxic payload comprises a cytotoxin, a cytotoxic drug, a radioisotope, or a nanoparticle.

70. 70. The targeted therapeutic molecule of claim 69, wherein the cytotoxin comprises a holotoxin or a hemitoxin.

71. The cytotoxic drug may be actinomycin D, anthracyclines, auristatins, calicheamicin, camptothecin, CC1065, colchicine, cytochalasin B, daunorubicin, 1-dehydrotestosterone, dihydroxyanthracenedione, dolastatins, doxorubicin, duocarmycin, elinafide, emetine, ethidium bromide, etoposide, gramicidin D, glucocorticoids, lidocaine, maytansin, 70. The targeted therapeutic molecule of claim 69, comprising a cytochrome P450 compound selected from the group consisting of cytochrome P450 compounds, ...

72. The radioactive isotope is 228 Ac, 111 Ag, 124 Am, 74 As, 211 As, 209 At, 194 Au, 128 Ba, 7 Be, 206 Bi, 245 Bk, 246 Bk, 76 Br, 11 C, 47 Ca, 254 Cf, 242 Cm, 51 Cr, 67 Cu, 153 Dy, 157 Dy, 159 Dy, 165 Dy, 166 Dy, 171 Er, 250 Es, 254 Es, 147 Eu, 157 Eu, 52 Fe, 59 Fe, 251 Fm, 252 Fm, 253 Fm, 66 Ga, 72 Ga, 146 Gd, 153 Gd, 68 Ge, 170 Hf, 171 Hf, 193 Hg, 193 mHg, 160 mHo, 130 I, 131 I, 135 I, 114 mIn, 185 Ir, 42 K, 43 K, 76 Kr, 79 Kr, 81 mKr, 132 La, 262 Lr, 169 Lu, 174 mLu, 176 mLu, 257 Md, 260 Md, 28 Mg, 52 Mn, 90 M.O. 24 Na, 95 Nb, 138 Nd, 57 Ni, 66 Ni, 234 Np, 15 O. 182 Os, 189 mOs, 191 Os, 32 P. 201 Pb, 101 Pd, 143 P.R. 191 Pt, 243 Pu, 225 Ra, 81 Rb, 188 Re, 105 Rh, 211 Rn, 103 Ru, 35 S. 44 Sc, 72 Se, 153 Sm, 125 Sn, 91 Sr, 173 T, 154 Tb, 127 Te, 234 Th, 45 Ti, 166 Tm, 230 U. 237 U. 240 U. 48 V. 178 W, 181 W, 188 W, 125 Xe, 127 Xe, 133 Xe, 133 mXe, 135 Xe, 85 M.Y., 86 Y. 90 Y. 93 Y. 169 Yb, 175 Yb, 65 Zn, 71 mZn, 86 Zr, 95 Zr, and / or 97 70. The targeted therapeutic molecule of claim 69 comprising Zr.

73. 70. The targeted therapeutic molecule of claim 69, wherein the nanoparticle comprises a metallic nanoparticle, a liposome, or a polymeric nanoparticle.

74. 3. A formulation comprising cells genetically engineered to express the CAR system of claim 2.

75. 75. The formulation of claim 74, wherein the cells are T cells, natural killer cells, monocytes / macrophages, hematopoietic stem cells or hematopoietic progenitor cells.

76. 76. The formulation of claim 75, wherein the T cells are selected from CD3 T cells, CD4 T cells, CD8 T cells, central memory T cells, effector memory T cells, and / or naive T cells.

77. 76. The formulation of claim 75, wherein the T cells are CD4 T cells and / or CD8 T cells.

78. 75. The formulation of claim 74, further comprising a pharma- ceutically acceptable carrier.

79. 55. A composition comprising the targeted therapeutic agent of claim 54 and a pharma- ceutically acceptable carrier.

80. A method of treating a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of the formulation of claim 74 and / or the composition of claim 79, thereby treating the subject in need of treatment.

81. 81. The method of claim 80, wherein the subject in need of treatment has cancer.

82. 82. The method of claim 81, wherein the cancer comprises cancer cells that express FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, or FRAS1.

83. 82. The method of claim 81, wherein the cancer comprises leukemia.

84. 84. The method of claim 83, wherein the leukemia is acute myeloid leukemia (AML).

85. 85. The method of claim 84, wherein the AML comprises CBFA2T3 / GLIS2 AML.

86. The method of claim 81 , wherein the cancer comprises cancer cells that express FOLR1.

87. 87. The method of claim 86, wherein the cancer comprises leukemia, peritoneal cancer, fallopian tube cancer, ovarian cancer, endometrial cancer, cervical cancer, breast cancer, bladder cancer, renal cell carcinoma, pituitary tumor, lung cancer, uterine cancer, squamous cell carcinoma, ureteral cancer, urethral cancer, osteosarcoma, or transitional cell carcinoma.

88. 88. The method of claim 87, wherein the cancer is metastatic.

89. 88. The method of claim 87, wherein the ovarian cancer comprises epithelial ovarian cancer.

90. 88. The method of claim 87, wherein the breast cancer comprises triple negative breast cancer or HER2 breast cancer.

91. 88. The method of claim 87, wherein the lung cancer comprises lung adenocarcinoma or epithelial lung cancer, e.g., non-small cell lung cancer.

92. 81. The method of claim 80, wherein the preparation comprises autologous or allogeneic cells.

93. A method for treating a subject with CBFA2T3 / GLIS2 acute myeloid leukemia (AML), comprising administering to the subject a therapeutically effective amount of the formulation of claim 74 and / or the composition of claim 79, thereby treating the subject with CBFA2T3 / GLIS2 AML.

94. 94. The method of claim 93, wherein the preparation comprises autologous or allogeneic cells.